Prostate Cancer – Topic Hub

Explore Grand Rounds in Urology talks categorized Prostate Cancer.

Sort by Disease State / Sort by Treatment and Special Topics

Sort by Disease State

TitleSpeakerDisease StateRisk CategoryStage-groupCastration-responseLine of Therapy
LDR Brachytherapy in Community Practice: Expanding Access Through Collaborative CareE. David Crawford, MD2026Prostate Cancer
Cardiovascular Risk During Systemic Therapy for Prostate CancerE. David Crawford, MD2026Prostate Cancer
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Multidisciplinary Case ReviewDavid S. Morris, MD, FACS2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)HighInitial
PET Tumor Board: Discordant PSMA and FDG PET Findings in Concurrent Adenocarcinoma and Neuroendocrine Prostate CancerE. David Crawford, MD2025Prostate Cancer
PET Tumor Board: Negative PSMA PET Imaging in Biochemical Recurrence with Incidental Detection of Primary Lung AdenocarcinomaE. David Crawford, MD2026Prostate Cancer, Biochemical Recurrence (BCR)
PARP Inhibitors and Genomic Testing in Metastatic Prostate Cancer: Lessons from TALAPRO-3E. David Crawford, MD2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)Stage IVBCastration-Sensitive (CSPC/HSPC)Initial
Targeting Epigenetic Resistance in Advanced Prostate Cancer: BET and DNMT InhibitionE. David Crawford, MD2026Prostate Cancer, Metastatic Castration-Resistant (mCRPC)Stage IVBCastration-Resistant (CRPC)Refractory
Top 10 ASTRO 2025 Studies: Prostate and Bladder Cancer HighlightsSherief H. Gamie, MD, PhD2026
Germline and Somatic Testing in Prostate CancerGennady Bratslavsky, MD2026Prostate Cancer
Highlights of AUA, GU ASCO, ASCO, and ASTROHanan Goldberg, MD, MSc2026Bladder Cancer, Prostate Cancer, Renal Cancer
PCa Commentary | Volume 217 - September 2026Edward Weber, MD2026Prostate Cancer
How Do We Protect Quality of Life in the Era of Intensification?Andrew W. Hahn, MD2026Prostate Cancer
Are We Overusing Combination Therapy in mHSPC?Marijo Bilusic, MD, PhD2026Prostate Cancer, Localized
Treatment after AR Pathway Inhibition (ARPI) + Radioligand Therapy (RLT)Andrew W. Hahn, MD2026Prostate Cancer, Metastatic Castration-Resistant (mCRPC)Refractory
How Aggressive Should We Be in Oligometastatic Disease?Hanan Goldberg, MD, MSc2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)Salvage
State-of-the-Art: Is Testosterone the King?Abraham Morgentaler, MD, FACS2026Prostate Cancer
Immunotherapy When Nothing Else Works: Rational or Irrational Approach?Susan F. Slovin, MD, PhD2026Prostate Cancer, Metastatic Castration-Resistant (mCRPC)Stage IVBCastration-Resistant (CRPC)Refractory
Can Imaging Replace Biopsy in Selected Prostate Cancer Patients?Sherief H. Gamie, MD, PhD2026Localized/Locally Advanced, Prostate CancerInitial
History and Challenges of Early Detection of Prostate CancerE. David Crawford, MD2026Localized/Locally Advanced, Prostate CancerInitial
Is PSA Screening Still Broken or Finally Fixed?Sean P. Collins, MD, PhD2026Localized/Locally Advanced, Prostate CancerInitial
Health: Exercise, Diet, and Drugs in Prostate CancerLogan G. Briggs, MD2026Prostate Cancer
PCa Commentary | Volume 216 - August 2026Edward Weber, MD2026Prostate Cancer
Why Low-Dose-Rate Brachytherapy Deserves a Second LookE. David Crawford, MD2026Prostate Cancer, Localized, Locally AdvancedLow, IntermediateInitial
EMPIRE-2 Trial: Optimizing Molecular Imaging for Biochemical Recurrence After ProstatectomyE. David Crawford, MD2026Prostate Cancer, Biochemical Recurrence (BCR)
The Reality of Real World DataE. David Crawford, MD2026
Quality of Life, Adherence, and Adverse Events Among Patients with Advanced Prostate Cancer Treated with Relugolix: 6-Month Results of the OPTYX Multicenter RegistryRana R. McKay, MD, FASCO2025Prostate Cancer, Metastatic Castration-Resistant (mCRPC)Castration-Sensitive (CSPC/HSPC)Initial
The ARACOG Study: Neurourologic CognitionE. David Crawford, MD2026Prostate Cancer
Understanding PTEN Loss and the CAPItello-281 Trial in Metastatic Hormone-Sensitive Prostate CancerE. David Crawford, MD2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)Stage IVBCastration-Sensitive (CSPC/HSPC)Initial
Proven Science, Evolving Practice: The Role of Confirm mdx in Modern Post-Negative Biopsy ManagementJose De La Cerda, III, MD, MPH2026Prostate Cancer
PTEN Loss and AKT Inhibition in Metastatic Prostate CancerE. David Crawford, MD2026Prostate Cancer
PCa Commentary | Volume 214 - June 2026Edward Weber, MD2026Prostate Cancer
Suffering in Silence: The Unspoken Burdens of Informal CaregiversReena W. Cherry, MS, PA-C2025
My Journey to Focal Therapy of Prostate CancerHerbert Lepor, MD2026Localized/Locally Advanced, Prostate CancerIntermediateInitial
Controversies with Testosterone TherapyMohit Khera, MD, MBA, MPH2026Prostate Cancer, Metastatic Castration-Resistant (mCRPC)HighStage IVBCastration-Resistant (CRPC)Refractory
Prostate Cancer Screening Updates and PSA Risk StrategiesMichael A. Liss, MD, PhD, MAS, MBA, FACS2026Localized/Locally Advanced, Prostate CancerLowInitial
Proactive Management of Post-Prostatectomy Incontinence and Erectile DysfunctionKathleen M. Colella, MSN, APN-CNP, FAUNA2025
Radioligand Therapy UpdateRobert E. Reiter, MD, MBA2026Prostate Cancer, Metastatic Castration-Resistant (mCRPC)HighStage IVBCastration-Resistant (CRPC)Refractory
Penile Rehabilitation After Prostate Cancer: Lessons Learned from Protocol Development and ResearchHelen L. Bernie, DO, MPH2026Prostate CancerCastration-Sensitive (CSPC/HSPC)Salvage
The Undecided PCA Consult: Optimized Counseling, Treatment Choices, and Avoiding Decision RegretJonathan D. Tward, MD, PhD, FASTRO2026Prostate Cancer, Locally AdvancedIntermediateInitial
Brian J. Moran Distinguished Lecture: Prostate Brachytherapy: Why Cure Doesn’t Seal the DealGrgur Mirić, MD, FACR, FABS2026
Biomarkers in Advanced DiseaseMary-Ellen Taplin, MD2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)HighStage IVBCastration-Sensitive (CSPC/HSPC)Initial
Salvage Nodal Radiotherapy in the PET Era: Long-Term OutcomesBrian J. Davis, MD, PhD, FABS2026Prostate Cancer, Biochemical Recurrence (BCR)HighStage IVACastration-Sensitive (CSPC/HSPC)Salvage
Practical Selection for Doublet versus Triplet TherapyDaniel P. Petrylak, MD2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)HighStage IVBCastration-Sensitive (CSPC/HSPC)Initial
Testosterone and Prostate Cancer: From Dogma to DataHelen L. Bernie, DO, MPH2026Localized/Locally Advanced, Prostate CancerCastration-Sensitive (CSPC/HSPC)Salvage
PCa Commentary | Volume 213 - May 2026Edward Weber, MD2026Prostate Cancer, Biochemical Recurrence (BCR)Intermediate, High
Salvage Radiation After Radical Prostatectomy: Treat Immediately or Observe?Peter J. Rossi, MD, FABS, FASTRO2026Prostate Cancer, Biochemical Recurrence (BCR)HighCastration-Sensitive (CSPC/HSPC)Salvage
A Look at Oligometastatic Disease: Metastasis-Directed Therapy Versus SystemicJonathan D. Tward, MD, PhD, FASTRO2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)Stage IVBCastration-Sensitive (CSPC/HSPC)Salvage
MTI in Biochemical Recurrent Disease: What Threshold, Which Images?Peter F. Orio III, DO, MS, FABS, FASTRO2026Localized/Locally Advanced, Prostate CancerHighCastration-Sensitive (CSPC/HSPC)Initial
Selection and Management for Locally Advanced Disease Declining Clinical TrialsMary-Ellen Taplin, MD2026Localized/Locally Advanced, Prostate CancerHighStage IIICastration-Sensitive (CSPC/HSPC)Initial
Avoiding Monotherapy: Any Progress?Andrew W. Hahn, MD2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)Castration-Sensitive (CSPC/HSPC)Initial
Alternate Therapy UpdatesDaniel P. Petrylak, MD2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)HighCastration-Sensitive (CSPC/HSPC)Initial
Rethinking Focal Therapy: Whole-Gland Ablation for Select PatientsAbhinav Sidana, MD, MPH, FACS2026Localized/Locally Advanced, Prostate CancerIntermediateInitial
Salvage RARP Post AblationJohn W. Davis, MD, FACS2026Prostate Cancer, Biochemical Recurrence (BCR)Salvage
Case Discussions: Cases I Try to AvoidBehfar Ehdaie, MD, MPH2026Localized/Locally Advanced, Prostate CancerIntermediateInitial
MRI-Assisted Radiosurgery (MARS) for LDR/HDR/EBRT for Prostate Cancer TreatmentSteven J. Frank, MD, FACR, FABS, FASTRO2026Localized/Locally Advanced, Prostate CancerInitial
Novel Targeted Treatments for Metastatic Prostate CancerEvan Y. Yu, MD2025Prostate Cancer, Metastatic Castration-Resistant (mCRPC)Castration-Resistant (CRPC)Refractory
mCRPC: Lu-177 PSMA and BeyondWilliam K. Oh, MD2025Metastatic Castration-Resistant (mCRPC)Castration-Resistant (CRPC)Refractory
RARP Checklist for Early Career Efficiency and Troubleshooting SkillsJohn W. Davis, MD, FACS2026Localized/Locally Advanced, Prostate CancerInitial
Cardiovascular Side Effects of New Hormone Therapies for Prostate CancerWilliam K. Oh, MD2025Prostate Cancer, Metastatic Castration-Resistant (mCRPC)Castration-Sensitive (CSPC/HSPC)Initial
Which PSMA Radiotracer is Best for Which Setting?Alberto Vargas, MD2025Prostate Cancer
High Resolution Micro Ultrasound: Can It Replace MRI?Laurence Klotz, MD, FRCSC2026Localized/Locally Advanced, Prostate Cancer
What to do with Positive PSMA PET Detected Nodes?Christian P. Pavlovich, MD2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)HighCastration-Sensitive (CSPC/HSPC)Initial
Focal Therapy Update: Selection, Outcomes, TrialsBehfar Ehdaie, MD, MPH2026Localized/Locally Advanced, Prostate CancerIntermediateInitial
Salvage Post Radiation: When Can More Radiation Be Offered?Steven J. Frank, MD, FACR, FABS, FASTRO2026Prostate Cancer, Biochemical Recurrence (BCR)Castration-Sensitive (CSPC/HSPC)Salvage
Current and Planned NRG Prostate Cancer TrialsJeff M. Michalski, MD, MBA, FACR, FASTRO2026Localized/Locally Advanced, Prostate CancerHighCastration-Sensitive (CSPC/HSPC)Initial
Optimal Management of Biochemical RecurrenceOscar B. Goodman, Jr., MD, PhD2025Prostate Cancer, Biochemical Recurrence (BCR)Castration-Sensitive (CSPC/HSPC)Salvage
What Type of Scanning Should Be Done in High-Risk Patients?Alberto Vargas, MD2025Localized/Locally Advanced, Prostate CancerHighInitial
Risks and Complications of Rectal SpacersJohn E. Sylvester, MD, FABS2025
Hormone-Sensitive Metastatic Prostate Cancer: 1, 2, or 3 Drugs?Evan Y. Yu, MD2025Prostate Cancer, Metastatic Castration-Resistant (mCRPC)Castration-Sensitive (CSPC/HSPC)Initial
Radiation in the Treatment of Oligometastatic Nodal DiseaseBrian J. Davis, MD, PhD, FABS2025Localized/Locally Advanced, Prostate CancerHighCastration-Sensitive (CSPC/HSPC)Initial
Genetic Testing: Utility Through the Disease Life CycleBrian T. Helfand, MD, PhD2026Localized/Locally Advanced, Prostate Cancer
Update on Racial Disparities in PSA Screening and DetectionYaw A. Nyame, MD, MS, MBA2026Localized/Locally Advanced, Prostate CancerHighInitial
Use of Biomarkers: Genomic Testing to Delete ADT with RadiationJonathan D. Tward, MD, PhD, FASTRO2026Localized/Locally Advanced, Prostate CancerLow, Intermediate, HighCastration-Sensitive (CSPC/HSPC)Initial
Robotic-Assisted Radical Prostatectomy (RARP)John W. Davis, MD, FACS2026Localized/Locally Advanced, Prostate CancerIntermediateInitial
Pelvic Nodal Irradiation in the Era of SBRTJonathan A. Haas, MD2025Prostate CancerHighCastration-Sensitive (CSPC/HSPC)Initial
Advances in Digital Pathology and Artificial IntelligenceM. Scott Lucia, MD2025Localized/Locally Advanced, Prostate Cancer
Genomic Testing: Current Value in the Era of MRI and Clinical Prognostic FactorsMatthew R. Cooperberg, MD, MPH2026
Focal Therapy: Bridging a Treatment Gap and Building a Framework for SuccessKyrollis Attalla, MD2025Localized/Locally Advanced, Prostate CancerInitial
Radiation Therapy: When Should Hormone Therapy Be Used and for How Long?Nelson N. Stone, MD2025Localized/Locally Advanced, Prostate CancerHighCastration-Sensitive (CSPC/HSPC)Initial
Stereotactic Body Radiation Therapy (SBRT) vs Radical ProstatectomyJonathan A. Haas, MD2025
How to Biopsy for Focal Therapy and Determine FailureNelson N. Stone, MD2025
Elevated PSA with Prior Negative Biopsy: When to Repeat versus ObserveMatthew R. Cooperberg, MD, MPH2026Localized/Locally Advanced, Prostate Cancer
PSA Screening in 2026: Updates on MRI and Adjunct Biomarker UseYaw A. Nyame, MD, MS, MBA2026
PSMA PET at Low PSA: Managing a Solitary Suspicious Lesion After Radiation and ADTE. David Crawford, MD2025
Borderline Molecular Targeted Imaging Results: Case StudiesBrian T. Helfand, MD, PhD2026Prostate Cancer, Biochemical Recurrence (BCR)HighCastration-Sensitive (CSPC/HSPC)Salvage
Emerging Molecular Targeted Imaging AgentsRobert E. Reiter, MD, MBA2026
Preserving Post-Prostatectomy Sexual Function: Pills, Pumps, or InjectionsRyan Nasseri, MD2025
Advantages of Prostate Cancer Rectal SpacersBrian J. Davis, MD, PhD, FABS2025
SBRT and BrachytherapyRichard G. Stock, MD2025
Novel Indications for Molecular Targeted Imaging (Focus on PSMA PET)Scott T. Tagawa, MD2026Prostate Cancer, Non-metastatic Castration-Resistant (nmCRPC)Castration-Resistant (CRPC)Refractory
Transperineal Fusion Prostate BiopsiesLisa Cunningham, APRN, NP-C2025
Interpreting PSMA PET After Prostatectomy: A Case of Missed RecurrenceE. David Crawford, MD2025
ADT and Cardiovascular Risk: Insights from the REVELUTION StudySagar A. Patel, MD2025Localized/Locally Advanced, Prostate CancerCastration-Sensitive (CSPC/HSPC)Initial
Optimal Patient Selection and Exclusion for MTIDavid M. Albala, MD2026
When Not to Treat with Androgen Deprivation TherapyMary-Ellen Taplin, MD2026
Panel Discussion Session 1: TechCon: AI and Novel Technologies in Prostate CancerChristian P. Pavlovich, MD2026
MRI-Targeted Biopsy Alone: Precision Without RedundancyEvan Kovac, MD, CM, FRCSC2025
Biopsy Specimen Handling and Integrity: Is it Time for a System Change?M. Scott Lucia, MD2025
Navigating Hormone Therapy in Prostate Cancer: Strategies to Reduce Side Effects and Prolong SurvivalLaurence Klotz, MD, FRCSC2026
Navigating the Management of mCSPC From Mono to Quadruple TherapiesE. David Crawford, MD2026
Adjuvant/Salvage Radiotherapy Following ProstatectomyRichard G. Stock, MD2025
Technical Advances for Robotic Laparoscopic ProstatectomyAshutosh K. Tewari, MD, MBBS, MCh, FRCS2025
Rescuing ADT and ARPI: Benefits from ToxicitiesAndrew W. Hahn, MD2026Prostate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)Castration-Sensitive (CSPC/HSPC)Initial
Immunomodulation Plus IMRT in Intermediate and High-Risk Prostate Cancer: Phase III Randomized TrialJohn E. Sylvester, MD, FABS2025
Proton Therapy for Prostate CancerBrian J. Davis, MD, PhD, FABS2025
Promising Advances from Industry: Diagnostics, Devices, and TherapyChristian P. Pavlovich, MD2026
Where Will Artificial Intelligence Impact Prostate Cancer Diagnostics and Therapy?David M. Albala, MD2026
MRI Fusion Biopsy: The Role of Both Targeted and Systematic Core SamplingMichael S. Leapman, MD, MHS2025
How Biopsy Length Influences Diagnostic and Treatment PlanningNelson N. Stone, MD2025
Why Are mpMRIs Negative in Men with Clinically Significant Prostate Cancer?Alberto Vargas, MD2025
Pathological Markers and AIAdam Cole, MD, FS2025
Case Discussions: Surveillance and Recurrence in Focal TherapyArvin K. George, MD2025
PCa Commentary | Volume 212 - April 2026Edward Weber, MD2025
Best Use of MRI for Focal TherapyAlberto Vargas, MD2025
Treating Neuroendocrine Prostate CancerOscar B. Goodman, Jr., MD, PhD2025
Role of Radiation in Metastatic Prostate Cancer: Primary and Metastatic SitesCurtiland Deville, Jr., MD, FASTRO, FACR2025
Doublet vs Triplet Therapy for Newly Diagnosed Metastatic Prostate CancerMohammad O. Atiq, MD, FACP2025
Quantitative MRI Reading: Applications in Prostate CancerVictoria Y. Bird, MD2025
The Role of the Pathologist in the Selection and Monitoring of Patients for Active SurveillanceM. Scott Lucia, MD2025
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Evaluating Optimal Systemic Treatment Strategies - DoubletJ. Michael Randall, MD2025
Prostatype Genomics: Filling Unmet Needs in Prostate Cancer ManagementGerald L. Andriole, Jr., MD2025
Germline and Somatic MarkersLeonard G. Gomella, MD, FACS2025
Medical Oncology Perspective on Integration of Molecular Imaging and Treatment for mCRPCDiogo Assed Bastos, MD, PhD2025Prostate Cancer, Metastatic Castration-Resistant (mCRPC)Castration-Resistant (CRPC)Refractory
Micro-Ultrasound for Prostate Cancer: Promising or Fool’s Errand?Ardeshir R. Rastinehad, DO, FACOS2025
Radiology and Theranostics in CRPCSherief H. Gamie, MD, PhD2025
Parp Inhibitors: Evidence, Indications and Side EffectsMohammad O. Atiq, MD, FACP2025
Radiopharmaceutical Design and Molecular ImagingKatherine Whittaker Ferrara, PhD2025
Influence of Family History, Race, and Genetic Markers on Prostate Cancer ScreeningEvan Kovac, MD, CM, FRCSC2025
Evaluating Triplet Therapy in Metastatic Hormone-Sensitive Prostate CancerSharon Choi, MD, PhD2025
Should Prostate MRI Be the Primary Screening Approach?Michael S. Leapman, MD, MHS2025
Focal Therapy Patient Selection: Urologist PerspectiveGeoffrey Sonn, MD2025
Biochemical Recurrence (BCR) Treatment: Comparing Targeted Approaches for Rising PSA, ADT + EnzalutamideJ. Michael Randall, MD2025
Deciphering the Role of MRI in Prostatic Disease “Risk Stratification”Ardeshir R. Rastinehad, DO, FACOS2025
Pulsed Electrical Field Treatment of Prostate CancerBenjamin Schurhamer, MD, MHCI2025
Metastatic Castration-Resistant Prostate Cancer (mCRPC): SequencingYu-Wei Chen, MD, MS2025
Molecular Imaging at Prostate Cancer Biochemical RecurrenceHong Song, MD, PhD2025
Long-Term Outcomes of PSMA PET/CT-Guided Radiotherapy in Biochemical Failure Patients Post-Radical Prostatectomy: A 5-Year Follow-Up AnalysisAndrea Di Giorgio, MD2025
Introduction to Advanced Prostate Cancer Management: Description of Terminology and Review of NCCN GuidelinesBenjamin J. Martin, MD2025
Radiopharmaceuticals in Advanced Prostate Cancer ManagementSteven P. Rowe, MD, PhD2025
Metastatic Castration-Resistant Prostate Cancer (mCRPC): Emerging Therapeutic ApproachesSharon Choi, MD, PhD2025
Back to the Future: Cryotherapy for Focal Prostate Cancer AblationYoed Rabin, BS, MS, DSc2025
Transrectal Biopsy Versus Local Anaesthetic Transperineal Biopsy Evaluation (TRANSLATE) in Prostate Cancer DetectionRichard J. Bryant, MBChB, PhD, FRCS2025
Recurrent Prostate Cancer: Enzalutamide Monotherapy and AlternativesJuan Javier-DesLoges, MD, MS, FACS2025
The Who and What of Focal Therapy for Prostate CancerArdeshir R. Rastinehad, DO, FACOS2025
Advances in Molecular Targeted Imaging (MTI)Sherief H. Gamie, MD, PhD2025
Whole Gland Ablation vs. Partial Gland AblationAbhinav Sidana, MD, MPH, FACS2025
Navigating the Management of mCSPC from Mono to Quadruple TherapiesE. David Crawford, MD2025
Prostate Cancer Aquablation (PCAq): A Novel Technique for Subtotal Resection of ProstateBrian T. Helfand, MD, PhD2025
Old School, New Insight: Histomorphology in the Modern Biomarker Era of Risk Stratification of Prostate CancerJane K. Nguyen, MD, PhD2025
Optimal Management of Patients Presenting with Locally Advanced Prostate Cancer in 2025Raja B. Khauli, MD, FACS2025
Could the Clinic Be the ‘One-Stop Shop’ for Prostate Cancer?Rahul D. Mehan, MD2025
Pro: Focal Therapy for Prostate CancerJuan Javier-DesLoges, MD, MS, FACS2025
Navigating the Challenges of Early Detection of Prostate CancerE. David Crawford, MD2025
Focal Therapy Fallout: Managing Complications and RecurrenceSamir S. Taneja, MD2025
Water Vapor Thermal Therapy for Prostate CancerArvin K. George, MD2025
Evaluation and Management of Men with Localized and Recurrent Prostate Cancer: Next Generation Risk StratificationAlastair D. Lamb, MA, MBChB, PhD, FRCS2025
Augmented Reality Guided Prostate BiopsiesArchan Khandekar, MD2025
Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-upDaniel Margolis, MD2025
Genetic Testing in Prostate Cancer ManagementAbhinav Sidana, MD, MPH, FACS2025
Evaluating 68Ga-PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective StudyAndrea Di Giorgio, MD2025
Principles of Focal Salvage Treatment for Radiorecurrent Prostate Cancer – Is it Feasible?Giancarlo Marra, PhD2025
Evidence Update in Focal Therapy: 2025Patrick T. Gomella, MD, MPH, FACS, EMT-P2025
HIFU in Prostate Cancer: Evolution, Evidence, and Emerging FrontiersSébastien Crouzet, MD, PhD2025
Energy Sources and Emerging Clinical IndicationsJurgen Fütterer, MD, PhD2025
Urologist Led Advanced Prostate Cancer Clinic (APCC): Tips, Tricks, and PitfallsBenjamin J. Martin, MD2025
Optimizing Ablative Modality for Treatment Outcome: Quid Quando UbiSamir S. Taneja, MD2025
A Deeper Look into the Favorable Intermediate-Risk PatientsDeepika Bhagwat, MD, BCMAS2025
Future Indications of PET PSMA Imaging in Localized Prostate CancerAshley E. Ross, MD, PhD2025
Focal Therapy in Prostate Cancer: Ready for Prime Time?Bruno Nahar, MD2025
Novel and Emerging Pathological Factors in Localized and Recurrent Prostate CancerGladell P. Paner, MD2025
The Role of Pathologists in PlanningAdam Cole, MD, FS2025
Surveillance After Focal TherapyGopal N. Gupta, MD, FACS2025
Role of PSMA Imaging in Selecting Patients for Biopsies (Urologic Perspective)Lorenzo Bianchi, MD, PhD, FEBU2025
The Use of PSMA PET/CT Scan in Patients with Prostate Cancer Treated with Focal TherapyGiovanni Lughezzani, MD2025
Overview of the Current Approaches to Standardized MRI ReportingFrancesco Giganti, MD, PhD2025
PCa Commentary | Volume 211 - March 2026Edward Weber, MD2025
Con: Focal Therapy for Prostate Cancer – Another Unnecessary ToolAditya Bagrodia MD, FACS2025
Treatment Intensification Strategies: Approaches to Optimize Outcomes for High-Risk Localized DiseaseJ. Michael Randall, MD2025
Androgen Receptor Signaling Inhibitors: Evidence, Indications and Side Effects in HSPCAshley E. Ross, MD, PhD2025
State of the Art and Future Directions in Prostate Biopsies: Imaging PerspectiveFergus Coakley, MD2025
Early Detection Saves Lives: PCEC’s Mission to Expand PSA ScreeningMolly Turner, MBA2026
What the Urologist Needs to Know about Molecular Targeted Imaging (MTI) and TheranosticsSean P. Collins, MD, PhD2025
Integrated Diagnostics for Risk Stratification and Active SurveillanceSanoj Punnen, MD, MAS, MBA2025
Lesional Management in Early Prostate CancerMark Emberton, MD, FRCS2025
The Gut Microbiome and Cancer ResistanceMichael A. Liss, MD, PhD, MAS, MBA, FACS2025
RadiopharmaceuticalsSean P. Collins, MD, PhD2025
Integration of MRI with Histology, Genomics, and ProteomicsSteven S. Raman, MD2025
Molecular ImagingMichael Hofman MBBS, FRACP, FAANMS, FICIS, GAICD2025
Focal Therapy vs Radical Treatment for Prostate CancerSébastien Crouzet, MD, PhD2025
Highlights from ASCO GU 2026: An Intra-patient Contemporaneous Comparison of 18F-piflufolastat and 18F-flotufolastat Urinary Radioactivity and Local and Pelvic Region Detection Rates in Men with Low Prostate-specific Antigen Biochemical Recurrence of Prostate Cancer after Radical ProstatectomyBrian T. Helfand, MD, PhD2026
Highlights from ASCO GU 2026: Patient Reported Outcomes (PRO) and Tolerability of Capivasertib (capi) plus Abiraterone (abi) versus Placebo (pbo) plus Abi in Patients (pts) with PTEN-deficient Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281Daniel J. George, MD, FASCO2026
Highlights from ASCO GU 2026: First-in-human Assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation Results of the Phase 1 PAnTHa StudyFred Saad, MD, FRCS, CQ, FCAHS2026
2026 GU ASCO Discussant Review: Abstracts Covering the PEACE-3 Trial and BRCAAway StudyEvan Y. Yu, MD2026
Gleason Pattern 4 Quantification as a Replacement for Gleason ScoringAndrew J. Vickers, PhD2025
Screening Strategies: Debating Optimal Approaches – Risk-Stratified ScreeningBrent Rose, MD2025
PCa Commentary | Volume 210 - February 2026Edward Weber, MD2025
PSMA PET/CT in Prostate Cancer ImagingSherief H. Gamie, MD, PhD2025
Active Surveillance 2025 Update: If We Are in Favor of Screening, We Must Avoid OvertreatmentChristopher J. Kane, MD, MS, FACS2025
PSA: Universal ScreeningAditya Bagrodia MD, FACS2025
Post Ablation Imaging: Interpretation and Standardized ReportingSadhna M. Verma, MD, MBA, FSAR2025
Strategies to Improve Patient Selection: Role of Additional Imaging and BiomarkersCeli Varol, MBBS, FRACS2025
Salvage Prostatectomy in 2025Brant A. Inman, MD, MS, FRCSC2025
Point Counter Point: Software-Based Fusion for FocalPatrick T. Gomella, MD, MPH, FACS, EMT-P2025
Point Counter Point: The Case for CognitiveAlexander Kenigsberg, MD2025
Patient Selection: Fusion and Confirmatory BiopsyArvin K. George, MD2025
Fireside Chat with Vic LombardiE. David Crawford, MD2026
Panel Discussion: MRI and PSMA DiscordanceAbhinav Sidana, MD, MPH, FACS2025
Pitfalls of PSMA PET Imaging: False Positive, Equivocal, False Negative, Intraprostatic UptakeSteven P. Rowe, MD, PhD2025
Prostate MRI Update — What’s New on the Horizon?Sadhna M. Verma, MD, MBA, FSAR2025
PCa Commentary | Volume 209 - January 2026Edward Weber, MD2025
Focal Therapy for Metastatic Disease in Prostate CancerBart A. Frizzell, MD2025
Embracing the Practice of Interventional UrologyArdeshir R. Rastinehad, DO, FACOS2025
Blood-Based Biomarkers in Prostate CancerBrant A. Inman, MD, MS, FRCSC2025
When to Consider Salvage XRT in Delayed BCRBart A. Frizzell, MD2025
Future of PathologyAdam Cole, MD, FS2025
The Role of Spacing Devices in Modern Prostate XRTDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2025
Management of Localized Prostate Cancer: Targeted TherapyThomas J. Polascik, MD, FACS2025
MRI After FT – Toronto ExperienceSangeet Ghai, MD, FRCR2025
Radiation Therapy UpdatesSean P. Collins, MD, PhD2025
Combination Therapy RevisitedPeter R. Carroll, MD, MPH2025
Micro-Ultrasound and Irreversible Electroporation (IRE) for Treatment of Prostate CancerXiaosong Meng, MD, PhD2025
Focal Therapy for Localized Prostate Cancer: Why Hasn’t it Become the Standard of Care?Rafael Sanchez-Salas, MD2025
Guidelines for Management of Advanced PC: NCCN and BeyondMarc B. Garnick, MD2025
Surveillance Strategies After Focal TherapyIzak Faiena, MD, MSCR2025
Radiation Surgery Research in Group PracticeSteven E. Finkelstein, MD, DABR, FACRO2025
Diagnostic and Prognostic BiomarkersWilliam P. Parker, MD, FACS2025
Focal Therapy Recurrences and ManagementAbhinav Sidana, MD, MPH, FACS2025
Review and Update – Imaging for Improving Post-Ablation Assessment and Developing Short-Term Patient OutcomesFaina Shtern, MD2025
Navigating the Challenges of Early DetectionPeter R. Carroll, MD, MPH2025
Microbiome and CancerMichael A. Liss, MD, PhD, MAS, MBA, FACS2025
Radiologic Perspective on Integration of Molecular Imaging and TreatmentAndrei H. Iagaru, MD, FACNM2025
Focal Brachytherapy for Prostate CancerDaniel Y. Song, MD2025
Clinical and Prognostic Implications of Cancer Visibility on Imaging: Radiology PerspectiveAlberto Vargas, MD2025
Novel Targeted Treatment and Integration with Precision DiagnosticsDaniel P. Petrylak, MD2025
Immunotherapy in Prostate CancerSandy Srinivas, MD2025
How Has the SP Robot Affected Our Approach to Radical Prostatectomy?Jeremy Slawin, MD, MBA2025
Treatment De-Escalation: Strategies to Optimize Risk/Benefit in Advanced Prostate CancerA. Edward Yen, MD2025
PSMA-Targeted Therapy - Clonal Heterogeneity, Neuroendocrine Differentiation, and Finding the Right Sequence of Systemic TreatmentVikas Prasad, MD, PhD2025
Human–AI Interaction in Prostate Cancer Detection and Diagnosis: Ways to Team UpEvis Sala, MD, PhD, FRCR, FRCP2025
Deep Phenotyping of Prostate Cancer via Multi-Modal Imaging and AI to Discover High-Risk PhenotypesRakesh Shiradkar, PhD2025
Active Surveillance for Prostate Cancer: Practical Update for the Practicing UrologistJustin J. Badal, MD2025
Sequencing of TreatmentArnulf Stenzl, MD2025
Determining the Benefit of Therapy for Biochemically Recurrent Prostate CancerDavid J. Einstein, MD2025
Sequencing Lu-177 PSMA-directed RLTMichael J. Morris, MD2025
Candidates and Follow-Up for Lu-177 PSMAMichael J. Morris, MD2025
A PCa Case of PSA Recurrence After Retropubic RP, XRT & a Case of Diffusely mPCa Developing Castration ResistanceDavid S. Morris, MD, FACS2025
A Case of CRPC Using PSMA PET Imaging & a Case of Gleason 9, PSA of 200, and Slowly Rising PSADavid S. Morris, MD, FACS2025
Clinical Use of Lutetium-177–PSMA-617 for Metastatic Castrate Resistant Prostate CancerEvan Y. Yu, MD2025
Prostate Cancer Risk Assessment in Black MenAdam B. Murphy, MD, MBA, MSCI2025
Overview of Liquid Biomarkers in Prostate CancerE. David Crawford, MD2025
A PCa Case of PSA Rising After RP, Salvage XRT, ADT & a Case of Rising PSA After Triplet TherapyDavid S. Morris, MD, FACS2025
Driving Broader Impact: The Emerging Role of Radio-Ligand TherapiesIlya Gipp, MD, PhD2025
From Silos to Synergy: Data-Driven Strategies in Prostate Cancer CareIlya Gipp, MD, PhD2025
Emerging Advances in Precision Radiation Treatment and ImmunotherapySteven E. Finkelstein, MD, DABR, FACRO2025
A Calibration Tool for ADC Measurements in Prostate CancerXavier Golay, MS, PhD2025
Micro-Ultrasound-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis (OPTIMUM Trial)Laurence Klotz, MD, FRCSC2025
PET Tumor Board: Case 8 – A Case of An 81-year-old Man with High-risk Prostate Cancer with Initial PSA of 8.4 and a Large Peripheral Zone LesionE. David Crawford, MD2025
State of the Art and Future Directions in Prostate Biopsies: Urological PerspectiveAlastair D. Lamb, MA, MBChB, PhD, FRCS2025
Large-Scale, Prospective, Clinical Validation Study of the Diagnostic Performance of IsoPSA Without and in Combination with Multi-Parametric MRI for the Detection of High Grade Prostate CancerMark Stovsky, MD, MBA, FACS2025
PCa Commentary | Volume 208 - December 2025Edward Weber, MD2025
Genomics and Natural History of MRI Invisible vs Visible Cancers: Implications for Clinical PracticeLaurence Klotz, MD, FRCSC2025
MRI PI-RADS Standardization and Clinical EvaluationClare Tempany, MB, BCh, BAO2025
Radiology & Theranostics in Castrate Resistant Prostate Cancer (CRPC)Sherief H. Gamie, MD, PhD2025
Newly Identified Germline Mutations Associated with Prostate Cancer Risk and AggressivenessBrian T. Helfand, MD, PhD2025
Can PSMA-PET Improve Outcomes in Prostate Cancer?Sean P. Collins, MD, PhD2025
PCa Commentary | Volume 207 - November 2025Edward Weber, MD2025
PET Tumor Board–Case 7: A Case of a 71-year-old with PSA of 6.3, High PSA Density, and a PI-RADS 4 LesionE. David Crawford, MD2025
Lessons Learned from High Impact Randomized TrialsMira Keyes, MD, FRCPC, FABS2025
Pelvic Lymph Node Management - Radiation ApproachJason A. Efstathiou, MD, DPhil2025
Focal Therapies for Prostate Cancer - Recurrent versus Persistent Disease ManagementBrian T. Helfand, MD, PhD2025
WSAUA 2025: External Validation of an AI-Based Digital Pathology Model (MMAI) for Post-Prostatectomy PrognosisKevin Shee, MD, PhD2025
WSAUA 2025: PSMA PET Imaging and Theranostics in Prostate Cancer: Current Landscape and Future DirectionsJack R. Andrews, MD2025
WSAUA 2025: Micro-Ultrasound (Micro-US), MRI, and PSMA PET in Prostate Cancer: Whole-Mount Correlation StudyWayne G. Brisbane, MD2025
Preparing Your Patient for ProstatectomyRachel Hastings, PA-C2025
Interpreting PSMA PET/CT Scan ReportsSherief H. Gamie, MD, PhD2025
A Review of Prostate Cancer Perirectal SpacersJonathan D. Tward, MD, PhD, FASTRO2025
Post-ESMO 2025 Highlights: Advances in Prostate Cancer ResearchAndrew W. Hahn, MD2025
PCa Commentary | Volume 206 - October 2025Edward Weber, MD2025
Update on Göteborg-2 Trial: PSA Screening Followed by MRIJonas Hugosson, MD2025
Update on PRAISE-U Project - European Union Initiative in PC ScreeningMonique Roobol, PhD, MSc2025
Update on PROSCREEN: A Randomized Population-Based Screening Trail Combining PSA Kallikrein Panel and MRIAnssi Auvinen, MD, PhD2025
Organized Prostate Cancer Testing (OPT) in SwedenAnders Bjartell, MD, PhD, FEBU2025
Advancing Risk - Stratified Screening and Early DetectionSigrid V. Carlsson, MD, PhD, MPH2025
Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)Peter Albers, MD2025
Biomarkers for Prostate CancerRachel Hastings, PA-C2025
PET Tumor Board – Case 6: A Case of a 57-year-old with an Elevated PSA and Small Prostate VolumeE. David Crawford, MD2025
New Concepts in Molecularly Targeted Radiation in Prostate CancerA. Oliver Sartor, MD2025
Advanced Prostate Cancer Clinics (APCC) - LUGPA PerspectiveRonald P. Kaufman, Jr., MD2025
Challenging the Role of Pelvic Lymph Node Dissection at Robotic ProstatectomyJohn W. Davis, MD, FACS2025
Identification and Management of High-Risk Screening PopulationsBrian T. Helfand, MD, PhD2025
Biochemical Recurrence after Radical ProstatectomyChristian P. Pavlovich, MD2025
PCa Commentary | Volume 205 - September 2025Edward Weber, MD2025
Prostate Cancer Management Decisions from Germline and Somatic TestingLeonard G. Gomella, MD, FACS2025
PET Tumor Board Case 5: A Case of a 77-year-old Prostate Cancer Patient with Ulcerative Colitis and Uncertain PET FindingsE. David Crawford, MD2025
PET Tumor Board – Case 4: A Case of a 66-year old Male with Elevated PSA of 9.06 and MRI Showing PI-RADS Category 4 and 5E. David Crawford, MD2025
Update on Telesurgery and Novel Robotic SystemsDavid M. Albala, MD2025
PCa Commentary | Volume 204 - August 2025Edward Weber, MD2025
PET Tumor Board - Case 3: 62-year-old BRCA2-Positive Prostate Cancer Survivor with PSA RecurrenceE. David Crawford, MD2025
Prostate Cancer Detection Biomarkers, MRIAdam S. Kibel, MD2025
PCa Commentary | Volume 203 - July 2025Edward Weber, MD2025
Artificial Intelligence for Improving Prostate Cancer ManagementWayne G. Brisbane, MD2024
Patient Selection for Focal Therapy - Radiologic PerspectiveJurgen Fütterer, MD, PhD2024
Genomic Biomarker RoundtableLeonard G. Gomella, MD, FACS2025
PET Tumor Board - Case 2: A Case of a 72-year-old with Rising PSA and MRI Showing PI-RADSv2.1 Categories 4 and 5E. David Crawford, MD2025
Away from the Gleason Score and Towards Quantification of Pattern 4 for Treatment Decision Making in Localized Prostate CancerAndrew J. Vickers, PhD2024
Prostate Cancer: Current Treatment LandscapeAnne E. Lizardi, DNP, CRNP, RNFA2025
Prostate Cancer: Prevalence and Risk FactorsAnne E. Lizardi, DNP, CRNP, RNFA2025
Treatment of Prostate Cancer: Evaluation and DiagnosisAnne E. Lizardi, DNP, CRNP, RNFA2025
Focal Therapy Patient Selection: Urologist PerspectiveGeoffrey Sonn, MD2024
Need to Know: Rapid Fire PET Tumor Board DiscussionsE. David Crawford, MD2025
Prediction of Extraprostatic Disease: Updates on NeuroSAFE, Histologic Scanner, Conventional Nomograms/Imaging, & AI-Assisted Prostate Cancer MappingDavid M. Albala, MD2025
Interview of Dr. Neil H. Baum, MD on Prostate Cancer: Expert Advice for Helping Your Loved OneNeil H. Baum, MD2025
PET Tumor Board - Case 1: A Case of a 55-year-old Prostate Cancer Survivor with Rising PSA Five Years After Radical ProstatectomyE. David Crawford, MD2025
Secondary Biomarkers for Prostate Cancer Clinical Overview 2025Christian P. Pavlovich, MD2025
Darolutamide Plus Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume in the Phase 3 ARANOTE StudyE. David Crawford, MD2025
Radiopharmaceuticals in Advanced Prostate CancerSteven P. Rowe, MD, PhD2024
ADT and RadiationMira Keyes, MD, FRCPC, FABS2025
Staging Updates: Whole Body MRI and PET Imaging for Prostate CancerBrian T. Helfand, MD, PhD2025
Can Imaging Replace Prostate Biopsy - Primary Detection, Active Surveillance and Recurrent PCa?Veeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert2024
PARP in mCRPCDaniel P. Petrylak, MD2025
Focal Brachytherapy in 2025Peter J. Rossi, MD, FABS, FASTRO2025
mHSPC: Latest Approaches and Clinical TrialsTanya B. Dorff, MD2025
Optimizing Utilization of PSMA PET into a Urological PracticeDavid M. Albala, MD2025
The Undecided PCA Consult: Optimized Counseling, Treatment Choices, Avoiding Decision RegretJonathan D. Tward, MD, PhD, FASTRO2025
Grade Group 1 at Biopsy - Do We Need to Know More?John W. Davis, MD, FACS2025
Tips and Tricks of Endoscopic Anatomical Enucleation of the ProstatePierluigi Bove, MD2025
Biopsy Updates: Do We Have Clarity?Ronald P. Kaufman, Jr., MD2025
Treating Oligometastatic Prostate Cancer in the PSMA PET EraAndrew W. Hahn, MD2025
Updates on Global Screening Trials: Where Are We Headed Next?R. Jonathan Henderson, MD2025
MRI-Assisted Radiosurgery (MARS) Management of High Risk and Recurrent Prostate CancerSteven J. Frank, MD, FACR, FABS, FASTRO2025
Panel Discussion: Molecular Targeted Imaging (MTI)Christian P. Pavlovich, MD2025
MyProstateScore 2.0 (MPS2): A Novel, Noninvasive Urine Test Prior to Prostate BiopsyJeffrey J. Tosoian, MD, MPH2025
Transurethral Ultrasound Guided Prostate Ablation (TULSA): Clinical Trials and Real-world ResultsChristian P. Pavlovich, MD2025
Should Screening be Altered Based on Germline and Family History?Sigrid V. Carlsson, MD, PhD, MPH2024
PCa Commentary | Volume 202 - June 2025Edward Weber, MD2025
PCa Commentary | Volume 200 - April 2025Edward Weber, MD2025
Treating Neuroendocrine Prostate CancerWilliam K. Oh, MD2024
Transperineal Prostate Biopsy in the Office Setting Anesthetic ConsiderationsMichael A. Gorin, MD2024
UroVision Interview - Simon Criteria for Biomarkers in Urologic OncologyE. David Crawford, MD2025
Which Patients Do You Struggle With the Most, and What Makes You Sweat?John W. Davis, MD, FACS2025
Real-Time Intraoperative Neuromonitoring of Erectile and Urinary Functions During Radical ProstatectomyArthur L. Burnett II, MD, MBA, FACS2025
Current Advances of Liquid Biopsies in Prostate CancerEdwin M. Posadas, MD, FACP2025
Permanent Prostate Brachytherapy - Brian J. Moran Distinguished LectureBrian J. Davis, MD, PhD, FABS2025
Need to Know: UroVision Interview - Simon Criteria for Biomarkers in Urologic OncologyE. David Crawford, MD2025
UroVation Interview: Envision Sciences - Advancing Cancer Diagnosis and PrognosisE. David Crawford, MD2025
Managing Recurrence After Radical ProstatectomyAdam S. Kibel, MD2025
PCa Commentary | Volume 201 - May 2025Edward Weber, MD2025
Role of Whole Gland Ablation in Prostate CancerJames S. Wysock, MD, MSc2024
Digital Pathology for Detecting Prostate Cancer - TruCore PathologyAdam Cole, MD, FS2025
Hydrogel Rectal Spacer: Radiopaque vs. Non-radiopaqueRichard G. Stock, MD2024
Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of ColorQuoc-Dien Trinh, MD, MBA2024
Prostate Cancer in the Veteran Population RoundtablePeter F. Orio III, DO, MS, FABS, FASTRO2025
PROWESS: (PROstate Cancer Wearables, Exercise, and Structured Supports)Jamie Jacobs, PhD2024
Utilization and Disparity in Prostate Cancer Risk Assessment ToolsMichael S. Leapman, MD, MHS2024
Treatment of Oligometastatic DiseaseMary-Ellen Taplin, MD2024
Brachytherapy: The Historical Evolution, Techniques, and Efficacy in Prostate Cancer ManagementJohn E. Sylvester, MD, FABS2024
Prostate-Specific Antigen Response With Darolutamide Plus Androgen-Deprivation Therapy In Patients With Metastatic Hormone-Sensitive Prostate Cancer In ARANOTEE. David Crawford, MD2025
Panel Discussion: TechCon: Novel and New Technologies in Prostate CancerDavid M. Albala, MD2025
Prostate Cancer Risk Assessment in Black MenAdam B. Murphy, MD, MBA, MSCI2024
UTUC Staging, Diagnosis, Intraureteralpelvis Therapy, Endoscopic ManagementJennifer A. Linehan, MD2024
Intratumoral Immunotherapy for Cancer: Update 2024 of a Novel ApproachDavid G. Bostwick, MD, MBA, FCAP2024
Using Genetic Testing in Prostate Cancer: When and HowAlan H. Bryce, MD2024
Radiation Dose and Hormone Therapy: How Much is Enough?Nelson N. Stone, MD2024
Diet and Prostate Cancer: What We Need to Know to Tell our PatientsStacy Loeb, MD2024
Post-Treatment Assessment and Creating Imaging-Based Short- and Intermediate-Term Patient OutcomesFaina Shtern, MD2024
Management of High Risk Prostate CancerAdam S. Kibel, MD2025
Role of Digital Pathology and AI in Improving Diagnostic AccuracyDavid G. Bostwick, MD, MBA, FCAP2024
5-Alpha Reductase Inhibitors Increase the Risk of Aggressive Prostate Cancer: Fact or MythGerald L. Andriole, Jr., MD2025
Point Counterpoint: Risk Stratification for Biopsy - BiomarkersJuan Javier-DesLoges, MD, MS, FACS2024
Point Counterpoint: Risk Stratification for Biopsy - MRIPeter A. Pinto, MD2024
Adaptive RadiotherapyRichard G. Stock, MD2024
Starting a Transperineal Prostate Biopsy Program Cost Effective Strategy for ImplementationRichard C. Wu, MD2024
MicroUltrasound of the ProstateGerald L. Andriole, Jr., MD2025
Holmium Laser Enucleation of the Prostate (HoLEP): Current Era Techniques and OutcomesAmy E. Krambeck, MD2025
Point Counterpoint: Is Focal Therapy Ready for Prime Time (No)Michael Rothberg, MD2024
Point Counterpoint: Is Focal Therapy Ready for Prime Time (Yes)Ruben Olivares, MD2024
Immunotherapy in Prostate CancerSandy Srinivas, MD2024
PCa Commentary | Volume 198 - February 2025Edward Weber, MD2025
Expanding Treatment Options at Ambulatory Surgical Centers: LDR Brachytherapy for Prostate CancerE. David Crawford, MD2024
PCa Commentary | Volume 199 - March 2025Edward Weber, MD2025
PCa Commentary | Volume 197 - January 2025Edward Weber, MD2024
Gleason Scoring Has Served Us Well for More than 50 Years, But It Is Time to Start AfreshAndrew J. Vickers, PhD2024
PIRADS V2.1 - What a Urologist Needs to Know?Sadhna M. Verma, MD, MBA, FSAR2024
Multi-Disciplinary Approach to Advanced Prostate Cancer CareKelvin A. Moses, MD, PhD, FACS2024
Oral Abstracts - SV Recurrences After RadiationAaron E. Katz, MD, FACS2024
Through the Perineum or Through the Rectum: How to Best Biopsy the ProstateGuilherme Godoy, MD, MS2024
Energy Selection Ablative Technologies for Focal TherapyAndre Abreu, MD2024
PCa Commentary | Volume 196 - December 2024Edward Weber, MD2024
Utility of Micro-Ultrasound in Prostate Cancer Active SurveillanceAdam Kinnaird, MD, PhD, FRCSC2024
Bi Parametric Optimized 15 min Prostate MRI Protocol - Are we there yet?Mukesh Harisinghani, MD2024
Future Directions (FD) in Molecular Targeted Imaging (MTI) and Theranostics DiscussionRobert E. Reiter, MD, MBA2024
Update on the PROFILE and IMPACT StudiesJana McHugh, MB Bch BAO (Hons), MRCPI, FFR2023
Update: Studies Combining Secondary Biomarkers and MRILeonard G. Gomella, MD, FACS2025
Climacturia After Radical Prostatectomy: What is It? Why is It? How Do We Treat It?Brian S. Christine, MD2024
Horizons of Diagnosis and Treatment with PSMA PET MRIPaul D. Maroni, MD2024
Key Principles from the 2024 AUA Guidelines Updates on Salvage Prostate Cancer TherapyJustin J. Badal, MD2024
Results of the PRIME Trial Biparametric Versus Multiparametric MRI for Prostate Cancer Detection - ImpliVeeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert2024
Year in Review: Emerging Data and Advances in Prostate Cancer ScreeningSigrid V. Carlsson, MD, PhD, MPH2024
Update of Changes in the Early Detection of Prostate Cancer NCCN Guidelines 2024Preston C. Sprenkle, MD2024
Complications of Focal Therapy - Risk Factors, Timepoints, ManagementAmir Lebastchi, MD2024
KEYNOTE LECTURE - Introduction of Disruptive Technologies The Lessons From the Minimally Invasive SurgeryRalph V. Clayman, MD2024
Mechanisms and Management of RecurrencesAbhinav Sidana, MD, MPH, FACS2024
Oral Abstracts - Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia’s LIBERATE RegistryMohammadmehdi Adhami, MD2024
Oral Abstracts - Spacial Characterization and AI-Driven Prevention of Residual Cancer Following Focal TherapyPreston C. Sprenkle, MD2024
Oral Abstracts - Best Clinical Practices for Transperineal Postate BiopsyLorenzo Ramacciotti, MD2024
Outcomes of Recent Clinical Trials for Focal TherapyDerek J. Lomas, MD2024
Interpretation of Post Focal Therapy Imaging Target and PifabSadhna M. Verma, MD, MBA, FSAR2024
Optimal Surveillance Algorithm Following Focal Therapy of Prostate CancerHerbert Lepor, MD2024
The Changing Landscape of Focal Therapy for Prostate CancerHerbert Lepor, MD2024
Patient Selection: How to Pick a Focal Therapy CandidateDerek J. Lomas, MD2024
Urologist Led Advanced Prostate Cancer Practice Tips, Tricks and PitfallsAaron Berger, MD2024
TRAVERSE: Meaning of the Testosterone Safety TrialsMartin M. Miner, MD2024
The BARCODE 1 Study: Enrichment of Prostate Cancer Detection in Those with Higher Polygenic RiskRos Eeles, PhD, FRCP, FRCR2023
Metastatic Castrate Resistant Prostate Cancer - Immunotherapy and PARP InhibitorsAlan Tan, MD2024
Optimal Management of Biochemically Recurrent Nonmetastatic Prostate CancerAaron Berger, MD2024
Oligometastatic Prostate CancerDaniel Y. Song, MD2024
Metastatic Castrate Sensitive Prostate CancerRana R. McKay, MD, FASCO2024
Genetic Testing in Prostate Cancer ManagementAbhinav Sidana, MD, MPH, FACS2024
Course Introduction: Description of Terminology and Review of GuidelinesNatalie Reizine, MD2024
Optimizing Flow: Practical AI Applications in UrologyArun Rai, MD, MBA, MS2024
AI and Prostate Imaging and BiopsyBaris Turkbey, MD2024
Introduction to AI in HealthcareGiovanni Cacciamani, MD, MSc, FEBU2024
Rectal SpacerAbhinav Sidana, MD, MPH, FACS2024
Clinical Trials in Focal TherapyIzak Faiena, MD, MSCR2024
Prostate Cancer SurvivorshipHumberto Villarreal, MD, MSCI2024
Population of Men with Advanced Prostate Cancer: Sequencing of TreatmentArnulf Stenzl, MD2024
Radiation Therapy Planning Using Advanced Imaging – Pearls and PitfallsSean P. Collins, MD, PhD2024
Novel Targeted TherapiesDaniel P. Petrylak, MD2024
Transforming Prostate Cancer Care - The Emerging Role of Radio-Ligand TherapiesIlya Gipp, MD, PhD2024
Transperineal vs Transrectal Biopsy Clinical Trials: Mo' Data Mo' ProblemsArvin K. George, MD2024
PSMA PET for Preoperative Planning of Prostate Cancer: Nodes, Nerves and MarginsJames S. Wysock, MD, MSc2024
PET Scanning in Primary Detection of Prostate CancerSteven P. Rowe, MD, PhD2024
Utility of Micro-Ultrasound in Prostate Cancer Active SurveillanceStefano Fanti, MD2024
Current Status of External Validation of Inter-Reader Reproducibility for the Prostate Imaging Quality (PI-QUAL)Liang Wang, MD, PhD2024
Integrated Diagnostics for Risk Stratification and Active SurveillanceSanoj Punnen, MD, MAS, MBA2024
Emerging Role of Focal Therapy in the Management of Prostate CancerDaniel Y. Song, MD2024
Focal Brachytherapy for Prostate CancerBruno Nahar, MD2024
How to Best Select Doublet vs. Triplet Therapy in MCSPCScott B. Sellinger, MD, FACS2024
Criteria for the Development and Validation of Radiomic Tests in Diagnosis and Treatment of Prostate CancerErich Huang, PhD2024
Novel and Emerging Pathological Factors in Localized and Recurrent Prostate CancerGladell P. Paner, MD2024
Highlights from GU ASCO and ASCO 2024A. Edward Yen, MD2024
Keynote Lecture: Has Prostate Cancer Mortality Increased?Sigrid V. Carlsson, MD, PhD, MPH2024
Diet, Exercise, and Lifestyle: What Do We Know?Sigrid V. Carlsson, MD, PhD, MPH2024
Systemic Immunotherapy in Prostate CancerWilliam K. Oh, MD2024
Biology of the Radiotheranostic ApproachAlberto Vargas, MD2024
AI and Machine Learning: What the Future HoldsSigrid V. Carlsson, MD, PhD, MPH2024
How AI Improves Imaging InterpretationAlberto Vargas, MD2024
CAPTAIN: A Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation of the Prostate versus Radical ProstatectomyXiaosong Meng, MD, PhD2024
Novel Ways of Targeting the Androgen ReceptorDaniel P. Petrylak, MD2024
MRI in Localized and Recurrent Prostate CancerBaris Turkbey, MD2024
Genomics and Natural History of MRI Invisible vs Visible Cancers - Implications for Clinical PracticeLaurence Klotz, MD, FRCSC2024
PCa Commentary | Volume 195 - November 2024Edward Weber, MD2024
Update on PRAISE-U Project – European Union Initiative in PC ScreeningMonique Roobol, PhD, MSc2024
Overview of Liquid BiomarkersE. David Crawford, MD2024
Optimization of Prostate Biopsy – Micro-Ultrasound versus MRI (OPTIMUM)Laurence Klotz, MD, FRCSC2024
MRI PI-RADS Standardization and Clinical EvaluationClare Tempany, MB, BCh, BAO2024
Optimizing MRI Techniques for Prostate Cancer DiagnosisFergus Coakley, MD2024
Results from the Norwegian Prostate Cancer Consortium (NPCC)Jan Oldenburg, MD, PhD2024
Connected Care and Latest Developments in Prostate Cancer ManagementIlya Gipp, MD, PhD2024
Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)Peter Albers, MD2024
Overview of MCED - Performance and Impact on Prostate CancerEric A. Klein, MD2024
MRI-Based Prostate Cancer Screening in an Era of MCEDsMark Emberton, MD, FRCS2024
How Has the SP Robot Affected Our Approach to Radical Prostatectomy?Jeremy Slawin, MD, MBA2024
How has the SP Robot Affected Our Approach to Radical Prostatectomy?Jeremy Slawin, MD, MBA2024
The Bespoke Future of Cancer CareLeonard G. Gomella, MD, FACS2024
Differentiating PSMA Diagnostics & TherapeuticsPhillip J. Koo, MD2024
PCa Commentary | Volume 194 - October 2024Edward Weber, MD2024
Devastated Outlet in MenOuida L. Westney, MD2024
Alan Partin Lecture: The Genomics and Natural History of Visible vs. Invisible CancersLaurence Klotz, MD, FRCSC2024
Putting Germline Testing into Context: A Primer and Current KnowledgeAlan H. Bryce, MD2024
Micro Ultrasound and MRI of the ProstateGerald L. Andriole, Jr., MD2024
The Battle of Biopsies: Results of a Multi-institutional Randomized Trial of Transrectal vs Transperitoneal Prostate BiopsyMohamad E. Allaf, MD2024
Early Continence Recovery after Robotic Assisted Radical Prostatectomy: The Role of Prostatic ShapePierluigi Bove, MD2024
Renal Ablation Technologies – Impact on the Treatment of Small Renal MassesThomas W. Jarrett, MD2024
PCa Commentary | Volume 193 - September 2024Edward Weber, MD2024
Updates on the RADAR SeriesE. David Crawford, MD2024
mpMRI of the Prostate and Correlation with CT +/- PSMA PET findings: Prostate Imaging Lessons for the UrologistDesencia E. Thomas, MD2024
Counseling Men with Favorable Intermediate Risk Disease- How to Advise, What Evidence Do You Share?Dov Kadmon, MD2024
Advances in Treating the Primary and Sites of Metastases in Oligometastatic Prostate CancerJason A. Efstathiou, MD, DPhil2024
Getting Started with Focal Therapy for Prostate CancerIzak Faiena, MD, MSCR2024
Update on the State of the Art Radiation Treatments for Prostate CancerPeter F. Orio III, DO, MS, FABS, FASTRO2024
Rectal Spacing for All Forms of Radiation: Cryotherapy, HIFU, Tesla, and MorePeter F. Orio III, DO, MS, FABS, FASTRO2024
Role of Precision Medicine in the Diagnosis and Management of Prostate CancerLeonard G. Gomella, MD, FACS2024
Biomarkers for Radiation TherapyPeter F. Orio III, DO, MS, FABS, FASTRO2024
How Well Do You Know Doublets and Triplets? - A Pop QuizMarc B. Garnick, MD2024
Telesurgery for Prostate Cancer: Where Are We in 2024? - This Is a Novel Topic and Gaining Traction Around the WorldDavid M. Albala, MD2024
Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future DirectionsAndrew W. Hahn, MD2024
Advances and Controversies in Theranostic Approaches to Prostate CancerEric M. Rohren, MD, PhD, FACR2023
Quality Improvement American College of Radiology Program in Prostate MRIAndrei Purysko, MD2023
KEYNOTE LECTURE: Too Little or Just Enough? The Role of Focal Therapy in ProtecT EraFreddie Hamdy, MD2024
The Battle of Biopsies: Results of a Multi-institutional Randomized Trial of Transrectal vs Transperitoneal Prostate BiopsyMohamad E. Allaf, MD2024
Micro Ultrasound and MRI of the ProstateGerald L. Andriole, Jr., MD2024
Integrating Care in Advanced Prostate CancerJohn W. Davis, MD, FACS2024
PARPi in mCRPCDaniel P. Petrylak, MD2024
PCa Commentary | Volume 192 - August 2024Edward Weber, MD2024
Focal versus Radical - At What CostDeepika Reddy, MD2024
Panel Discussion: PROSTATE SAMPLING AND SPACINGSrinivas Vourganti, MD2024
Pelvic Lymph Node Dissection During Radical Prostatectomy: Should We Do It?Isaac Y. Kim, MD, PhD, MBA2023
Panel Discussion: Didactic Session 7: Emerging TherapiesWilliam K. Oh, MD2023
Panel Discussion: Didactic Session 6: Advanced DiseaseWilliam K. Oh, MD2023
Case Studies in Advanced Prostate CancerWilliam K. Oh, MD2023
Panel Discussion: Didactic Session 4: Advances in RadiotherapySteven J. Frank, MD, FACR, FABS, FASTRO2023
Panel Discussion: Didactic Session 3: Focal TherapyArvin K. George, MD2022
Panel Discussion: Didactic Session 2: RadioprotectionLeonard S. Marks, MD2022
Panel Discussion: Didactic Session 1: Prostate BiopsyJames A. Eastham, MD, FACS2022
Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET ImagingAndrew W. Hahn, MD2024
Clinical Trials in Focal Therapy - Endpoint, Design, UpdatesTaimur Shah, MD2024
Is It Cold in Here? Focal Cryoablation for Prostate CancerLouis Krane, MD2024
Pew Pew! Laser Applications for Prostate AblationSteven E. Canfield, MD2024
Versatile Irreversible ElectroporationPhillip Stricker, MBBS2024
Pearls and Pitfalls Of PSMA PETSandeep Arora, MBBS, FSAR2023
The Risks and Benefits of Rectal SpacersSrinivas Vourganti, MD2024
Imaging and Biomarkers in Patient Selection for Focal AblationEzekiel Becher, MD2024
The When and How of Post-Ablation SurveillanceSoroush Rais-Bahrami, MD2024
Novel Molecular Tracers for Prostate ImagingBaris Turkbey, MD2023
Artificial Intelligence for Improving Prostate Cancer Diagnosis and TreatmentMartin Eklund, PhD2023
The Prostate Cancer ProteomePaul C. Boutros, PhD, MBA2024
PSMA PET ImagingPhillip J. Koo, MD2023
Integration of Histology, Genomics and Proteomics with MRISteven S. Raman, MD2024
Why We Need Organized Screening ProgramsHendrik Van Poppel MD, PhD2024
Welcome and Opening RemarksFaina Shtern, MD2024
Embracing a New Normal of Innovation: Radiation Oncology Advances in Precision Diagnosis and Treatment for Prostate CancerSteven E. Finkelstein, MD, DABR, FACRO2024
Panel Discussion Part Two: PROSTATE IMAGINGBaris Turkbey, MD2024
Case Discussion 1 - Patient and Treatment SelectionAbhinav Sidana, MD, MPH, FACS2024
The Application of Stimulated Raman Histology to Urologic Malignancies - Human and Artificial Intelligent AssessmentJames S. Wysock, MD, MSc2024
The Baked Potato (Prostate): Focal Microwave AblationPeter K.F. Chiu, MD, PhD, FRCSEd2024
High Intensity Focused Ultrasound Ablation Outcomes - TR, In BoreBehfar Ehdaie, MD, MPH2024
Margin Call: Focal vs. Regional AblationPreston C. Sprenkle, MD2024Localized/Locally Advanced, Prostate Cancer
PSMA Imaging as a Biomarker for Early Stage Prostate CancerRobert E. Reiter, MD, MBA2024
Update on Robotic Prostatectomy PSMA Scanning - Setting up a Program in Your PracticeDavid M. Albala, MD2024
Imaging for High-Risk Prostate Cancer: The Guidelines and BeyondJay D. Raman, MD2023
Infections Following Prostate Needle Biopsy – An Evidence-Based Approach to Tackling A Common ProblemJay D. Raman, MD2023
PCa Commentary | Volume 191 - July 2024Edward Weber, MD2024
An Expert Discussion of Testosterone Nadir and Clinical Outcomes in Patients with Advanced Prostate Cancer: A Post Hoc Analysis of Triptorelin Pamoate Phase III StudiesNeal D. Shore, MD, FACS
The Importance of Diagnosing and Treating Oligometastatic Prostate Cancer and ADT UsageMarc B. Garnick, MD2024
International, Multi-Disciplinary Consensus on Treatment of Advanced Prostate CancerSilke Gillessen, MD2024
Radiation Therapy Planning Using Advanced Imaging – Pearls and PitfallsSean P. Collins, MD, PhD2024
Focal Therapy for Prostate Cancer: Role of BrachytherapyDaniel Y. Song, MD2024
Understanding Metastatic Castration-Resistant Prostate CancerShell Liang, PhD2024
PCa Commentary | Volume 190 - June 2024Edward Weber, MD2024
Emergent Applications of Prostate Cancer Mapping with Artificial IntelligenceAlan Priester, PhD2024
Convergent Therapeutics: Next-Generation Targeted RadiotherapiesPhilip Kantoff, MD2024
Clinical Evaluation and Management of Men with Localized and Recurrent Prostate CancerJan Philipp Radtke, MD, MBA2024
Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging Based Short and Intermediate OutcomesDaniel Margolis, MD2024
Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate CancerAndrew W. Hahn, MD2024
Clinical Trial of STHLM3 and MRITobias Nordstrom, MD, PhD2024
Prostate Cancer Screening Practices in EuropeMonique Roobol, PhD, MSc2024
NCCN Guidelines for Early Detection of Prostate Cancer 2023Preston C. Sprenkle, MD2024
Advanced Prostate Cancer: Sequencing of TreatmentArnulf Stenzl, MD2024
The Microbiome and Prostate CancerMichael A. Liss, MD, PhD, MAS, MBA, FACS2024
Multi-modality (MRI+PET) Imaging for Improved Detection of csPCDavid Margel, MD, PhD2024
Combination of Prostate Ablation with Systemic Therapy for Management of ProstateAbhinav Sidana, MD, MPH, FACS2024
Patient Selection for Prostate Cancer Focal Therapy: Urologic PerspectiveGeoffrey Sonn, MD2024
PSMA in Metastatic Prostate Cancer: Imaging as BiomarkerLouise Emmett, MD, FAANMS, FRACP, MBChB2024
Doublets and Triplets: Patient SelectionDavid S. Morris, MD, FACS2024
Diagnostic and Prognostic Biomarkers for Prostate CancerEricka Bagi, BSN, RN2024
Precision Diagnostics and Emerging Treatment StrategiesDavid M. Nanus, MD2024
Novel Targeted Treatment and Its Integration with Precision DiagnosticsDaniel P. Petrylak, MD2024
Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)Peter Albers, MD2024
PCa Commentary | Volume 189 - May 2024Edward Weber, MD2024
Micro-ultrasound and MRI for Visualization of Prostate CancerWayne G. Brisbane, MD2024
The Modern (Overlapping) Relationship Between Active Surveillance and Focal TherapyMark Emberton, MD, FRCS2024
LuPSMA: Imaging-Based Patient Eligibility Role of Tumor Heterogeneity & FDGHossein Jadvar, MD, PhD, MPH, MBA2024
PCa Commentary | Volume 188 - April 2024Edward Weber, MD2024
Industry Perspective: Illuccix® for Gallium-68-PSMA-11 PET Imaging of Prostate CancerBradley Fehrenbach, MD, MBA2024
Focal Therapy is Now Ready for Prime TimeHashim Ahmed, MD, PhD2024
Industry Perspective: BioProtect Balloon Implant™ SystemDaniel Y. Song, MD2024
PI-RADS Standardization and Risk Assessment - Recent Advances and Future PlansClare Tempany, MB, BCh, BAO2024
Focal CryoablationMichael A. Gorin, MD2023
Focal HIFUArvin K. George, MD2023
Integrated Diagnostics (Radiogenomics) and Patient Selection and Monitoring for Active Surveillance, Surgical, and Radiation TreatmentSanoj Punnen, MD, MAS, MBA2024
Construction and Multi-Center Validation of the Radiomics Model for Non-Invasive Identification of Active Surveillance CandidatesLiang Wang, MD, PhD2024
Selection and Outcomes of Image-Guided, Minimally-Invasive TreatmentAbhinav Sidana, MD, MPH, FACS2024
PCa Commentary | Volume 186 - February 2024Edward Weber, MD2024
ADT is the Building Block for Advanced Prostate Cancer TherapyE. David Crawford, MD
Molecular Imaging: PSMA PET/CTMichael Hofman MBBS, FRACP, FAANMS, FICIS, GAICD2024
Year in Review: Emerging Data and Advances in Prostate Cancer ScreeningSigrid V. Carlsson, MD, PhD, MPH2024
Prognostic and Predictive MarkersAshley E. Ross, MD, PhD2023
MRI-Based Prostate Cancer Screening in an Era of MCEDsMark Emberton, MD, FRCS2023
PCa Commentary | Volume 185 - January 2024Edward Weber, MD2024
Prostate: Anatomic ConsiderationsThomas M. Wheeler, MD2023
Optimizing MRI Targeted Biopsy - Including Endorectal Imaging for Tumor Localization and In-Bore Biopsy for Tissue DiagnosisFergus Coakley, MD2023
Update on IMPACT – Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers and Men with Lynch SyndromeRos Eeles, PhD, FRCP, FRCR2023
PCa Commentary | Volume 184 - December 2023Edward Weber, MD2023
Prostate Cancer Detection-Integrated Clinical SolutionDonald Baker, R.T.(R)(CT)(MR)2024
The Role of Radiotherapy in Oligometastatic Prostate Cancer and How to Treat the Primary in De Novo Oligometastatic DiseaseDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2023
Testosterone to Improve the Diagnosis and Treatment of Prostate CancerMohit Khera, MD, MBA, MPH2023
Industry Perspective: Image-Guided Focal Laser Ablation for Prostate Cancer with CLS-TRANBERGSijo J. Parekattil, MD, FACS2023
Physics of Intraoperative Dose Planning for Focal BrachytherapyRen-Dih Sheu, PhD, DABR2023
PCa Commentary | Volume 183 - November 2023Edward Weber, MD2023
Novel Targeted Treatments for Metastatic DiseaseAlan H. Bryce, MD2023
Identifying Mutations and Optimizing Use of PARP InhibitorsWilliam K. Oh, MD2023
Cardiovascular Side Effects of Advanced Disease TherapiesWilliam K. Oh, MD2023
Immunotherapy in Metastatic Prostate CancerA. Oliver Sartor, MD2023
Metastatic Castrate-Resistant Prostate Cancer: Options and Possible SequencesA. Oliver Sartor, MD2023
Management of mHSPC-Singlets and Doublets and TripletsAlan H. Bryce, MD2023
Focal Brachytherapy for Prostate CancerJuanita M. Crook, MD, FRCPC2023
Transrectal Fusion BiopsyLeonard S. Marks, MD2023
PSMA Radiopharmaceuticals: Update 2023A. Oliver Sartor, MD2023
Treatment of Oligometastatic DiseaseJuanita M. Crook, MD, FRCPC2023
New Spacer Technology for Prostate Cancer Radiation TherapyPeter F. Orio III, DO, MS, FABS, FASTRO2023
Adjuvant-Salvage Radiotherapy Following ProstatectomyRichard G. Stock, MD2023
PCa Commentary | Volume 182 - October 2023Edward Weber, MD2023
The Evolution of the Role of Radical Prostatectomy in Prostate CancerLeonard S. Marks, MD2023
MRI Fusion Focal TherapyLeonard S. Marks, MD2023
Transperineal Fusion BiopsyMichael A. Gorin, MD2023
Combining Brachytherapy with SBRTRichard G. Stock, MD2023
MRI-Assisted Salvage Radiosurgery (MARS) Planning and TreatmentSteven J. Frank, MD, FACR, FABS, FASTRO2023
Sculpted Rectal Spacing for Focal BrachytherapyNelson N. Stone, MD2023
Active Surveillance: Intermediate Disease and High-Volume Grade Group 1 Prostate CancerJames A. Eastham, MD, FACS2023
Optimizing Biopsy Approach Before Precision ProstatectomyArvin K. George, MD2023
PCa Commentary | Volume 181 - September 2023Edward Weber, MD2023
PCa Commentary | Volume 180 - August 2023Edward Weber, MD2023
2023 Legislative and Regulatory Issues UpdateDavid M. Albala, MD2023
Future Directions in Smart Prostate Cancer Screening – Highlights from the 6th Annual Global Summit on Precision Diagnosis and Treatment of Prostate CancerFaina Shtern, MD2023
Appropriate Use of PSMA PET in Clinical PracticeGeoffrey B. Johnson, MD, PhD2023
Integration of Augmented Reality (AR) and Extended Reality (XR) into Urology Training and PracticeNelson N. Stone, MD2023
PCa Commentary | Volume 179 - July 2023Edward Weber, MD2023
Management of Disease Recurrence in Localized Prostate CancerLaurence Klotz, MD, FRCSC2023
Clinical Update on PSMA Diagnostics and TherapiesPhillip J. Koo, MD2023
Molecular ImagingAndrei H. Iagaru, MD, FACNM2023
Implications of the FDA Approval of Combination Talazoparib & Enzalutamide TherapyNeeraj Agarwal, MD, FASCO2022
Challenging Case Discussion Panel: Men's HealthMartin M. Miner, MD2023
Identification of Localized DiseasePeter F. Orio III, DO, MS, FABS, FASTRO2023
Multidisciplinary Approach to the Management of Advanced Prostate CancerDaniel P. Petrylak, MD2023
Implementation of Markers in Clinical PracticeDavid S. Morris, MD, FACS2023
Case Discussion: Early Detection of Prostate CancerThomas E. Keane, MD2023
Early Detection of Prostate Cancer: Navigating the Challenges in 2023E. David Crawford, MD2023
PCa Commentary | Volume 178 - June 2023Edward Weber, MD2023
Radioligand Therapy in Prostate CancerGeoffrey B. Johnson, MD, PhD2023
PSA Screening in 2023Gerald L. Andriole, Jr., MD2023
Therapeutic Radiopharmaceuticals in Prostate Cancer: What the Urologist Needs to KnowPhillip J. Koo, MD2023
Results From TRITON3Alan H. Bryce, MD2023
Review of the New Standard in Treatment and Global Issues: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis InhibitorsMarc B. Garnick, MD2023
Prostate MicroultrasoundGerald L. Andriole, Jr., MD2023
PCa Commentary | Volume 177 - May 2023Edward Weber, MD2023
MR Fusion Targeted Therapy: Emerging Management for Localized Prostate Cancer?Fernando J. Bianco, MD2023
Fusion-guided Ablation with Koelis ProMap-FTNiranjan Nayar, MHA2023
RADAR 6 & 7 | Detection of Advanced Prostate Cancer RecurrenceE. David Crawford, MD2023
Complications of Robotic Prostatectomy: Incidence, Predictors, Prevention, and ManagementJay D. Raman, MD2023
mCRPC – Inroads in Improved OutcomesDaniel P. Petrylak, MD2023
Forward Progress in Molecular Markers for Prostate CancerMatthew R. Cooperberg, MD, MPH2023
Selecting Candidates for Focal TherapyAbhinav Sidana, MD, MPH, FACS2022
Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Rana R. McKay, MD, FASCO2023
Prostate Cancer Screening in 2023Sigrid V. Carlsson, MD, PhD, MPH2023
PCa Commentary | Volume 176 - April 2023Edward Weber, MD2023
Patient's Journey: Experience with mCRPC and the Lutetium (Pluvicto) ShortageE. David Crawford, MD2022
OPTIMUM Trial – Current and Emerging Evidence Supporting 29MHz High- Precision, Real-Time Micro-UltrasoundPreston C. Sprenkle, MD2022
NCCN Guidelines for Treatment of Localized Prostate CancerKelvin A. Moses, MD, PhD, FACS2022
Modalities, Maps and Margins: Optimizing Oncologic EfficacyMark Emberton, MD, FRCS2022
Need to Know: Experience with Lutetium (Pluvicto) for Prostate Cancer TheranosticsEdwin M. Posadas, MD, FACP2022
Need to Know: The Impact of a Restricted Supply of Lutetium (Pluvicto)E. David Crawford, MD2022
Rationale for Focal TherapySamir S. Taneja, MD2022
PCa Commentary | Volume 175 - March 2023Edward Weber, MD2023
Liquid Biomarkers and MRI in Prostate Cancer – Complementary?Sanoj Punnen, MD, MAS, MBA2022
Cardiovascular Complications in Patients Undergoing ADTMarc B. Garnick, MD2022
Prostate Anatomy and Clinical Pathologic ConsiderationsThomas M. Wheeler, MD2022
ADT as Foundational Therapy, and the Need for Consensus on Consistent T Suppression, Goals, Monitoring, and Delaying Time to CRPCE. David Crawford, MD
How the Addition of Multiparametric MRI has Changed a Private Practice Setting in Prostate ScreeningRichard G. Barr, MD, PhD, FACR, FSRU, FAIUM2022
The Manogram: Role of MRI in Prostate Cancer ScreeningPeter A. Pinto, MD2022
PCa Commentary | Volume 174 - February 2023Edward Weber, MD2023
IP1-Prostagram Screening Study: Comparing PSA, MRI and UltrasoundHashim Ahmed, MD, PhD2022
PET Imaging for Selection of Focal Therapy CandidatesJérémie Calais, MD, PhD2022
Interviews with Icons – Urology Education and the Future of PCa Screening, Detection, and ManagementNeil H. Baum, MD2022
PCa Commentary | Volume 173 - January 2023Edward Weber, MD2023
Prostate MRI for the UrologistSadhna M. Verma, MD, MBA, FSAR2022
Prostate Biopsy Considerations – Transrectal vs. PerinealGuilherme Godoy, MD, MS2022
Deep Learning Accelerated MRI of the Prostate for Increased Throughput and MRI-targeted Biopsy for Improved Prostate Tissue Sampling - Sponsored by Siemens HealthineersMukesh Harisinghani, MD2022
Impact of PCa Risk on PCa Early DetectionA. Karim Kader, MD, PhD2023
Prostate Micro-ultrasoundGerald L. Andriole, Jr., MD2023
PSMA PET Imaging: A Primer for the Urologist or OncologistPhillip J. Koo, MD2022
PCa Commentary | Volume 172 - December 2022Edward Weber, MD2022
Virtual Genetics Board for Enhancing Knowledge and Practice of Prostate Cancer Genetic Testing - The ENGAGEMENT StudyVeda N. Giri, MD2022
PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer - AUA Abstract ReviewE. David Crawford, MD2022
New Standards of Care for Advanced Prostate CancerWilliam K. Oh, MD2022
Utilizing Molecular Characterization of Invasive Bladder Cancer: What It Means Now and In the FutureJennifer A. Linehan, MD2022
Appropriate Use of PSMA PET in Clinical PracticeThomas Hope, MD2022
Advanced Prostate Cancer Clinical Trials UpdatesDavid S. Morris, MD, FACS2022
PCa Commentary | Volume 171 - November 2022Edward Weber, MD2022
Current Status of PSMA PET in the United StatesPhillip J. Koo, MD2022
Transperineal Mapping Biopsy: Does Technique Matter?Nelson N. Stone, MD2022
Genetic Testing for Identifying Who is at Risk of Prostate Cancer and Lethal CancerJianfeng Xu, MD, MS, MPH, DrPH2022
Brachytherapy: The Royal Flush of Radiation Treatment for Men with High-Risk Prostate CancerMira Keyes, MD, FRCPC, FABS2022
Updates in Prostate Cancer BiomarkersMatthew R. Cooperberg, MD, MPH2022
How to Integrate PSMA PET Findings Into Treatment AlgorithmsJérémie Calais, MD, PhD2022
PCa Commentary | Volume 169 - September 2022Edward Weber, MD2022
Germline Genetics and Prostate Cancer Evolution and AggressivityPaul C. Boutros, PhD, MBA2021
Brachytherapy: What's New and Where are We Going?Peter J. Rossi, MD, FABS, FASTRO2022
Personalization of Prostate Cancer Care Through Integration of DataIlya Gipp, MD, PhD2021
Experience with 18F-rhPSMA7.3 for Prostate CancerWolfgang Weber, MD2021
Just the Beginning: What's Next for Radiotheranostics in Prostate Cancer?Geoffrey B. Johnson, MD, PhD2022
Doctor Knows Best? Why Prostate Cancer Care Must Be Transformed Into Digital HealthMichael H. Johnson, MD, FACS2021
PSMA PET-CT: Clinical ApplicationsNeal D. Shore, MD, FACS2022
Prostate High Dose-Rate (HDR) Brachytherapy as Boost and MonotherapyGerard Morton, MD, FABS2021
ADT Side Effects: Cardiovascular DiseaseE. David Crawford, MD
Transurethral Ultrasound Ablation (TULSA)Robert Princenthal, MD2022
Practical Applications and Clinical Utility of PYLARIFY Injection: Implications for Urology and Radiation OncologyPhillip J. Koo, MD2022
Utilization of Focal Therapy for Patients Discontinuing Active Surveillance of Prostate Cancer: Recommendations of an International Delphi ConsensusThomas J. Polascik, MD, FACS2022
Abstract Commentary: Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan StudiesBenjamin H. Lowentritt, MD, FACS2022
Burning Questions and Controversies in the Management of Advanced Prostate Cancer PatientsScott B. Sellinger, MD, FACS2022
The Wild, Wild West of Radiation Oncology: An Update on Radiation Tools, Toys and TrialsPeter F. Orio III, DO, MS, FABS, FASTRO2022
Forward Progress in Molecular Markers in Prostate CancerMatthew R. Cooperberg, MD, MPH2022
ABS Initiatives to Enhance Training the Next Generation of BrachytherapistsDaniel G. Petereit, MD, FASTRO2021
ADT and Cognitive HealthMark A. Moyad, MD, MPH2022
Active Surveillance 2022: Who Qualifies, Who Does Not and How Should it be MonitoredLaurence Klotz, MD, FRCSC2022
Bone Health and ADTMark A. Moyad, MD, MPH2022
Racial Justice and Prostate CancerChristopher J. Kane, MD, MS, FACS2022
Industry Perspective: ConfirmMDx and Improving the Identification of Men at Risk for Clinically Significant Prostate CancerWim Van Criekinge, PhD2022
MRI-guided Transurethral Ultrasound Ablation (TULSA) for Prostate CancerLaurence Klotz, MD, FRCSC2022
Socioeconomic Aspects of Prostate BrachytherapyPeter F. Orio III, DO, MS, FABS, FASTRO2022
Highlights from the 5th Global Summit on Precision Diagnosis and Treatment of Prostate CancerFaina Shtern, MD2022
Genetic Testing & Next Generation DNA SequencingAlan H. Bryce, MD2022
PCa Commentary | Volume 166 - June 2022Edward Weber, MD2022
ADT and Brachytherapy: The Good, the Bad, and the UglyMira Keyes, MD, FRCPC, FABS2022
PCa Commentary | Volume 165 - May 2022Edward Weber, MD2022
Industry Perspective: AR-V7 Testing for Men with Advanced Stage Prostate CancerDaniel Shoskes, MD, MSc, FRCSC2022
Updates in Treatment Using ADT and Anti-AndrogensE. David Crawford, MD2022
High Intensity Focused Ultrasound for Prostate CancerHao G. Nguyen, MD, PhD2022
Role of Prostate Brachytherapy in Gleason 8-10 DiseasePeter F. Orio III, DO, MS, FABS, FASTRO2022
How to Utilize MRI for Focal Therapy PlanningSamir S. Taneja, MD2022
Focal Prostate CryotherapyThomas J. Polascik, MD, FACS2022
PSMA Targeted Therapies and the Role of the UrologistPhillip J. Koo, MD2022
Comparative Outcomes: Prostate Brachytherapy vs. EBRT vs. SBRT for Low/Intermediate Risk DiseaseMichael J. Zelefsky, MD2022
PCa Commentary | Volume 164 - April 2022Edward Weber, MD2022
Cancer Control in 1379 Men Undergoing HIFU: A Multi-institute 15-year ExperienceMark Emberton, MD, FRCS2022
Combining Therapy with SBRT and BrachytherapyRichard G. Stock, MD2022
ExactVu™ Micro-Ultrasound for Diagnosis of Prostate CancerPriya N. Werahera, PhD2022
Pathologist's Perspective on Biopsy Results: Transperineal Mapping vs. Fusion BiopsyM. Scott Lucia, MD2022
A Biochemical Definition of Cure Following Brachytherapy of Prostate CancerJuanita M. Crook, MD, FRCPC2022
Overview of the State of Genetic Testing and Future Applications in Prostate CancerBrian T. Helfand, MD, PhD2022
PCa Commentary | Volume 163 - March 2022Edward Weber, MD2021
Industry Perspective: The Oncotype DX Genomic Prostate Score Assay TestDaniel Shoskes, MD, MSc, FRCSC2022
Active Surveillance or Focal Therapy as Primary ManagementLaurence Klotz, MD, FRCSC2022
Prostate Imaging Elevated By Deep LearningMukesh Harisinghani, MD2022
Current and Emerging Role of Radiogenomics in Risk Assessment for Focal TherapyJohn Feller, MD2020
Management of Men With PI-RADS 4-5 Lesions and Negative BiopsySamir S. Taneja, MD2022
Active Surveillance: Who Qualifies, Who Does Not and How Should it be MonitoredLaurence Klotz, MD, FRCSC2022
Long-Term Outcomes with Monotherapy for LR and fIR Prostate CancerTimothy N. Showalter, MD, MPH, MBA2022
GU ASCO Symposium 2022 SummaryUlka Vaishampayan, MD2022
The Myths and Facts About Prostate BrachytherapySteven J. Frank, MD, FACR, FABS, FASTRO2022
Point-Counterpoint: Management of mCRPCRana R. McKay, MD, FASCO2022
The Sentinel Prostate Cancer Platform: Validation StudiesLaurence Klotz, MD, FRCSC2022
PSMA: Current State of the Art and Future VisionPhillip J. Koo, MD2022
Brachytherapy for Prostate CancerMira Keyes, MD, FRCPC, FABS2022
Urologic Perspective on the Current and Emerging Role of Multi-Modality Imaging and RadiogenomicsMohummad Minhaj Siddiqui, MD2022
PCa Commentary | Volume 162 - February 2022Edward Weber, MD2022
Active Surveillance - When Can You Continue Watching and When Do You Intervene?Michael A. Brooks, MD2022
Transperineal Biopsy & Classification of Risk Using Novel Gleason Pattern QuantificationBehfar Ehdaie, MD, MPH2022
Decisional Tools to Determine Need for Biopsy and Re-Biopsy in Men with Elevated PSAsGuilherme Godoy, MD, MS2020
Point-Counterpoint: Management of mCRPCAlan H. Bryce, MD2022
Point-Counterpoint: Management of mCRPC (Con)Alan H. Bryce, MD2022
Point-Counterpoint: Management of mCRPC (Pro)Rana R. McKay, MD, FASCO2020
MRI Guided Focal Laser AblationAytekin Oto, MD, MBA2022
Standard Treatments and Global PerspectiveMarc B. Garnick, MD2022
Reinforcing Consistent Testosterone Suppression in ADTE. David Crawford, MD
Local Therapy - Managing Locoregional (LR) Complications in Metastatic Prostate CancerA. Edward Yen, MD2021
Updates in mpMRIKirsten L. Greene, MD, MAS, FACS2021
PCa Commentary | Volume 161 - January 2022Edward Weber, MD2022
Changing Paradigm in Testosterone Therapy Treatment OptionsMohit Khera, MD, MBA, MPH2021
Use of MRI-Targeting Increases Overdiagnosis and OvertreatmentAndrew J. Vickers, PhD2021
Active Surveillance - When Can You Continue Watching and When Do You Intervene?Dov Kadmon, MD2022
Active Surveillance - When Can You Continue Watching and When Do You Intervene?Guilherme Godoy, MD, MS2022
Early Detection of Prostate Cancer: Navigating the Challenges in 2021E. David Crawford, MD2021
Panel Discussion – Focus on PSMAPhillip J. Koo, MD2021
Considerations to Improve Screening for Prostate CancerGerald L. Andriole, Jr., MD2021
Final Results from ACIS Trial of Apalutamide Plus Abiraterone/Prednisone in Patients with Chemo-Naive mCRPCRaoul S. Concepcion, MD, FACS2021
Updates of Changes in the Early Detection of Prostate Cancer NCCN Guidelines 2021Preston C. Sprenkle, MD2021
Urologic Perspective on the Clinical Utility of and Emerging Data on Micro-UltrasoundRafael Sanchez-Salas, MD2021
Radiologic Perspective on the Clinical Utility of and Emerging Data on Micro-UltrasoundSangeet Ghai, MD, FRCR2021
MRI: Can It Be Used to Plan Ablative Therapies?Robert E. Reiter, MD, MBA2021
PCa Commentary | Volume 160 - December 2021Edward Weber, MD2021
Emerging Role of PSMA ImagingSteven P. Rowe, MD, PhD2021
Role of ADT with RadiationSteven E. Finkelstein, MD, DABR, FACRO2021
PCa Commentary | Volume 159 - November 2021Edward Weber, MD2021
Use of Polygenic Risk Scores for Prostate Cancer ScreeningPeter R. Carroll, MD, MPH2021
Real World Utilization of Guideline Based Therapy in mCSPC: Update From the 2021 ASCO Annual MeetingNeeraj Agarwal, MD, FASCO2021
TITAN Phase 3 Trial with Apalutamide in Metastatic Castration Sensitive Prostate CancerNeeraj Agarwal, MD, FASCO2021
International Prostate Cancer Update 2021 Session Review: Next Generation Imaging - Focus on PSMAPhillip J. Koo, MD2021
The OPTIMUM Trial: 29 MHz Micro-Ultrasound vs. MRI in Diagnosis of Prostate CancerGerald L. Andriole, Jr., MD2021
Next Generation Imaging for Localization of Recurrent Prostate CancerBrian T. Helfand, MD, PhD2021
The PRONOUNCE Trial: The Cardiovascular Safety of Degarelix vs. LeuprolideThomas E. Keane, MD2021
International Prostate Cancer Update 2021 Session Review: Localized Prostate Cancer, Including ADT and Radiation OncologyLaurence Klotz, MD, FRCSC2021
Prostate Cancer Early Detection 2021Peter R. Carroll, MD, MPH2021
GUIDE - A New Initiative For a National Bio RepositoryE. David Crawford, MD2021
International Prostate Cancer Update 2021 Session Review: Biomarkers and Genetic TestingAlan H. Bryce, MD2021
Image-Guided Focal Treatment of Prostate CancerScott Eggener, MD2021
Recent Advancements in PI-RADS: mpMRI vs. bpMRIJelle Barentsz, MD, PhD2021
PCa Commentary | Volume 158 - October 2021Edward Weber, MD2021
MRI-Guided Focal Therapy: Initial Quality-of-Life and Oncologic OutcomesJames A. Eastham, MD, FACS2021
Integrating Theranostics Into a Group PracticeDavid M. Albala, MD2021
Treatment for Prostate Cancer with MRI-Guided Transurethral UltrasoundLaurence Klotz, MD, FRCSC2021
Active Surveillance in Favorable Intermediate-Risk Prostate CancerJames A. Eastham, MD, FACS2021
PSMA PET Imaging at Time of DiagnosisPeter R. Carroll, MD, MPH2021
Updates in ADT: Managing Adverse EffectsLaurence Klotz, MD, FRCSC2021
Efficacy of Enzalutamide Plus ADT in Men with De Novo (M1) mHSPC Versus Progression to mHSPC: Post Hoc Analysis of the Phase III ARCHES TrialDaniel P. Petrylak, MD2021
Focal Cryosurgery: Outcomes and ObservationsThomas J. Polascik, MD, FACS2021
Updates on PSMA Imaging and PSMA CAR T TherapyDaniel P. Petrylak, MD2021
PCa Commentary | Volume 157 - September 2021Edward Weber, MD2021
High Intensity Focused Ultrasound for Prostate Cancer: Guidelines, Complications, and OutcomesArvin K. George, MD2021
Role of PARP Inhibitors in Prostate CancerDaniel P. Petrylak, MD2021
Contemporary Brachytherapy: A View from the ABSIn Memory of Brian J. Moran, MD2021
Next Generation Imaging in Prostate Cancer - PYLARIFYE. David Crawford, MD2021
The Third Dimension in Prostate Cancer DiagnosisFrancisco G. La Rosa, MD2021
Testosterone Therapy in Men with Biochemical Recurrence and Metastatic Prostate CancerAbraham Morgentaler, MD, FACS2021
Radiation Oncology Perspective: Image-Guided Metastasis-Directed TherapySteven E. Finkelstein, MD, DABR, FACRO2021
Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate CancerDaniel J. George, MD, FASCO2021
The Prostate – Highlights of Prostate Cancer Advances As Covered in ASCO-SEPMarc B. Garnick, MD2021
Review of Sentinel Assay for Prostate Cancer DiagnosisLaurence Klotz, MD, FRCSC2021
Early Diagnosis of Prostate Cancer: A Path ForwardE. David Crawford, MD2021
PCa Commentary | Volume 156 - August 2021Edward Weber, MD2021
The Veteran's Prostate Cancer Treatment and Research ActGregory F. Murphy, MD2021
Patient Advocacy for Prostate Conditions: Advocate PerspectiveWendy L. Poage, MHA2021
Germline Genetics in Prostate CancerBrian T. Helfand, MD, PhD2021
Can We Trust TRUS Biopsies?Francisco G. La Rosa, MD2021
Prostate Cancer Risk Assessment: Focus on Early PSA and Hereditary RiskGerald L. Andriole, Jr., MD2021
Current Status of PSMA DiagnosticsJérémie Calais, MD, PhD2021
Genetic Testing and Prostate CancerRaoul S. Concepcion, MD, FACS2021
What’s New in Active Surveillance for Prostate Cancer in 2021Laurence Klotz, MD, FRCSC2021
Next Generation Imaging for Prostate CancerPhillip J. Koo, MD2021
Management of Biochemical RecurrencePeter R. Carroll, MD, MPH2021
Update on New Approaches Combining Brachytherapy with ImmunotherapySteven E. Finkelstein, MD, DABR, FACRO2021
Diet Only and Prostate CancerMark A. Moyad, MD, MPH2021
Surveillance After Image-Targeted Focal TherapyThomas J. Polascik, MD, FACS2021
Deciphering the Changing Landscape of Differential Delay in Cancer Diagnoses in Community Radiation and Medical OncologyMitchell O. Finkelstein2021
Future Trials of Lutetium-177Daniel P. Petrylak, MD2021
Role of ADT with RadiationKevin D. Healey, MS2021
Management of Oligometastatic DiseaseRobert E. Reiter, MD, MBA2021
Radium-223 Trial UpdatesDaniel P. Petrylak, MD2021
PCa Commentary | Volume 155 - July 2021Edward Weber, MD2021
Evaluation and Management of Localized and Recurrent Prostate Cancer: Genetic Cancer ProfilingAlan Pollack, MD, PhD2021
International Prostate Cancer Update 2021 Session Review: Men’s Prostate HealthE. David Crawford, MD2021
MRI-US Fusion Target Management of Prostate Cancer in the Office SettingFernando J. Bianco, MD2021
Current and Emerging Role of Radiogenomics in Risk AssessmentJohn Feller, MD2020
Pay for Performance Model to Improve Quality of Active Surveillance in Low-Risk Prostate CancerFranklin Gaylis, MD, FACS2021
Leveraging the EMR to Improve Quality in Clinical PracticeFranklin Gaylis, MD, FACS2021
Does the Radiation Dose Required to Eradicate Local Disease Differ by Gleason Grade Group?Nelson N. Stone, MD2021
Leveraging the EMR to Improve Quality in Risk Stratification for Prostate CancerFranklin Gaylis, MD, FACS2021
Screening and Prevention of Prostate Cancer 2021 (Part 3): Incorporating MRI for Early DetectionSigrid V. Carlsson, MD, PhD, MPH2021
Application of MRI Fusion Biopsy Results to Focal TherapyLeonard S. Marks, MD2021
The Role of Molecular Imaging to Improve Cancer Control Post-ProstatectomyPeter J. Rossi, MD, FABS, FASTRO2021
Screening and Prevention of Prostate Cancer 2021 (Part 2): Who Needs a Biopsy?Sigrid V. Carlsson, MD, PhD, MPH2021
Current and Emerging Imaging Tools for Improving Risk Assessment and Selection of Patients for BiopsyClare Tempany, MB, BCh, BAO2020
Screening and Prevention of Prostate Cancer 2021 (Part 1): Evidence for PSA ScreeningSigrid V. Carlsson, MD, PhD, MPH2021
PCa Commentary | Volume 153 - May 2021Edward Weber, MD2020
Does Anatomic Rectal Displacement Improve Dosimetry and Reduce Injury?Richard G. Stock, MD2021
Transrectal mpMRI Fusion BiopsyLeonard S. Marks, MD2021
Androgen Society 3rd Annual Meeting Review (Day 1)Abraham Morgentaler, MD, FACS2021
Freehand Transperineal Prostate Biopsy Under Local AnesthesiaMichael A. Gorin, MD2021
Management of Recurrent Prostate Cancer After Focal TherapyKelly L. Stratton, MD2021
The TRANSFORMER Study: Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With mCRPCSamuel R. Denmeade, MD2021
Can One Biopsy Event Determine Type and Amount of Focal Therapy Treatment?Nelson N. Stone, MD2021
Focal Therapy Compared to Radical ProstatectomySteven N. Gange, MD, FACS2021
Non-Invasive Molecular Imaging and its Impact on Management of the Localized Disease and Suspected RecurrenceAndrei H. Iagaru, MD, FACNM2021
TheraP Trial and Effectiveness of Lu-PSMA-617Daniel J. George, MD, FASCO2021
Pathologist's Perspective on Focal TherapyM. Scott Lucia, MD2021
Overview of Image-Guided, Minimally-Invasive Focal TreatmentJim C. Hu, MD, MPH2021
HIFU Bill Coding 2021Mark N. Painter, CPMA, MBS2021
Relugolix and Concomitant Treatment for Advanced Prostate CancerDaniel J. George, MD, FASCO2021
Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to SurgeryJ. Kellogg Parsons, MD, MHS, FACS2021
Brachytherapy and Focal Therapy OutcomesRichard G. Stock, MD2021
Case Study on HIFU for Prostate CancerVahan Kassabian, MD, FACS, FRCS (C)2021
Integrated Multi-Modality Diagnostic Evaluation of Prostate CancerSanoj Punnen, MD, MAS, MBA2021
Current State-of-the-Art Molecular and Multi-Modality Imaging and Theranostics of Prostate CancerWolfgang Weber, MD2021
Image-Guided Minimally-Invasive Whole Gland TreatmentSteven S. Raman, MD2021
The Case for Standard ImagingMichael L. Glodé2021
Rationale for Focal Therapy for Prostate CancerAbhinav Sidana, MD, MPH, FACS2021
Biomarkers and Clinical Decisions - Integrating with Clinical Parameters, Imaging & Prognostic InstrumentsMatthew R. Cooperberg, MD, MPH2021
Cardiovascular & Metabolic Risk Profiles of Hormonal Agents for Managing Advanced Prostate CancerCelestia S. Higano, MD2021
Active Surveillance 2021 - Patient Selection, Monitoring, and Innocuous InterventionsLaurence Klotz, MD, FRCSC2021
Castration Resistant Prostate Cancer - Developments and Challenges from 2020Emmanuel S. Antonarakis, MD2021
Active Surveillance 2021 - Imaging and BiomarkersLaurence Klotz, MD, FRCSC2021
Germline Genetics and Prostate Cancer Evolution and AggressivityPaul C. Boutros, PhD, MBA2021
Non-Metastatic CRPC: Finding Advanced Disease with Next Gen Imaging MattersGerald L. Andriole, Jr., MD2021
Future Directions in Molecular and Multi-Modality Imaging and Theranostics of Prostate CancerPhillip J. Koo, MD2021
The miR Scientific Sentinel AssayLaurence Klotz, MD, FRCSC2021
Liquid Diagnostics and Prostate CancerE. David Crawford, MD2021
HIFU Focal Therapy: Prostate Cancer - Emerging Data and Clinical Utility vs. Standard CareAndre Abreu, MD2020
New Prescribing Information on Survival Benefit for Nubeqa® (Darolutamide) ApprovedNeal D. Shore, MD, FACS2021
Active Surveillance Criteria and Follow-up ProtocolMichael A. Brooks, MD2021
High Intensity Focused Ultrasound (HIFU) Ablation in a Salvage SettingJohn H. Jurige, Jr., MD2021
Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate CancerRana R. McKay, MD, FASCO2020
The HERO Study and the Approval of RelugolixNeal D. Shore, MD, FACS2020
Current Clinical Utility of MRI and Multi-Modality ImagingMasoom Haider, MD2020
Optimize Erectile Function Following Radical ProstatectomyMohit Khera, MD, MBA, MPH2020
In My Opinion: Biomarkers for the Diagnosis of Prostate CancerMichael A. Gorin, MD2020
Pros and Cons of Perineal vs. TRUS-Guided Prostate BiopsiesE. David Crawford, MD2020
Role of MR-Targeted Prostate Biopsy in Active SurveillanceBehfar Ehdaie, MD, MPH2020
PSMA PET Imaging in Advanced Prostate CancerJérémie Calais, MD, PhD2020
Clinical Case Discussion: Metastatic Prostate Cancer and Evidence for More Precision TherapyA. Edward Yen, MD2020
PSMA PET Gallium Scan Approved by FDARobert E. Reiter, MD, MBA2020
Focal Therapy (HIFU): Functional and Oncological OutcomesMark Emberton, MD, FRCS2020
Urologic Debate Part 2: MRI vs. Molecular Markers: Which One Should I Use? Markers PerspectiveE. David Crawford, MD2020
Urologic Debate Part 1: MRI vs. Molecular Markers - Which One Should I Use? MRI PerspectiveGuilherme Godoy, MD, MS2020
Patient Selection for Focal Therapy: What is an Optimal Biopsy Strategy?Kae Jack Tay, MBBS, MRCS(Ed), MMed (Surgery), MCI, FAMS (Urology)2020
Use of Germline and Somatic Molecular Testing in Prostate Cancer DiagnosisGuilherme Godoy, MD, MS2020
Advances in Imaging: a Radiologist’s PerspectivePhillip J. Koo, MD2020
Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening StatementJoseph C. Presti, Jr., MD, FACS2020
PET Imaging for Prostate CancerGerald L. Andriole, Jr., MD2020
Trials in Neoadjuvant Therapy for Patients with High-Risk Localized Prostate CancerRana R. McKay, MD, FASCO2020
Updates in PARP Inhibition and Germline Testing in Prostate CancerAlan H. Bryce, MD2020
Updates in BrachytherapyPeter J. Rossi, MD, FABS, FASTRO2020
Panel Discussion: Next Generation Genomics and Prostate Cancer BiomarkersLeonard G. Gomella, MD, FACS2020
Updates in Focal Therapy of Prostate CancerThomas J. Polascik, MD, FACS2020
Genetics and Biomarkers for Prostate Cancer and Bladder CancerAlan H. Bryce, MD2020
Germline Testing for Active SurveillanceBrian T. Helfand, MD, PhD2020
Kaiser Permanente Prostate Cancer Risk Calculator 1.0Joseph C. Presti, Jr., MD, FACS2020
Updates in Screening: Prostate Cancer GuidelinesGerald L. Andriole, Jr., MD2020
PCa Patients on ADT- Improving Bone Health Monitoring Through Specialty Clinic CollaborationMegan E. Milne, MD2020
Genetic Risk Score for Prostate Cancer ScreeningBrian T. Helfand, MD, PhD2020
Accuracy of ExactVu™ Micro-Ultrasound for Diagnosis of Prostate CancerPriya N. Werahera, PhD2020
Improving Specificity of PSA Screening with Serum and Urine Markers - Who Doesn’t Need a Prostate Biopsy?Daniel W. Lin, MD2020
HIFU: The European ExperienceRafael Sanchez-Salas, MD2020
Clinical Implications of Genetics in Prostate CancerA. Karim Kader, MD, PhD2020
Management of mCRPC in ChinaBo Dai, MD, PhD2020
Immunotherapy TrialsDaniel P. Petrylak, MD2020
HIFU for Prostate Cancer in AsiaSunao Shoji, MD, PhD2020
Genetic Testing and Next Generation DNA Sequencing in Prostate CancerAlan H. Bryce, MD2020
Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19Richard G. Harris, MD, FACS2020
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019Veda N. Giri, MD2020
Theranostics & Radiopharmaceutical TrialsDaniel P. Petrylak, MD2020
Evaluation and Management of Recurrent Prostate Cancer Following Radiation TherapyAaron E. Katz, MD, FACS2020
GRU Challenging Case: Androgen Deprivation TherapyNeal D. Shore, MD, FACS2020
A Better Abiraterone: The Backdoor Pathway for Intracrine Androgen MetabolismJames L. Mohler, MD2020
Molecular Imaging For Staging and Advanced Disease – Axumin and PSMARobert E. Reiter, MD, MBA2020
Chemotherapy TrialsDaniel P. Petrylak, MD2020
Changing Landscape of mHSPC: New Approaches to an Old ProblemMichael S. Cookson, MD, MMHC2020
Usefulness of Adjustable Needle Sizes for BiopsiesJelle Barentsz, MD, PhD2020
Crossing the Divide from Transrectal to Transperineal BiopsyMichael A. Gorin, MD2020
Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19Richard G. Harris, MD, FACS2020
New Approaches to Combining Brachytherapy with ImmunotherapySteven E. Finkelstein, MD, DABR, FACRO2020
Genetics and Genomic Biomarkers: How Molecular Markers and mpMRI Play a RoleR. Jonathan Henderson, MD2020
Epidemiology & Genomics of Prostate Cancer in Asian MenYao Zhu, MD, PhD2020
Challenging Cases in Advanced Prostate Cancer: nmCRPCR. Jonathan Henderson, MD2020
MRI-Guided Transurethral Ultrasound Ablation (TULSA) in Patients with Localized Prostate CancerLaurence Klotz, MD, FRCSC2020
The Use of MRI to Determine the Target for Focal TherapyJelle Barentsz, MD, PhD2020
Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate CancerE. David Crawford, MD2019
29MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate BiopsiesNeal D. Shore, MD, FACS2020
Genetic Testing in Prostate CancerMohammad O. Ramadan, MD2019
Phase 1 Trial of ARV-110 in Patients with mCRPCDaniel P. Petrylak, MD2020
Anti-Androgen TrialsDaniel P. Petrylak, MD2020
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate CancerNeal D. Shore, MD, FACS2020
Panel on Androgen Deprivation Therapy: A Closer Review of the Cardiovascular RiskThomas E. Keane, MD2020
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate CancerCelestia S. Higano, MD2020
Multiparametric MRI for the Detection of Clinically Significant Prostate CancerJelle Barentsz, MD, PhD2020
The Capacity of MRI to Predict Extracapsular DiseaseJelle Barentsz, MD, PhD2020
Androgen Deprivation Therapy: A Closer Review of the Role of Anti-AndrogensThomas E. Keane, MD2020
What Role Do Markers Play in Establishing Active Surveillance or Definitive Care?Gerald L. Andriole, Jr., MD2020
Diet, Exercise + Prostate CancerDavid Utz2020
Are MRI Fusion Biopsies Necessary for Urologists?Jelle Barentsz, MD, PhD2020
Challenging Cases in Advanced Prostate Cancer- mHSPCE. David Crawford, MD2020
Next Generation Biomarkers - As Reflex, Combination, or First Line?E. David Crawford, MD2020
Radiation, Immunotherapy + the Abscopal EffectDavid Utz2020
What Does Suspicion for Prostate Cancer Mean, and What Metric Defines Prostate Cancer Risk?Jelle Barentsz, MD, PhD2020
Surgery for Recurrent Prostate CancerDavid Utz2020
Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate CancerAlan H. Bryce, MD2019
Prostate Imaging and Biopsy ControversiesNeal D. Shore, MD, FACS2020
New Concepts in Cavernous Nerve Localization and Functional Recovery after Radical ProstatectomyArthur L. Burnett II, MD, MBA, FACS2020
Cesium-131 Prostate Brachytherapy: A Single Institutional Long-Term ExperienceRonald M. Benoit, Jr., MD2020
Clinical Trial: Exercise For Metabolic DysregulationDavid Utz2020
Integrating MRI and Molecular Markers to Detect Aggressive Prostate CancerSanoj Punnen, MD, MAS, MBA2019
Technical and Diagnostic Limitations to Partial Prostate Ablation for Prostate CancerMichael O. Koch, MD2019
Advanced Prostate Cancer: What’s ChangingRichard G. Harris, MD, FACS2020
Recognizing and Managing the Side Effects of Androgen Deprivation TherapyAlicia K. Morgans, MD, MPH2019
Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS StudyE. David Crawford, MD2020
Dr. Oliver Sartor on COVID-19: This Week in New Orleans and The Race for A TreatmentDavid Utz2020
Dr. Susan Slovin: NYC + Covid-19 April 1, 2020David Utz2020
The Role of Genetic Testing in Prostate CancerA. Karim Kader, MD, PhD2020
Clinical Trial: PROVENGE® + Active SurveillanceDavid Utz2020
Sarcopenia in the Prostate Cancer PatientMark A. Moyad, MD, MPH2020
Review of the Role of MRI-Targeted Biopsy vs Systematic Biopsy in Prostate CancerMukesh Harisinghani, MD2019
Exercise and Prostate Cancer: Prevention and Bettering Outcomes in Localized and Advanced DiseaseArturo Mendoza-Valdés, MD2020
The Prostate – Most Diseased Organ in the Male BodyRyan P. Terlecki, MD, FACS2020
Urinary Health Issues Following Treatment for Prostate CancerRyan P. Terlecki, MD, FACS2020
Ethnic Disparities in Sexual Dysfunction Outcomes After Prostate Cancer Treatment: Myth or Reality?Arthur L. Burnett II, MD, MBA, FACS2020
State of the Art: Nutrition and Prostate CancerMark A. Moyad, MD, MPH2020
Transperineal Prostate Biopsy Under Local Anesthesia: Systematic and MRI-Ultrasound Fusion BiopsyPeter K.F. Chiu, MD, PhD, FRCSEd2020
Combining Radiation + ImmunotherapyDavid Utz2020
Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy (RARP): Rationale, Selection & TechniqueDaniel C. Parker, MD2019
New Approaches to Metastatic Hormone Sensitive Prostate CancerMichael S. Cookson, MD, MMHC2019
Helping Patients Navigate the World of Clinical TrialsDavid Utz2020
Prostate Cryoablation: Tips and TricksThomas J. Polascik, MD, FACS2020
Expanding the Role of Surgical Management of High-Risk Prostate CancerMichael O. Koch, MD2019
Current and Emerging Imaging Tools for Improving Risk Assessment, Selection of Patients for Biopsy, and Tissue SamplingSangeet Ghai, MD, FRCR2019
Testosterone Therapy in Men with Organ-Confined Gleason 6-7 Prostate Cancer After Radical ProstatectomyCarolyn A. Salter, MD2020
The Live Primary Cell Phenotypic Test (LPCP) for Prostate CancerDavid M. Albala, MD2019
Contrast-Enhanced Ultrasound of the ProstateEthan J. Halpern, MD2019
The Cardiovascular Effects of Orchiectomy Versus LHRH AgonistsJeremy Y.C. Teoh, MBBS, FRCSEd, FCSHK, FHKAM2020
More Arrows in Our Quiver - Targeting the Adaptive Molecular Landscape of Advanced Prostate CancerMartin Gleave, MD, FRCSC, FACS2019
Recent Clinical Radionuclide Therapy Advances in mCRPCUlka Vaishampayan, MD2020
Overview of Treatment for Advanced Prostate Cancer, including Metastatic Disease – Novel TreatmentChristopher J. Sweeney, MBBS2019
Prostate Cancer Initial Staging and Evaluation of Recurrent Disease with PSMA-Targeted PETSteven P. Rowe, MD, PhD2019
Biochemical Recurrence After Local Therapy: Assessment and ManagementPeter R. Carroll, MD, MPH2019
Treating a Patient Denied Coverage Based on Not Conforming to NCCN GuidelinesJames L. Mohler, MD2020
Molecular Imaging of Prostate CancerWolfgang Weber, MD2019
Considerations for the Clinical Impact of Next Generation Imaging in Prostate CancerAshley E. Ross, MD, PhD2019
Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Con ArgumentDavid Utz2019
Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Pro ArgumentA. Karim Kader, MD, PhD2019
Image-Guided Biopsy and TreatmentDaniel Margolis, MD2019
Standard Treatment for Advanced Prostate CancerDavid M. Nanus, MD2020
Radiation Oncology Perspective on Treatment Planning of Localized DiseaseAshesh B. Jani, MD, MSEE, FASTRO2019
Precision Radiation Therapy: Low- to Intermediate-Risk Prostate CancerMichael J. Zelefsky, MD2019
Germline Predisposition for Prostate Cancer Among African Americans and Other Minorities: What Do We Know?Curtis A. Pettaway, MD2020
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and AggressivenessColin C. Pritchard, MD, PhD2020
Prostate Cancer Screening & Genetic Testing: The NCCN PerspectiveDavid Utz2020
Current NCCN Recommendations for Prostate Cancer Genetic TestingJames L. Mohler, MD2020
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling PerspectiveScott M. Weissman, MS, LCGC2020
Next Generation Updates: Advances in Radiation Oncology: Prostate CancerDavid C. Beyer, MD2019
The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials PerspectiveWilliam L. Dahut, MD2020
Is MRI Fusion Biopsy the New Gold Standard of Diagnosis? Con ArgumentE. David Crawford, MD2019
Current Prostate Cancer Genetic Testing Capabilities and ConsiderationsRobert Pilarski, MS, LGC, MSW, LSW2020
Is MRI Fusion Biopsy the New Gold Standard of Diagnosis? Pro ArgumentA. Karim Kader, MD, PhD2019
The HERO Study and the Approval of RelugolixDaniel J. George, MD, FASCO2020
The Effect of Local Antibiogram-Based Augmented Antibiotic Prophylaxis on Infection-Related Complications Following Prostate BiopsyRaoul S. Concepcion, MD, FACS2019
ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life-Prolonging Therapy in mHSPC PatientsAndrew J. Armstrong, MD, MSc, FACP2019
Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Christopher J. Sweeney, MBBS2019
Genetic Testing in Prostate Cancer: Ethical & Legal ConsiderationsVictor R. Cotton, MD, JD2019
Radiation Oncology Perspective on Treatment of Oligometastatic DiseaseJason A. Efstathiou, MD, DPhil2019
State of the Art in “Smart” Prostate Cancer Screening: Defining the Need for Precision DiagnosticsSigrid V. Carlsson, MD, PhD, MPH2019
PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM MutationsMaha H. Hussain, MD, FACP, FASCO2019
Multi-Parametric MRIMasoom Haider, MD2019
nmCRPC: Is Navigating the M0 Space the Next Moon Shot?E. David Crawford, MD2019
RADAR III: Next Generation ImagingE. David Crawford, MD2019
Radiogenomics in Active Surveillance: How Can We Integrate mpMRI and Genomics to Monitor Prostate CancerSanoj Punnen, MD, MAS, MBA2019
Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate CancerNeal D. Shore, MD, FACS2019
Non-Invasive Molecular Imaging - FluciclovineGerald L. Andriole, Jr., MD2019
Integration of Germline Testing in Prostate Cancer ScreeningThomas J. Polascik, MD, FACS2019
Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier ScoreFred Saad, MD, FRCS, CQ, FCAHS2019
Novel Combination of Circulating miRNAs for Specific Detection in Prostate CancerFumihiko Urabe, MD, PhD2019
Prostate Cancer Genetic Testing: How to Hedge Bets in Selecting Patients for Surveillance, and When to Pull the Trigger on TreatmentMichael A. Brooks, MD2019
A Urologist's Perspective on Germline TestingMichael S. Cookson, MD, MMHC2019
Regionally Advanced Prostate CancerA. Edward Yen, MD2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate CancerNeil F. Mariados, MD2019
TITAN Study Leads to FDA Approval of Apalutamide for Patients with Metastatic Castration-Sensitive Prostate CancerKim N. Chi, MD2019
Multicenter Clinical Trial of Real-Time Prostate Cancer Diagnosis Using Optical Spectroscopy Guided Prostate BiopsyJames S. Wysock, MD, MSc2019
Image Guided Prostate BiopsyGerald L. Andriole, Jr., MD2019
Locally Advanced Prostate CancerDov Kadmon, MD2019
Current State of Exosome-Based BiomarkersJohan Skog, PhD2019
Hormone Therapy in High Risk Prostate CancerPatrick W. McLaughlin, MD2019
Discussion of FDA Industry Guidelines for Developing Gonadotropin-Releasing Hormone Analogues for Advanced Prostate CancerBen Eppard2019
Focus on Prostate Microultrasound: Fluciclovine and PSMA Gallium PETRyan S. Hsi, MD, FACS2019
Management of Localized High-Risk Prostate CancerAdam S. Kibel, MD2019
Surgery versus Radiation Therapy - A Surgeon's PerspectiveAdam S. Kibel, MD2019
Neoadjuvant Therapy for High-Risk Prostate CancerAdam S. Kibel, MD2019
Advanced PET Imaging for Prostate Cancer StagingNelson N. Stone, MD2019
The Staggering Benefit of PSA Screening in Potentially Lethal Prostate CancerPatrick W. McLaughlin, MD2019
Focal Therapy of Prostate CancerLeonard S. Marks, MD2019
Screening for Prostate Cancer: PSA: Why 1.5 is the New 4.0E. David Crawford, MD2019
Temporal Shifts in Grade and Stage of Prostate Cancer: A Whole Mount AnalysisM. Scott Lucia, MD2019
Germline and Somatic Mutations: Can They Change Therapy?William K. Oh, MD2019
FDA Guidance for Developing Gonadotropin-Releasing Hormone Analogues for Treating Advanced PCaBen Eppard2019
Transperineal Mapping Biopsy Defines Tumor Type and LocationNelson N. Stone, MD2019
Salvage Lymph Node Dissection for Prostate CancerPaul D. Maroni, MD2019
MRI-US Image Fusion Prostate BiopsyJohn F. Ward, MD, FACS2019
Does the PROMIS Trial Impact Prostate Cancer Screening?John F. Ward, MD, FACS2019
Androgen Targeted Therapy Across the Continuum of Prostate CancerE. David Crawford, MD2019
Prostate Cancer GenomicsDavid Utz2019
Progress in Prostate Cancer GradingM. Scott Lucia, MD2019
Can MRI Be Used to Select Patients for Focal Therapy or To Guide Therapy?Robert E. Reiter, MD, MBA2019
AR Resistance Mechanisms: Focusing on Variants and TestingRaoul S. Concepcion, MD, FACS2019
MRI/US Fusion BiopsyLeonard S. Marks, MD2019
Pathologist’s Perspective on Focal TherapyM. Scott Lucia, MD2019
The Importance of a Post-Treatment Biopsy in the Management of Patients Treated with Radiotherapy for Localized Prostate CancerMichael J. Zelefsky, MD2019
3DBiopsy™: Transperineal Mapping Biopsy in 2019Nelson N. Stone, MD2019
Long-term Morbidity of ADT and Radiation TherapyNelson N. Stone, MD2019
The Use of Genomic Markers and Prostate Biopsy DecisionsE. David Crawford, MD2019
New Considerations for Oligometastatic Prostate CancerRaoul S. Concepcion, MD, FACS2019
Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate CancerGerald L. Andriole, Jr., MD2019
Bone Metastases and Mortality: Can We Be Doing More?Leonard G. Gomella, MD, FACS2019
TRUS Biopsy, MRI, and PROMIS TrialPriya N. Werahera, PhD2019
Prostate Cancer Screening: The Latin American PerspectiveArturo Mendoza-Valdés, MD2019
Emerging Indications for a Novel Absorbable Hydrogel SpacerLawrence I. Karsh, MD2019
Timing of ADT with Chemotherapy in 2019Thomas E. Keane, MD2019
Summarizing the RADAR GuidelinesPhillip J. Koo, MD2018
Point Counterpoint: The Optimal Nadir T Level on ADT Is <20mg/mLJohn W. Davis, MD, FACS2019
Navigating the M0 SpaceE. David Crawford, MD2018
Second Opinion Diagnosis in Prostate PathologyFrancisco G. La Rosa, MD2019
Androgen Receptor Targeted Treatments of Prostate Cancer Slide DeckE. David Crawford, MD2019
Pivotal Trial of MRI-Guided Transurethral Ultrasound Ablation in Men with Localized Prostate CancerScott Eggener, MD2019
Prostate Cancer - No Biopsy in Case of a Normal MRISigrid V. Carlsson, MD, PhD, MPH2019
How to Optimize the Use of Prostate-specific Antigen in the Current EraSigrid V. Carlsson, MD, PhD, MPH2019
Prompt Prostate Genetic Score: A New Tool for Targeted Prostate Cancer ScreeningA. Karim Kader, MD, PhD2016, 2019
Androgen Annihilation as a New Therapeutic Paradigm in Advanced Prostate CancerR. Jonathan Henderson, MD2019
PARP in Combination with Standard-of-Care TreatmentDaniel P. Petrylak, MD2019
Focal Therapy for Localized Prostate Cancer: Is There a “Middle Ground” Between Active Surveillance and Definitive Treatment?John W. Davis, MD, FACS2019
Prostate Cancer Active Surveillance in 2019Sigrid V. Carlsson, MD, PhD, MPH2019
MicroRNA Expression Profiles Identify Clinically Significant Prostate CancerLaurence Klotz, MD, FRCSC2016, 2019
AR-V7 Predicts Response in CRPCRaoul S. Concepcion, MD, FACS2018
MR Guided BiopsyJohn C. Chang, MD, PhD2018
RADAR III | Next Generation Imaging PresentationE. David Crawford, MD2019
New Applications and Clinical Possibilities in Prostate Cancer with Micro-UltrasoundE. David Crawford, MD2019
Using High Resolution Micro-Ultrasound for Prostate Biopsies for Active SurveillanceLaurence Klotz, MD, FRCSC2019
29 MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate BiopsiesNeal D. Shore, MD, FACS2019
Navigating the M0 Space- Results of RADAR IIINeal D. Shore, MD, FACS2019
RADAR III | Next Generation ImagingE. David Crawford, MD2019
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to KnowMichael S. Cookson, MD, MMHC2018
It is Not Time to Abandon Transrectal Prostate Biopsy for Perineal BiopsyErik P. Castle, MD, FACS2018
It is Time to Abandon Transrectal Prostate Biopsy for Perineal BiopsyDavid Utz2018
Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate CancerPhillip J. Koo, MD2018
Agonists vs. Antagonists for the Treatment of Advanced Prostate CancerThomas E. Keane, MD2019
There is a Role for Currently Available Biomarkers: Genomics in the Risk Stratification of Prostate CancerDavid Utz2018
Biomarkers in Localized Prostate Cancer: Sure You Can, But Why Would You?Alan H. Bryce, MD2018
Prostate Cancer and Early Detection: Should We Follow the NCCN Guidelines?Sigrid V. Carlsson, MD, PhD, MPH2018
Prostate Cancer Screening: The NCCN PerspectiveDavid Utz2018
The USPSTF Prostate Cancer Screening Recommendation: A Swinging PendulumSigrid V. Carlsson, MD, PhD, MPH2018
The Pros of Focal Therapy for Prostate CancerJeffrey A. Jones, MD2018
Prostate Cancer Focal Therapy: Is it the Right Time for your Practice?John W. Davis, MD, FACS2018
Prostate Cancer Early Diagnosis ScreeningGuilherme Godoy, MD, MS2018
Role of MRI in the Current Management of Prostate CancerDov Kadmon, MD2018
The Pros and Cons of Imaging for Biopsy GuidanceGuilherme Godoy, MD, MS2018
The Pros and Cons of Genomic Markers for Biopsy GuidanceJohn W. Davis, MD, FACS2018
DNA Specimen Provenance Assay: Preventing Overdiagnosis of Prostate CancerTed Schenberg2018
Immunotherapy for Castration Resistant Prostate CancerDaniel P. Petrylak, MD2018
Next Generation Prostate Brachytherapy for AblationThomas J. Pugh, MD2018
A Novel Micro-Ultrasound System for Improving Transrectal Prostate BiopsyNeal D. Shore, MD, FACS2018
The Role of Targeting DNA Repair Mutations in Advanced Prostate Cancer with PARP InhibitorsDaniel P. Petrylak, MD2018
PSMA Imaging: Beyond MRI in Prostate CancerRobert E. Reiter, MD, MBA2018
Emerging Technology in Radiation Oncology: Indications for a Novel Absorbable Hydrogel SpacerSteven E. Finkelstein, MD, DABR, FACRO2018
Use of Radiopharmaceuticals: Updates on Ongoing Clinical TrialsPhillip J. Koo, MD2018
Genomic Markers and DNA Sequencing TestingDaniel W. Lin, MD2018
PCa Commentary | Volume 127 - October 2018Edward Weber, MD2018
Testosterone Replacement and Focal TherapyMohit Khera, MD, MBA, MPH2018
Mapping Pathology as a Guide to Focal Therapy: The Role of Mapping Biopsies and Tissue MarkersM. Scott Lucia, MD2018
The Future of Genomic Markers and DNA Sequencing in Prostate CancerDaniel W. Lin, MD2018
Hypofractionation for Prostate CancerDavid Utz2018
Genetic Testing for Inherited Prostate CancerLeonard G. Gomella, MD, FACS2018
FDUS 2018 - Next Generation Therapeutic Layering and SequencingLeonard G. Gomella, MD, FACS2018
FDUS 2018 - Next Generation Advanced and Castration-Resistant Prostate CancerEvan Y. Yu, MD2018
FDUS 2018 - Next Generation Imaging in Localized Prostate CancerPhillip J. Koo, MD2018
Sequencing of Adjuvant TherapiesDaniel P. Petrylak, MD2018
Prostatectomy: What is the Future?John F. Ward, MD, FACS2018
Should Testosterone Levels Influence Decision to Biopsy?Mohit Khera, MD, MBA, MPH2018
PCa Commentary | Volume 126 - September 2018Edward Weber, MD2018
Long-Term Outcomes of HDRJuanita M. Crook, MD, FRCPC2018
Long-Term Outcomes of Permanent BrachytherapyRichard G. Stock, MD2018
How Does Radiobiology Guide Dose, Fraction, and Source Selection?David Utz2018
Minimizing Morbidity and Maximizing Outcomes with ADTLaurence Klotz, MD, FRCSC2018
Neuroendocrine Tumors | Not so Rare?Josh Mailman, MBA2018
Does Radiation Therapy Favor Radical Prostatectomy in Long-Term QOL?Juanita M. Crook, MD, FRCPC2018
NET Background and TherapyArturo Loaiza-Bonilla, MD, MSEd, FACP2018
Prevention and Management of Rectal ToxicityRichard G. Stock, MD2018
Focal BrachytherapyJuanita M. Crook, MD, FRCPC2018
Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice | Interesting CasesRobert Flavell, MD, PhD2018
Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer PracticePhillip J. Koo, MD2018
Focal CryotherapyJohn F. Ward, MD, FACS2018
Adjuvant or Salvage RT Post-Radical ProstatectomyDavid Utz2018
Determining Patterns of Failure: Advanced ImagingRichard G. Stock, MD2018
Update on Prostatectomy Versus Observation TrialsGerald L. Andriole, Jr., MD2018
Changing Distribution, Size and Grade of Prostate Cancer: Whole-Mount Prostatectomy AnalysisM. Scott Lucia, MD2018
Should MRI Be Used to Monitor for AS? Pro ArgumentPeter A. Pinto, MD2018
Should MRI Be Used to Monitor for AS? Con ArgumentNelson N. Stone, MD2018
3DBiopsy™ Transperineal Mapping BiopsyNelson N. Stone, MD2018
AUA/ASTRO/SUO Guidelines on Clinically Localized Prostate CancerRiccardo Autorino, MD, PhD, FEBU2018
Biomarkers for Prostate Cancer: Whom to TreatGerald L. Andriole, Jr., MD2018
Prostate Cancer Screening: Who? Why? How?Gerald L. Andriole, Jr., MD2018
Management of Post Prostatectomy Vesicourethral StenosisChris M. Gonzalez, MD, MBA, FACS2018
Is Focal Ablation of Prostate Cancer Ready for Prime Time?David Utz2018
Radical Prostatectomy for Oligometastatic Prostate Cancer: Is There Any Benefit?Riccardo Autorino, MD, PhD, FEBU2018
Screening for Prostate Cancer: PSA: Why 1.5 is the New 4E. David Crawford, MD2018
Transperineal Prostate Biopsy: State of the ArtRoberto Miano, MD2018
Multimodal Approach to Advanced Prostate CancerMartin Gleave, MD, FRCSC, FACS2018
SpaceOAR Hydrogel - Prostate-Rectum Spacing in Radiation TherapyLawrence I. Karsh, MD2018
The LUGPA Alternative Payment Model (APM) on Newly Diagnosed PCa and the Role of Active SurveillanceR. Jonathan Henderson, MD2018
M0 Space and The SPARTAN TrialEric J. Small, MD, FASCO2018
Advanced Disease — A Real Need for Understanding and Shared CareDaniel P. Petrylak, MD2018
Integrating the AUA Guidelines into Your PracticeMichael S. Cookson, MD, MMHC2018
Bone Metastases and Mortality — Can We Be Doing More?Leonard G. Gomella, MD, FACS2018
Update on Radiopharmaceuticals— Choosing a Companion Drug to Radium-223Phillip J. Koo, MD2018
The Role of Molecular Imaging in Managing High Risk and Recurrent Prostate CancerRobert E. Reiter, MD, MBA2018
Immunotherapy 101 for the UrologistRaoul S. Concepcion, MD, FACS2018
The Role of Targeting DNA Repair with PARPDavid Utz2018
Timing of ADT and ChemotherapyThomas E. Keane, MD2018
New Considerations for Oligometastatic Prostate CancerThomas J. Pugh, MD2018
Point Counterpoint in ADT—Agonists versus AntagonistsLawrence I. Karsh, MD2018
Current Mortality Rates on Prostate Cancer PatientsJohn W. Davis, MD, FACS2018
Current Findings on High Intensity Focused Ultrasound (HIFU)Neil E. Fleshner, MD, MPH, FRCSC2018
MR/US Fusion Target Office Cryoablation: Short-term OutcomesFernando J. Bianco, MD2018
The Ups and Downs of MRI Interrogation of the GlandRobert E. Reiter, MD, MBA2018
3D Biopsy – The Complete Interrogation of the GlandNelson N. Stone, MD2018
Prostate Inflammation and Prostate Cancer: What do I need to know?J. Curtis Nickel, MD, FRCSC2018
AR-V7 in Castration Resistant Prostate CancerEmmanuel S. Antonarakis, MD2018
Prostate BrachytherapyIn Memory of Brian J. Moran, MD2018
Active Surveillance: From Biology to Bedside Who fails, why, and how can we prevent this?Laurence Klotz, MD, FRCSC2018
The Role of FSH in Prostate CancerMarc B. Garnick, MD2018
Updates on the ERSPC and the PLCO TrialsGerald L. Andriole, Jr., MD2018
The Evolution of Understanding the USPSTF: Recommendations and ControversyNeal D. Shore, MD, FACS2018
An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPCMaha H. Hussain, MD, FACP, FASCO2018
The Burden of Prostate Cancer Today and in the FuturePatrick C. Walsh, MD2018
The Role of Genetic Testing for Inherited Prostate Cancer RiskVeda N. Giri, MD2017
Molecular Diagnostic of Prostate Cancer Based on Non Invasive Liquid BiopsiesJack A. Schalken, PhD2018
Imaging of Prostate Cancer Patients Following Definitive TherapyPhillip J. Koo, MD2017
Radiogland Therapy Optimization of PSMA-Targeted RadiationScott T. Tagawa, MD2018
An Overview of MRI Guided Biopsies for Prostate CancerRobert Abouassaly, MD, MS2017
Novel Hormonal Therapies for Prostate CancerAlan H. Bryce, MD2017
MRI in the Management of Prostate Cancer: What Urologists Need to KnowMichael S. Cookson, MD, MMHC2017
Updates in Radiation Oncology: Of Brachytherapy and BeamsDavid C. Beyer, MD2017Localized/Locally Advanced, Prostate Cancer, Locally Advanced
HIFU: Ready for Prime TimeDavid C. Beyer, MD2017
HIFU is not Ready for Prime TimeErik P. Castle, MD, FACS2017Localized/Locally Advanced, Prostate Cancer
Timing and Optimization of Radium 223 in CRPCPhillip J. Koo, MD2017
Therapeutic Use of Genetic Testing in Advanced Prostate CancerAlan H. Bryce, MD2017
Prostate Cancer Survivorship: Value to Patients & ProvidersRyan P. Terlecki, MD, FACS2017Localized/Locally Advanced, Prostate Cancer
Germline and Somatic DNA Repair Defects in Prostate CancerAlan H. Bryce, MD2017
Sexual and Urinary Health After Treatment for Prostate CancerRyan P. Terlecki, MD, FACS2017Localized/Locally Advanced, Prostate Cancer
Testosterone and the ProstateE. David Crawford, MD2017
The Negative Impact of Testosterone TreatmentRyan P. Terlecki, MD, FACS2017
Erectile Dysfunction and the Detection of Subclinical Cardiovascular DiseaseRyan P. Terlecki, MD, FACS2017
The Role Of Shared Decision Making in Prostate CancerMatt T. Rosenberg, MD2017
Identifying the Toothless Lions in Prostate CancerE. David Crawford, MD2017
Biomarkers: A Way Forward with Prostate Cancer Early DetectionE. David Crawford, MD2017
Prostate Cancer: Why the Controversy?Michael S. Cookson, MD, MMHC2017
Testosterone Therapy, the FDA, and CVD Risk ControversiesMatt T. Rosenberg, MD2017
ERA 223 Study | Concerns About Using Radium-223 and AbirateroneE. David Crawford, MD2017
Prostate Physiology: The Most Diseased Organ in the Male BodyRyan P. Terlecki, MD, FACS2017
Urinary Molecular Marker Tests in Bladder Cancer: An Overview of CxbladderSiamak Daneshmand, MD2017
Q&A Ask the Expert | Re-Evaluating Patients with Gleason 8Francisco G. La Rosa, MD2017
Hereditary Prostate CancerDavid Utz2017
To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part IDavid Utz2017
To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part IINelson N. Stone, MD2017
Therapeutic Layering for Treating Castration Resistant Prostate CancerE. David Crawford, MD2017
Ask the Expert: What Are Some of the Challenges for Urologists Treating Metastatic Castrate Resistant Prostate Cancer Patients?Lawrence I. Karsh, MD2017
Ask the Expert: What Combinations of Immunotherapy for Prostate Cancer Are Most Promising?Raoul S. Concepcion, MD, FACS2017
Ask the Expert: What Combination Drugs with Radium-223 Are Best for Treating Prostate Cancer?Leonard G. Gomella, MD, FACS2017
Shared Decision MakingMatt T. Rosenberg, MD2017
Ask the Expert: Do Low Volume Metastatic Disease Patients Benefit from Early Docetaxal?Michael S. Cookson, MD, MMHC2017
Ask the Expert: Will More Individuals Over Time Be Diagnosed with Prostate Cancer?Gerald L. Andriole, Jr., MD2017
Ask the Expert: What Are Some Considerations When First Treating Prostate Cancer Patients?Daniel P. Petrylak, MD2017
What Tools Can Be Used to Predict Who Will Respond to Certain Prostate Cancer Drugs?Raoul S. Concepcion, MD, FACS2017
Ask the Expert: Should Radium-223 Be Used Earlier in Prostate Cancer Treatment?Leonard G. Gomella, MD, FACS2017
Ask the Expert: Which New Biomarkers Can Help Guide Treatment for Prostate Cancer?Daniel P. Petrylak, MD2017
Ask the Expert: Is Photodynamic Therapy Being Combined with Other Therapies?James A. Eastham, MD, FACS2017
Ask the Expert: What Changes Are Happening in Anti-Androgen Therapy for Prostate Cancer?Neal D. Shore, MD, FACS2017
Ask the Expert: Should Photodynamic Therapy Be Used as a Single or Multi-Pronged Treatment Strategy?James A. Eastham, MD, FACS2017
Ask the Expert: Which Non-Genomic Biomarkers Are Most Useful for Monitoring Patients After Initial Treatment?In memory of Alan W. Partin, MD, PhD2017
Ask the Expert: What Are the Barriers to Focal Therapy Becoming More Widely Accepted?Thomas J. Polascik, MD, FACS2017
Ask the Expert: For Which Patients Is Photodynamic Therapy Appropriate?James A. Eastham, MD, FACS2017
Ask the Expert: What Role Do Risk Stratification Tools Play in Focal Therapy?Thomas J. Polascik, MD, FACS2017
Ask the Expert: Which Non-Genomic Biomarkers Are the Most Useful for Stratifying Patients?In memory of Alan W. Partin, MD, PhD2017
Ask the Expert: What Are the Options in Treating Persistently Elevated PSA and Negative Biopsy?M. Scott Lucia, MD2017
Ask the Expert: How Can Genomic Markers Be Used Best to Stratify Which Patients to Treat?Gerald L. Andriole, Jr., MD2017
What Are Best Risk Stratification Tools When Placing Patient on Active Surveillance?Laurence Klotz, MD, FRCSC2017
Ask the Expert: Are There Genomic Tests to Determine Need for a Repeat Biopsy?M. Scott Lucia, MD2017
Should Androgen Receptor Targeting Be Given Earlier for Prostate Cancer?Charles J. Ryan, MD2017
Mortality Statistics After Prostatectomy and RadiationJohn W. Davis, MD, FACS2017
Ask the Expert: How Do Urologists and Medical Oncologists Differ in Their Approach to Prostate Cancer?Lawrence I. Karsh, MD2017
Other Side Effects: Perception vs. EvidenceNeal D. Shore, MD, FACS
Ask the Expert: What Changes Are Happening in Anti-Androgen Therapy?Neal D. Shore, MD, FACS2017
The Role of Genetic Testing and Next Generation Imaging for Prostate CancerLeonard G. Gomella, MD, FACS
Biomarkers for Localized Prostate CancerAshley E. Ross, MD, PhD2017
An Overview of the Management of Prostate Cancer with Androgen ReceptorsRaoul S. Concepcion, MD, FACS2017
What Are Ways to Improve PSA?Gerald L. Andriole, Jr., MD2017
Short Course: Prostate Cancer Prevention, Screening, and BiomarkersBen Eppard
When to Use Hormone Therapy with Radiation TherapyPatrick W. McLaughlin, MD2017
Intermittent HT, Quality of Life, and Testosterone RecoveryLaurence Klotz, MD, FRCSC2017
Testosterone and Prostate Cancer: Is There a Link?Abraham Morgentaler, MD, FACS2017
Nutrition and Prostate Cancer: What We Think We Know and What We Actually KnowStephen J. Freedland, MD2017
Patterns of Failure Following the Brachytherapy Management of Prostate CancerRichard G. Stock, MD2017
Post Prostatectomy RadiationPatrick W. McLaughlin, MD2017
Which Should We Use: Brachytherapy, Monotherapy, or Combined EBRT and BrachytherapyJuanita M. Crook, MD, FRCPC2017
Targeted Focal Therapy for Localized Prostate CancerArdeshir R. Rastinehad, DO, FACOS2017
Focal HIFUPerinchery Narayan, MD
Active Surveillance and Our Role in Local TherapyJuanita M. Crook, MD, FRCPC2017
Active Surveillance Results and Implications of Prospective StudiesLaurence Klotz, MD, FRCSC2017
Focal BrachytherapyJuanita M. Crook, MD, FRCPC2017
Urinary Morbidity: Prevention and ManagementNelson N. Stone, MD2017
The Anatomy of SuccessPatrick W. McLaughlin, MD2017
Targeted Prostate Biopsy Is the FutureArdeshir R. Rastinehad, DO, FACOS2017
3-Dimensional Image Guided BiopsyNelson N. Stone, MD2017
Association of Hypogonadism to LifestyleNelson N. Stone, MD2017
How Should We Monitor Patients During Surveillance?Michael S. Leapman, MD, MHS2017
Personalized Therapy for Prostate Cancer Due to Genetic TestingsStephen J. Freedland, MD2017
Metabolic Side Effects of ADTStephen J. Freedland, MD2017
Erectile Function After BrachytherapyNelson N. Stone, MD2017
Morbidity and Quality of Life: Brachytherapy or ProstatectomyJuanita M. Crook, MD, FRCPC2017
TRUS Biopsy: Does it Still Have a Role?Michael S. Leapman, MD, MHS2017
ADT Impact on Cardiovascular HealthJehonathan H. Pinthus, MD, PhD, FRCSC2017
Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Slide Deck from 2017 AUA SymposiumE. David Crawford, MD2017
Prostate Cancer: A Review of Current Prostate Cancer Markers and a Novel Model of OrganizationE. David Crawford, MD2017
Genetic Predictors of RadiosensitivityRichard G. Stock, MD2017
Can Genomics Improve Upon Best Clinical Risk Stratification?Michael S. Leapman, MD, MHS2017
Biomarkers: PSA, 4K, or PHI?Nelson N. Stone, MD2017
Radium-223 in Advanced DiseaseRichard G. Stock, MD
Role of Local Radiation Therapy in the Metastatic SettingRichard G. Stock, MD2017
Update on Radiopharmaceuticals: Choosing a Companion Drug to Radium-223Daniel P. Petrylak, MD2017
Novel Biomarker-Guided Treatment: PSMA, PAR, HDACs, etc.Daniel P. Petrylak, MD2017
Targeting AR in Castration-Resistant Prostate CancerRaoul S. Concepcion, MD, FACS2017
Neuroendocrine Prostate Cancer (NEPC)Jehonathan H. Pinthus, MD, PhD, FRCSC2017
New Concepts in Androgen Deprivation TherapyThomas E. Keane, MD2017
Point-Counterpoint: Early Chemotherapy is BetterDaniel P. Petrylak, MD2017
S.A.2M.2 : The Best “Natural” and Researched Heart Healthy Pills for Patients Concerned About Prostate CancerMark A. Moyad, MD, MPH2017
The Benefits and Challenges (Present and Future) for the Urologist Treating mCRPCLawrence I. Karsh, MD2017
Advanced Disease: A Real Need for Understanding and Shared CareDaniel P. Petrylak, MD2017
An Update of the European/Swedish Screening TrialDavid Utz2017
Non-genomic Biomarkers for Early Diagnosis and Prognosis Prevention of Prostate CancerIn memory of Alan W. Partin, MD, PhD2017
The "Who's" of Genomic Markers: Who to TreatGerald L. Andriole, Jr., MD2017
The "Who's" of Genomic Markers: Who to Re-BiopsyM. Scott Lucia, MD2017
The "Who's" of Genomic Markers: Who to BiopsyE. David Crawford, MD2017
Impact of the USPSTF Recommendations on ScreeningGerald L. Andriole, Jr., MD2017
What's New in Immunotherapy?Raoul S. Concepcion, MD, FACS2017
Vascular Targeted Photodynamic Therapy for Prostate TumorsJames A. Eastham, MD, FACS2017
Cryotherapy: Update on the International COLD RegistryJ. Stephen Jones, MD, FACS, MBA2017
MRI Guided Biopsy and AblationScott Eggener, MD2017
Updates in BrachytherapyMack Roach III, MD, FACR2017
Active Surveillance: Who is the Right Patient and What is the Right Protocol?Laurence Klotz, MD, FRCSC2017
Current Findings on High Intensity Focused Ultrasound (HIFU)Thomas J. Polascik, MD, FACS2017
New Horizons in Focal TherapyThomas J. Polascik, MD, FACS2017
Highlights from the 9th International Symposium on Focal Therapy and ImagingThomas J. Polascik, MD, FACS2017
Updating the Concepts of Biosynthesis Inhibitors and Anti-AndrogensNeal D. Shore, MD, FACS2017
Debate: How Should We Manage Oligometastatic Disease?Mack Roach III, MD, FACR2016
The Impact of Local Treatment of the Prostate in Patients with Newly Diagnosed Metastatic Prostate CancerPiet Ost, MD, PhD2017
Bone Targeted Agents in Metastatic Prostate Cancer: Denosumab, Bisphosphonates and Radium-223Noel Clarke, MBBS, FRCS, ChM2017
Managing Prostate Cancer in Elderly/Unfit PatientsNicolas Mottet, MD, PhD2017
EAU Guidelines for Monitoring Prostate Cancer Patients Under TreatmentNicolas Mottet, MD, PhD2017
Next Generation Sequencing of Prostate Tumors: Use of Individualized Biomarkers for Prognosis and TreatmentMartin Spahn, MD2017
Update on Mechanisms of Resistance in Castration-Resistant Prostate CancerKarim Fizazi, MD, PhD2017
Debate: Comparative Effectiveness of Surgery versus RadiationLaurence Klotz, MD, FRCSC2017
Sequencing, Combination or Individualised Treatment?Karim Fizazi, MD, PhD2017
Vitamin D and Prostate CancerThomas E. Keane, MD2017
Focal Therapy for Men with Intermediate Risk Prostate Cancer and a Solitary Lesion Should Be the Standard of CareMark Emberton, MD, FRCS2017
Predicting Survival of Men with Prostate Cancer after Radical ProstatectomyAxel Merseburger, MD, PhD2017
Prevalence of CVD and Assessment of CV Risk in Patients with Prostate CancerAlexander Lyon, MD, PhD2017
Active Surveillance or: Shrinking the Gray ZoneLaurence Klotz, MD, FRCSC2017
ADT: Mechanisms of CV DiseaseE. David Crawford, MD2017
Imaging of Metastatic Prostate Cancer: Whole Body MRI and Novel PET TechniquesAnwar R. Padhani, MBBS, FRCP, FRCR2017
The Role of PCP in Prostate Cancer Screening 2017Matt T. Rosenberg, MD2017
Current and Future Approaches to Androgen Deprivation Therapies: Focus of AntiandrogensE. David Crawford, MD2017
Role of mpMRI: Implication and ImplementationNelson N. Stone, MD2016
When to Biopsy: The Role for PSA and Novel BiomarkersStacy Loeb, MD2016
Why 1.5 is the New 4.0 for the PCP?Matt T. Rosenberg, MD2016
Prostate Cancer Screening: What We’ve Learned and Where We Should GoGerald L. Andriole, Jr., MD2016
Biomarkers in Genitourinary CancersE. David Crawford, MD2015
Historical View of Hormone Therapy: The European PerspectiveFrans M.J. Debruyne, MD, PhD2015
Highlights from the 24th International Prostate Cancer UpdateE. David Crawford, MD2014

Sort by Treatment and Special Topics

TitleSpeakerPrimary-topicTreatment-typeSpecial-topicDisease State
LDR Brachytherapy in Community Practice: Expanding Access Through Collaborative CareE. David Crawford, MD2026RadiationProstate Cancer
Cardiovascular Risk During Systemic Therapy for Prostate CancerE. David Crawford, MD2026Systemic TherapyProstate Cancer
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: A Multidisciplinary Case ReviewDavid S. Morris, MD, FACS2026Systemic TherapyPSMA PET Imaging, Bone Metastases/Bone Health, Molecular ProfilingProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
PET Tumor Board: Discordant PSMA and FDG PET Findings in Concurrent Adenocarcinoma and Neuroendocrine Prostate CancerE. David Crawford, MD2025Imaging & DiagnosticsProstate Cancer
PET Tumor Board: Negative PSMA PET Imaging in Biochemical Recurrence with Incidental Detection of Primary Lung AdenocarcinomaE. David Crawford, MD2026Imaging & DiagnosticsProstate Cancer, Biochemical Recurrence (BCR)
PARP Inhibitors and Genomic Testing in Metastatic Prostate Cancer: Lessons from TALAPRO-3E. David Crawford, MD2026Systemic TherapyHormone Therapy, Chemotherapy, Targeted TherapyMolecular Profiling, Clinical TrialsProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
Targeting Epigenetic Resistance in Advanced Prostate Cancer: BET and DNMT InhibitionE. David Crawford, MD2026Systemic TherapyMolecular Profiling, Clinical TrialsProstate Cancer, Metastatic Castration-Resistant (mCRPC)
Top 10 ASTRO 2025 Studies: Prostate and Bladder Cancer HighlightsSherief H. Gamie, MD, PhD2026
Germline and Somatic Testing in Prostate CancerGennady Bratslavsky, MD2026Prostate Cancer
Highlights of AUA, GU ASCO, ASCO, and ASTROHanan Goldberg, MD, MSc2026Clinical TrialsBladder Cancer, Prostate Cancer, Renal Cancer
PCa Commentary | Volume 217 - September 2026Edward Weber, MD2026Systemic TherapyProstate Cancer
How Do We Protect Quality of Life in the Era of Intensification?Andrew W. Hahn, MD2026Prostate Cancer
Are We Overusing Combination Therapy in mHSPC?Marijo Bilusic, MD, PhD2026Systemic TherapyProstate Cancer, Localized
Treatment after AR Pathway Inhibition (ARPI) + Radioligand Therapy (RLT)Andrew W. Hahn, MD2026Systemic TherapyHormone Therapy, Radiopharmaceutical/Radioligand Therapy, Chemotherapy, Immunotherapy, Targeted TherapyBone Metastases/Bone Health, Molecular Profiling, Clinical TrialsProstate Cancer, Metastatic Castration-Resistant (mCRPC)
How Aggressive Should We Be in Oligometastatic Disease?Hanan Goldberg, MD, MSc2026RadiationHormone Therapy, Ablative/Focal TherapyPSMA PET Imaging, Clinical TrialsProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
State-of-the-Art: Is Testosterone the King?Abraham Morgentaler, MD, FACS2026Systemic TherapyHormone TherapyClinical TrialsProstate Cancer
Immunotherapy When Nothing Else Works: Rational or Irrational Approach?Susan F. Slovin, MD, PhD2026Systemic TherapyMolecular Profiling, Clinical TrialsProstate Cancer, Metastatic Castration-Resistant (mCRPC)
Can Imaging Replace Biopsy in Selected Prostate Cancer Patients?Sherief H. Gamie, MD, PhD2026Imaging & DiagnosticsPSMA PET Imaging, Clinical TrialsLocalized/Locally Advanced, Prostate Cancer
History and Challenges of Early Detection of Prostate CancerE. David Crawford, MD2026Imaging & DiagnosticsLocalized/Locally Advanced, Prostate Cancer
Is PSA Screening Still Broken or Finally Fixed?Sean P. Collins, MD, PhD2026Imaging & DiagnosticsMolecular ProfilingLocalized/Locally Advanced, Prostate Cancer
Health: Exercise, Diet, and Drugs in Prostate CancerLogan G. Briggs, MD2026Systemic TherapyClinical TrialsProstate Cancer
PCa Commentary | Volume 216 - August 2026Edward Weber, MD2026Imaging & DiagnosticsOther Targeted TherapyBone Metastases/Bone HealthProstate Cancer
Why Low-Dose-Rate Brachytherapy Deserves a Second LookE. David Crawford, MD2026RadiationHormone Therapy, Radiopharmaceutical/Radioligand TherapyProstate Cancer, Localized, Locally Advanced
EMPIRE-2 Trial: Optimizing Molecular Imaging for Biochemical Recurrence After ProstatectomyE. David Crawford, MD2026Imaging & Diagnostics, RadiationPSMA PET Imaging, Molecular ProfilingProstate Cancer, Biochemical Recurrence (BCR)
The Reality of Real World DataE. David Crawford, MD2026Clinical Trials
Quality of Life, Adherence, and Adverse Events Among Patients with Advanced Prostate Cancer Treated with Relugolix: 6-Month Results of the OPTYX Multicenter RegistryRana R. McKay, MD, FASCO2025Systemic TherapyHormone TherapyClinical TrialsProstate Cancer, Metastatic Castration-Resistant (mCRPC)
The ARACOG Study: Neurourologic CognitionE. David Crawford, MD2026Prostate Cancer
Understanding PTEN Loss and the CAPItello-281 Trial in Metastatic Hormone-Sensitive Prostate CancerE. David Crawford, MD2026Systemic TherapyTargeted TherapyMolecular Profiling, Clinical TrialsProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
Proven Science, Evolving Practice: The Role of Confirm mdx in Modern Post-Negative Biopsy ManagementJose De La Cerda, III, MD, MPH2026Prostate Cancer
PTEN Loss and AKT Inhibition in Metastatic Prostate CancerE. David Crawford, MD2026Prostate Cancer
PCa Commentary | Volume 214 - June 2026Edward Weber, MD2026Prostate Cancer
Suffering in Silence: The Unspoken Burdens of Informal CaregiversReena W. Cherry, MS, PA-C2025
My Journey to Focal Therapy of Prostate CancerHerbert Lepor, MD2026SurgeryAblative/Focal TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
Controversies with Testosterone TherapyMohit Khera, MD, MBA, MPH2026Systemic TherapyHormone TherapyClinical TrialsProstate Cancer, Metastatic Castration-Resistant (mCRPC)
Prostate Cancer Screening Updates and PSA Risk StrategiesMichael A. Liss, MD, PhD, MAS, MBA, FACS2026Imaging & DiagnosticsMolecular ProfilingLocalized/Locally Advanced, Prostate Cancer
Proactive Management of Post-Prostatectomy Incontinence and Erectile DysfunctionKathleen M. Colella, MSN, APN-CNP, FAUNA2025
Radioligand Therapy UpdateRobert E. Reiter, MD, MBA2026Systemic TherapyRadiopharmaceutical/Radioligand TherapyClinical TrialsProstate Cancer, Metastatic Castration-Resistant (mCRPC)
Penile Rehabilitation After Prostate Cancer: Lessons Learned from Protocol Development and ResearchHelen L. Bernie, DO, MPH2026Systemic TherapyHormone TherapyClinical TrialsProstate Cancer
The Undecided PCA Consult: Optimized Counseling, Treatment Choices, and Avoiding Decision RegretJonathan D. Tward, MD, PhD, FASTRO2026SurveillanceProstate Cancer, Locally Advanced
Brian J. Moran Distinguished Lecture: Prostate Brachytherapy: Why Cure Doesn’t Seal the DealGrgur Mirić, MD, FACR, FABS2026
Biomarkers in Advanced DiseaseMary-Ellen Taplin, MD2026Imaging & DiagnosticsHormone TherapyMolecular ProfilingProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
Salvage Nodal Radiotherapy in the PET Era: Long-Term OutcomesBrian J. Davis, MD, PhD, FABS2026SurveillanceAblative/Focal TherapyPSMA PET ImagingProstate Cancer, Biochemical Recurrence (BCR)
Practical Selection for Doublet versus Triplet TherapyDaniel P. Petrylak, MD2026Systemic TherapyHormone TherapyMolecular ProfilingProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
Testosterone and Prostate Cancer: From Dogma to DataHelen L. Bernie, DO, MPH2026Systemic TherapyHormone TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
PCa Commentary | Volume 213 - May 2026Edward Weber, MD2026RadiationTargeted TherapyClinical TrialsProstate Cancer, Biochemical Recurrence (BCR)
Salvage Radiation After Radical Prostatectomy: Treat Immediately or Observe?Peter J. Rossi, MD, FABS, FASTRO2026RadiationHormone TherapyPSMA PET ImagingProstate Cancer, Biochemical Recurrence (BCR)
A Look at Oligometastatic Disease: Metastasis-Directed Therapy Versus SystemicJonathan D. Tward, MD, PhD, FASTRO2026RadiationAblative/Focal TherapyClinical TrialsProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
MTI in Biochemical Recurrent Disease: What Threshold, Which Images?Peter F. Orio III, DO, MS, FABS, FASTRO2026SurveillancePSMA PET ImagingLocalized/Locally Advanced, Prostate Cancer
Selection and Management for Locally Advanced Disease Declining Clinical TrialsMary-Ellen Taplin, MD2026Systemic TherapyHormone TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
Avoiding Monotherapy: Any Progress?Andrew W. Hahn, MD2026Systemic TherapyHormone TherapyProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
Alternate Therapy UpdatesDaniel P. Petrylak, MD2026Imaging & DiagnosticsHormone TherapyPSMA PET ImagingProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
Rethinking Focal Therapy: Whole-Gland Ablation for Select PatientsAbhinav Sidana, MD, MPH, FACS2026Systemic TherapyAblative/Focal TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
Salvage RARP Post AblationJohn W. Davis, MD, FACS2026SurgeryProstate Cancer, Biochemical Recurrence (BCR)
Case Discussions: Cases I Try to AvoidBehfar Ehdaie, MD, MPH2026Systemic TherapyAblative/Focal TherapyLocalized/Locally Advanced, Prostate Cancer
MRI-Assisted Radiosurgery (MARS) for LDR/HDR/EBRT for Prostate Cancer TreatmentSteven J. Frank, MD, FACR, FABS, FASTRO2026RadiationLocalized/Locally Advanced, Prostate Cancer
Novel Targeted Treatments for Metastatic Prostate CancerEvan Y. Yu, MD2025Systemic TherapyTargeted TherapyClinical TrialsProstate Cancer, Metastatic Castration-Resistant (mCRPC)
mCRPC: Lu-177 PSMA and BeyondWilliam K. Oh, MD2025Systemic TherapyRadiopharmaceutical/Radioligand TherapyPSMA PET ImagingMetastatic Castration-Resistant (mCRPC)
RARP Checklist for Early Career Efficiency and Troubleshooting SkillsJohn W. Davis, MD, FACS2026SurgeryLocalized/Locally Advanced, Prostate Cancer
Cardiovascular Side Effects of New Hormone Therapies for Prostate CancerWilliam K. Oh, MD2025Systemic TherapyHormone TherapyProstate Cancer, Metastatic Castration-Resistant (mCRPC)
Which PSMA Radiotracer is Best for Which Setting?Alberto Vargas, MD2025Imaging & DiagnosticsPSMA PET ImagingProstate Cancer
High Resolution Micro Ultrasound: Can It Replace MRI?Laurence Klotz, MD, FRCSC2026Imaging & DiagnosticsLocalized/Locally Advanced, Prostate Cancer
What to do with Positive PSMA PET Detected Nodes?Christian P. Pavlovich, MD2026Imaging & DiagnosticsHormone TherapyPSMA PET ImagingProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
Focal Therapy Update: Selection, Outcomes, TrialsBehfar Ehdaie, MD, MPH2026Systemic TherapyAblative/Focal TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
Salvage Post Radiation: When Can More Radiation Be Offered?Steven J. Frank, MD, FACR, FABS, FASTRO2026RadiationAblative/Focal TherapyClinical TrialsProstate Cancer, Biochemical Recurrence (BCR)
Current and Planned NRG Prostate Cancer TrialsJeff M. Michalski, MD, MBA, FACR, FASTRO2026RadiationHormone TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
Optimal Management of Biochemical RecurrenceOscar B. Goodman, Jr., MD, PhD2025Systemic TherapyHormone TherapyMolecular ProfilingProstate Cancer, Biochemical Recurrence (BCR)
What Type of Scanning Should Be Done in High-Risk Patients?Alberto Vargas, MD2025Imaging & DiagnosticsPSMA PET ImagingLocalized/Locally Advanced, Prostate Cancer
Risks and Complications of Rectal SpacersJohn E. Sylvester, MD, FABS2025
Hormone-Sensitive Metastatic Prostate Cancer: 1, 2, or 3 Drugs?Evan Y. Yu, MD2025Systemic TherapyHormone TherapyClinical TrialsProstate Cancer, Metastatic Castration-Resistant (mCRPC)
Radiation in the Treatment of Oligometastatic Nodal DiseaseBrian J. Davis, MD, PhD, FABS2025RadiationHormone TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
Genetic Testing: Utility Through the Disease Life CycleBrian T. Helfand, MD, PhD2026Imaging & DiagnosticsMolecular ProfilingLocalized/Locally Advanced, Prostate Cancer
Update on Racial Disparities in PSA Screening and DetectionYaw A. Nyame, MD, MS, MBA2026SurveillanceLocalized/Locally Advanced, Prostate Cancer
Use of Biomarkers: Genomic Testing to Delete ADT with RadiationJonathan D. Tward, MD, PhD, FASTRO2026Imaging & Diagnostics, Systemic Therapy, RadiationHormone TherapyMolecular Profiling, Clinical TrialsLocalized/Locally Advanced, Prostate Cancer
Robotic-Assisted Radical Prostatectomy (RARP)John W. Davis, MD, FACS2026SurgeryAblative/Focal TherapyLocalized/Locally Advanced, Prostate Cancer
Pelvic Nodal Irradiation in the Era of SBRTJonathan A. Haas, MD2025RadiationHormone TherapyPSMA PET ImagingProstate Cancer
Advances in Digital Pathology and Artificial IntelligenceM. Scott Lucia, MD2025Imaging & DiagnosticsMolecular ProfilingLocalized/Locally Advanced, Prostate Cancer
Genomic Testing: Current Value in the Era of MRI and Clinical Prognostic FactorsMatthew R. Cooperberg, MD, MPH2026
Focal Therapy: Bridging a Treatment Gap and Building a Framework for SuccessKyrollis Attalla, MD2025Systemic TherapyAblative/Focal TherapyLocalized/Locally Advanced, Prostate Cancer
Radiation Therapy: When Should Hormone Therapy Be Used and for How Long?Nelson N. Stone, MD2025RadiationHormone TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
Stereotactic Body Radiation Therapy (SBRT) vs Radical ProstatectomyJonathan A. Haas, MD2025
How to Biopsy for Focal Therapy and Determine FailureNelson N. Stone, MD2025
Elevated PSA with Prior Negative Biopsy: When to Repeat versus ObserveMatthew R. Cooperberg, MD, MPH2026Imaging & DiagnosticsMolecular ProfilingLocalized/Locally Advanced, Prostate Cancer
PSA Screening in 2026: Updates on MRI and Adjunct Biomarker UseYaw A. Nyame, MD, MS, MBA2026
PSMA PET at Low PSA: Managing a Solitary Suspicious Lesion After Radiation and ADTE. David Crawford, MD2025
Borderline Molecular Targeted Imaging Results: Case StudiesBrian T. Helfand, MD, PhD2026Imaging & DiagnosticsHormone TherapyPSMA PET ImagingProstate Cancer, Biochemical Recurrence (BCR)
Emerging Molecular Targeted Imaging AgentsRobert E. Reiter, MD, MBA2026
Preserving Post-Prostatectomy Sexual Function: Pills, Pumps, or InjectionsRyan Nasseri, MD2025
Advantages of Prostate Cancer Rectal SpacersBrian J. Davis, MD, PhD, FABS2025
SBRT and BrachytherapyRichard G. Stock, MD2025
Novel Indications for Molecular Targeted Imaging (Focus on PSMA PET)Scott T. Tagawa, MD2026Imaging & DiagnosticsRadiopharmaceutical/Radioligand TherapyPSMA PET ImagingProstate Cancer, Non-metastatic Castration-Resistant (nmCRPC)
Transperineal Fusion Prostate BiopsiesLisa Cunningham, APRN, NP-C2025
Interpreting PSMA PET After Prostatectomy: A Case of Missed RecurrenceE. David Crawford, MD2025
ADT and Cardiovascular Risk: Insights from the REVELUTION StudySagar A. Patel, MD2025Systemic TherapyHormone TherapyClinical TrialsLocalized/Locally Advanced, Prostate Cancer
Optimal Patient Selection and Exclusion for MTIDavid M. Albala, MD2026
When Not to Treat with Androgen Deprivation TherapyMary-Ellen Taplin, MD2026
Panel Discussion Session 1: TechCon: AI and Novel Technologies in Prostate CancerChristian P. Pavlovich, MD2026
MRI-Targeted Biopsy Alone: Precision Without RedundancyEvan Kovac, MD, CM, FRCSC2025
Biopsy Specimen Handling and Integrity: Is it Time for a System Change?M. Scott Lucia, MD2025
Navigating Hormone Therapy in Prostate Cancer: Strategies to Reduce Side Effects and Prolong SurvivalLaurence Klotz, MD, FRCSC2026
Navigating the Management of mCSPC From Mono to Quadruple TherapiesE. David Crawford, MD2026
Adjuvant/Salvage Radiotherapy Following ProstatectomyRichard G. Stock, MD2025
Technical Advances for Robotic Laparoscopic ProstatectomyAshutosh K. Tewari, MD, MBBS, MCh, FRCS2025
Rescuing ADT and ARPI: Benefits from ToxicitiesAndrew W. Hahn, MD2026Systemic TherapyHormone TherapyProstate Cancer, Metastatic Hormone-Sensitive (mHSPC/mCSPC)
Immunomodulation Plus IMRT in Intermediate and High-Risk Prostate Cancer: Phase III Randomized TrialJohn E. Sylvester, MD, FABS2025
Proton Therapy for Prostate CancerBrian J. Davis, MD, PhD, FABS2025
Promising Advances from Industry: Diagnostics, Devices, and TherapyChristian P. Pavlovich, MD2026
Where Will Artificial Intelligence Impact Prostate Cancer Diagnostics and Therapy?David M. Albala, MD2026
MRI Fusion Biopsy: The Role of Both Targeted and Systematic Core SamplingMichael S. Leapman, MD, MHS2025
How Biopsy Length Influences Diagnostic and Treatment PlanningNelson N. Stone, MD2025
Why Are mpMRIs Negative in Men with Clinically Significant Prostate Cancer?Alberto Vargas, MD2025
Pathological Markers and AIAdam Cole, MD, FS2025
Case Discussions: Surveillance and Recurrence in Focal TherapyArvin K. George, MD2025
PCa Commentary | Volume 212 - April 2026Edward Weber, MD2025
Best Use of MRI for Focal TherapyAlberto Vargas, MD2025
Treating Neuroendocrine Prostate CancerOscar B. Goodman, Jr., MD, PhD2025
Role of Radiation in Metastatic Prostate Cancer: Primary and Metastatic SitesCurtiland Deville, Jr., MD, FASTRO, FACR2025
Doublet vs Triplet Therapy for Newly Diagnosed Metastatic Prostate CancerMohammad O. Atiq, MD, FACP2025
Quantitative MRI Reading: Applications in Prostate CancerVictoria Y. Bird, MD2025
The Role of the Pathologist in the Selection and Monitoring of Patients for Active SurveillanceM. Scott Lucia, MD2025
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Evaluating Optimal Systemic Treatment Strategies - DoubletJ. Michael Randall, MD2025
Prostatype Genomics: Filling Unmet Needs in Prostate Cancer ManagementGerald L. Andriole, Jr., MD2025
Germline and Somatic MarkersLeonard G. Gomella, MD, FACS2025
Medical Oncology Perspective on Integration of Molecular Imaging and Treatment for mCRPCDiogo Assed Bastos, MD, PhD2025Systemic TherapyRadiopharmaceutical/Radioligand TherapyPSMA PET ImagingProstate Cancer, Metastatic Castration-Resistant (mCRPC)
Micro-Ultrasound for Prostate Cancer: Promising or Fool’s Errand?Ardeshir R. Rastinehad, DO, FACOS2025
Radiology and Theranostics in CRPCSherief H. Gamie, MD, PhD2025
Parp Inhibitors: Evidence, Indications and Side EffectsMohammad O. Atiq, MD, FACP2025
Radiopharmaceutical Design and Molecular ImagingKatherine Whittaker Ferrara, PhD2025
Influence of Family History, Race, and Genetic Markers on Prostate Cancer ScreeningEvan Kovac, MD, CM, FRCSC2025
Evaluating Triplet Therapy in Metastatic Hormone-Sensitive Prostate CancerSharon Choi, MD, PhD2025
Should Prostate MRI Be the Primary Screening Approach?Michael S. Leapman, MD, MHS2025
Focal Therapy Patient Selection: Urologist PerspectiveGeoffrey Sonn, MD2025
Biochemical Recurrence (BCR) Treatment: Comparing Targeted Approaches for Rising PSA, ADT + EnzalutamideJ. Michael Randall, MD2025
Deciphering the Role of MRI in Prostatic Disease “Risk Stratification”Ardeshir R. Rastinehad, DO, FACOS2025
Pulsed Electrical Field Treatment of Prostate CancerBenjamin Schurhamer, MD, MHCI2025
Metastatic Castration-Resistant Prostate Cancer (mCRPC): SequencingYu-Wei Chen, MD, MS2025
Molecular Imaging at Prostate Cancer Biochemical RecurrenceHong Song, MD, PhD2025
Long-Term Outcomes of PSMA PET/CT-Guided Radiotherapy in Biochemical Failure Patients Post-Radical Prostatectomy: A 5-Year Follow-Up AnalysisAndrea Di Giorgio, MD2025
Introduction to Advanced Prostate Cancer Management: Description of Terminology and Review of NCCN GuidelinesBenjamin J. Martin, MD2025
Radiopharmaceuticals in Advanced Prostate Cancer ManagementSteven P. Rowe, MD, PhD2025
Metastatic Castration-Resistant Prostate Cancer (mCRPC): Emerging Therapeutic ApproachesSharon Choi, MD, PhD2025
Back to the Future: Cryotherapy for Focal Prostate Cancer AblationYoed Rabin, BS, MS, DSc2025
Transrectal Biopsy Versus Local Anaesthetic Transperineal Biopsy Evaluation (TRANSLATE) in Prostate Cancer DetectionRichard J. Bryant, MBChB, PhD, FRCS2025
Recurrent Prostate Cancer: Enzalutamide Monotherapy and AlternativesJuan Javier-DesLoges, MD, MS, FACS2025
The Who and What of Focal Therapy for Prostate CancerArdeshir R. Rastinehad, DO, FACOS2025
Advances in Molecular Targeted Imaging (MTI)Sherief H. Gamie, MD, PhD2025
Whole Gland Ablation vs. Partial Gland AblationAbhinav Sidana, MD, MPH, FACS2025
Navigating the Management of mCSPC from Mono to Quadruple TherapiesE. David Crawford, MD2025
Prostate Cancer Aquablation (PCAq): A Novel Technique for Subtotal Resection of ProstateBrian T. Helfand, MD, PhD2025
Old School, New Insight: Histomorphology in the Modern Biomarker Era of Risk Stratification of Prostate CancerJane K. Nguyen, MD, PhD2025
Optimal Management of Patients Presenting with Locally Advanced Prostate Cancer in 2025Raja B. Khauli, MD, FACS2025
Could the Clinic Be the ‘One-Stop Shop’ for Prostate Cancer?Rahul D. Mehan, MD2025
Pro: Focal Therapy for Prostate CancerJuan Javier-DesLoges, MD, MS, FACS2025
Navigating the Challenges of Early Detection of Prostate CancerE. David Crawford, MD2025
Focal Therapy Fallout: Managing Complications and RecurrenceSamir S. Taneja, MD2025
Water Vapor Thermal Therapy for Prostate CancerArvin K. George, MD2025
Evaluation and Management of Men with Localized and Recurrent Prostate Cancer: Next Generation Risk StratificationAlastair D. Lamb, MA, MBChB, PhD, FRCS2025
Augmented Reality Guided Prostate BiopsiesArchan Khandekar, MD2025
Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-upDaniel Margolis, MD2025
Genetic Testing in Prostate Cancer ManagementAbhinav Sidana, MD, MPH, FACS2025
Evaluating 68Ga-PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective StudyAndrea Di Giorgio, MD2025
Principles of Focal Salvage Treatment for Radiorecurrent Prostate Cancer – Is it Feasible?Giancarlo Marra, PhD2025
Evidence Update in Focal Therapy: 2025Patrick T. Gomella, MD, MPH, FACS, EMT-P2025
HIFU in Prostate Cancer: Evolution, Evidence, and Emerging FrontiersSébastien Crouzet, MD, PhD2025
Energy Sources and Emerging Clinical IndicationsJurgen Fütterer, MD, PhD2025
Urologist Led Advanced Prostate Cancer Clinic (APCC): Tips, Tricks, and PitfallsBenjamin J. Martin, MD2025
Optimizing Ablative Modality for Treatment Outcome: Quid Quando UbiSamir S. Taneja, MD2025
A Deeper Look into the Favorable Intermediate-Risk PatientsDeepika Bhagwat, MD, BCMAS2025
Future Indications of PET PSMA Imaging in Localized Prostate CancerAshley E. Ross, MD, PhD2025
Focal Therapy in Prostate Cancer: Ready for Prime Time?Bruno Nahar, MD2025
Novel and Emerging Pathological Factors in Localized and Recurrent Prostate CancerGladell P. Paner, MD2025
The Role of Pathologists in PlanningAdam Cole, MD, FS2025
Surveillance After Focal TherapyGopal N. Gupta, MD, FACS2025
Role of PSMA Imaging in Selecting Patients for Biopsies (Urologic Perspective)Lorenzo Bianchi, MD, PhD, FEBU2025
The Use of PSMA PET/CT Scan in Patients with Prostate Cancer Treated with Focal TherapyGiovanni Lughezzani, MD2025
Overview of the Current Approaches to Standardized MRI ReportingFrancesco Giganti, MD, PhD2025
PCa Commentary | Volume 211 - March 2026Edward Weber, MD2025
Con: Focal Therapy for Prostate Cancer – Another Unnecessary ToolAditya Bagrodia MD, FACS2025
Treatment Intensification Strategies: Approaches to Optimize Outcomes for High-Risk Localized DiseaseJ. Michael Randall, MD2025
Androgen Receptor Signaling Inhibitors: Evidence, Indications and Side Effects in HSPCAshley E. Ross, MD, PhD2025
State of the Art and Future Directions in Prostate Biopsies: Imaging PerspectiveFergus Coakley, MD2025
Early Detection Saves Lives: PCEC’s Mission to Expand PSA ScreeningMolly Turner, MBA2026
What the Urologist Needs to Know about Molecular Targeted Imaging (MTI) and TheranosticsSean P. Collins, MD, PhD2025
Integrated Diagnostics for Risk Stratification and Active SurveillanceSanoj Punnen, MD, MAS, MBA2025
Lesional Management in Early Prostate CancerMark Emberton, MD, FRCS2025
The Gut Microbiome and Cancer ResistanceMichael A. Liss, MD, PhD, MAS, MBA, FACS2025
RadiopharmaceuticalsSean P. Collins, MD, PhD2025
Integration of MRI with Histology, Genomics, and ProteomicsSteven S. Raman, MD2025
Molecular ImagingMichael Hofman MBBS, FRACP, FAANMS, FICIS, GAICD2025
Focal Therapy vs Radical Treatment for Prostate CancerSébastien Crouzet, MD, PhD2025
Highlights from ASCO GU 2026: An Intra-patient Contemporaneous Comparison of 18F-piflufolastat and 18F-flotufolastat Urinary Radioactivity and Local and Pelvic Region Detection Rates in Men with Low Prostate-specific Antigen Biochemical Recurrence of Prostate Cancer after Radical ProstatectomyBrian T. Helfand, MD, PhD2026
Highlights from ASCO GU 2026: Patient Reported Outcomes (PRO) and Tolerability of Capivasertib (capi) plus Abiraterone (abi) versus Placebo (pbo) plus Abi in Patients (pts) with PTEN-deficient Metastatic Hormone-sensitive Prostate Cancer (mHSPC): CAPItello-281Daniel J. George, MD, FASCO2026
Highlights from ASCO GU 2026: First-in-human Assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation Results of the Phase 1 PAnTHa StudyFred Saad, MD, FRCS, CQ, FCAHS2026
2026 GU ASCO Discussant Review: Abstracts Covering the PEACE-3 Trial and BRCAAway StudyEvan Y. Yu, MD2026
Gleason Pattern 4 Quantification as a Replacement for Gleason ScoringAndrew J. Vickers, PhD2025
Screening Strategies: Debating Optimal Approaches – Risk-Stratified ScreeningBrent Rose, MD2025
PCa Commentary | Volume 210 - February 2026Edward Weber, MD2025
PSMA PET/CT in Prostate Cancer ImagingSherief H. Gamie, MD, PhD2025
Active Surveillance 2025 Update: If We Are in Favor of Screening, We Must Avoid OvertreatmentChristopher J. Kane, MD, MS, FACS2025
PSA: Universal ScreeningAditya Bagrodia MD, FACS2025
Post Ablation Imaging: Interpretation and Standardized ReportingSadhna M. Verma, MD, MBA, FSAR2025
Strategies to Improve Patient Selection: Role of Additional Imaging and BiomarkersCeli Varol, MBBS, FRACS2025
Salvage Prostatectomy in 2025Brant A. Inman, MD, MS, FRCSC2025
Point Counter Point: Software-Based Fusion for FocalPatrick T. Gomella, MD, MPH, FACS, EMT-P2025
Point Counter Point: The Case for CognitiveAlexander Kenigsberg, MD2025
Patient Selection: Fusion and Confirmatory BiopsyArvin K. George, MD2025
Fireside Chat with Vic LombardiE. David Crawford, MD2026
Panel Discussion: MRI and PSMA DiscordanceAbhinav Sidana, MD, MPH, FACS2025
Pitfalls of PSMA PET Imaging: False Positive, Equivocal, False Negative, Intraprostatic UptakeSteven P. Rowe, MD, PhD2025
Prostate MRI Update — What’s New on the Horizon?Sadhna M. Verma, MD, MBA, FSAR2025
PCa Commentary | Volume 209 - January 2026Edward Weber, MD2025
Focal Therapy for Metastatic Disease in Prostate CancerBart A. Frizzell, MD2025
Embracing the Practice of Interventional UrologyArdeshir R. Rastinehad, DO, FACOS2025
Blood-Based Biomarkers in Prostate CancerBrant A. Inman, MD, MS, FRCSC2025
When to Consider Salvage XRT in Delayed BCRBart A. Frizzell, MD2025
Future of PathologyAdam Cole, MD, FS2025
The Role of Spacing Devices in Modern Prostate XRTDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2025
Management of Localized Prostate Cancer: Targeted TherapyThomas J. Polascik, MD, FACS2025
MRI After FT – Toronto ExperienceSangeet Ghai, MD, FRCR2025
Radiation Therapy UpdatesSean P. Collins, MD, PhD2025
Combination Therapy RevisitedPeter R. Carroll, MD, MPH2025
Micro-Ultrasound and Irreversible Electroporation (IRE) for Treatment of Prostate CancerXiaosong Meng, MD, PhD2025
Focal Therapy for Localized Prostate Cancer: Why Hasn’t it Become the Standard of Care?Rafael Sanchez-Salas, MD2025
Guidelines for Management of Advanced PC: NCCN and BeyondMarc B. Garnick, MD2025
Surveillance Strategies After Focal TherapyIzak Faiena, MD, MSCR2025
Radiation Surgery Research in Group PracticeSteven E. Finkelstein, MD, DABR, FACRO2025
Diagnostic and Prognostic BiomarkersWilliam P. Parker, MD, FACS2025
Focal Therapy Recurrences and ManagementAbhinav Sidana, MD, MPH, FACS2025
Review and Update – Imaging for Improving Post-Ablation Assessment and Developing Short-Term Patient OutcomesFaina Shtern, MD2025
Navigating the Challenges of Early DetectionPeter R. Carroll, MD, MPH2025
Microbiome and CancerMichael A. Liss, MD, PhD, MAS, MBA, FACS2025
Radiologic Perspective on Integration of Molecular Imaging and TreatmentAndrei H. Iagaru, MD, FACNM2025
Focal Brachytherapy for Prostate CancerDaniel Y. Song, MD2025
Clinical and Prognostic Implications of Cancer Visibility on Imaging: Radiology PerspectiveAlberto Vargas, MD2025
Novel Targeted Treatment and Integration with Precision DiagnosticsDaniel P. Petrylak, MD2025
Immunotherapy in Prostate CancerSandy Srinivas, MD2025
How Has the SP Robot Affected Our Approach to Radical Prostatectomy?Jeremy Slawin, MD, MBA2025
Treatment De-Escalation: Strategies to Optimize Risk/Benefit in Advanced Prostate CancerA. Edward Yen, MD2025
PSMA-Targeted Therapy - Clonal Heterogeneity, Neuroendocrine Differentiation, and Finding the Right Sequence of Systemic TreatmentVikas Prasad, MD, PhD2025
Human–AI Interaction in Prostate Cancer Detection and Diagnosis: Ways to Team UpEvis Sala, MD, PhD, FRCR, FRCP2025
Deep Phenotyping of Prostate Cancer via Multi-Modal Imaging and AI to Discover High-Risk PhenotypesRakesh Shiradkar, PhD2025
Active Surveillance for Prostate Cancer: Practical Update for the Practicing UrologistJustin J. Badal, MD2025
Sequencing of TreatmentArnulf Stenzl, MD2025
Determining the Benefit of Therapy for Biochemically Recurrent Prostate CancerDavid J. Einstein, MD2025
Sequencing Lu-177 PSMA-directed RLTMichael J. Morris, MD2025
Candidates and Follow-Up for Lu-177 PSMAMichael J. Morris, MD2025
A PCa Case of PSA Recurrence After Retropubic RP, XRT & a Case of Diffusely mPCa Developing Castration ResistanceDavid S. Morris, MD, FACS2025
A Case of CRPC Using PSMA PET Imaging & a Case of Gleason 9, PSA of 200, and Slowly Rising PSADavid S. Morris, MD, FACS2025
Clinical Use of Lutetium-177–PSMA-617 for Metastatic Castrate Resistant Prostate CancerEvan Y. Yu, MD2025
Prostate Cancer Risk Assessment in Black MenAdam B. Murphy, MD, MBA, MSCI2025
Overview of Liquid Biomarkers in Prostate CancerE. David Crawford, MD2025
A PCa Case of PSA Rising After RP, Salvage XRT, ADT & a Case of Rising PSA After Triplet TherapyDavid S. Morris, MD, FACS2025
Driving Broader Impact: The Emerging Role of Radio-Ligand TherapiesIlya Gipp, MD, PhD2025
From Silos to Synergy: Data-Driven Strategies in Prostate Cancer CareIlya Gipp, MD, PhD2025
Emerging Advances in Precision Radiation Treatment and ImmunotherapySteven E. Finkelstein, MD, DABR, FACRO2025
A Calibration Tool for ADC Measurements in Prostate CancerXavier Golay, MS, PhD2025
Micro-Ultrasound-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis (OPTIMUM Trial)Laurence Klotz, MD, FRCSC2025
PET Tumor Board: Case 8 – A Case of An 81-year-old Man with High-risk Prostate Cancer with Initial PSA of 8.4 and a Large Peripheral Zone LesionE. David Crawford, MD2025
State of the Art and Future Directions in Prostate Biopsies: Urological PerspectiveAlastair D. Lamb, MA, MBChB, PhD, FRCS2025
Large-Scale, Prospective, Clinical Validation Study of the Diagnostic Performance of IsoPSA Without and in Combination with Multi-Parametric MRI for the Detection of High Grade Prostate CancerMark Stovsky, MD, MBA, FACS2025
PCa Commentary | Volume 208 - December 2025Edward Weber, MD2025
Genomics and Natural History of MRI Invisible vs Visible Cancers: Implications for Clinical PracticeLaurence Klotz, MD, FRCSC2025
MRI PI-RADS Standardization and Clinical EvaluationClare Tempany, MB, BCh, BAO2025
Radiology & Theranostics in Castrate Resistant Prostate Cancer (CRPC)Sherief H. Gamie, MD, PhD2025
Newly Identified Germline Mutations Associated with Prostate Cancer Risk and AggressivenessBrian T. Helfand, MD, PhD2025
Can PSMA-PET Improve Outcomes in Prostate Cancer?Sean P. Collins, MD, PhD2025
PCa Commentary | Volume 207 - November 2025Edward Weber, MD2025
PET Tumor Board–Case 7: A Case of a 71-year-old with PSA of 6.3, High PSA Density, and a PI-RADS 4 LesionE. David Crawford, MD2025
Lessons Learned from High Impact Randomized TrialsMira Keyes, MD, FRCPC, FABS2025
Pelvic Lymph Node Management - Radiation ApproachJason A. Efstathiou, MD, DPhil2025
Focal Therapies for Prostate Cancer - Recurrent versus Persistent Disease ManagementBrian T. Helfand, MD, PhD2025
WSAUA 2025: External Validation of an AI-Based Digital Pathology Model (MMAI) for Post-Prostatectomy PrognosisKevin Shee, MD, PhD2025
WSAUA 2025: PSMA PET Imaging and Theranostics in Prostate Cancer: Current Landscape and Future DirectionsJack R. Andrews, MD2025
WSAUA 2025: Micro-Ultrasound (Micro-US), MRI, and PSMA PET in Prostate Cancer: Whole-Mount Correlation StudyWayne G. Brisbane, MD2025
Preparing Your Patient for ProstatectomyRachel Hastings, PA-C2025
Interpreting PSMA PET/CT Scan ReportsSherief H. Gamie, MD, PhD2025
A Review of Prostate Cancer Perirectal SpacersJonathan D. Tward, MD, PhD, FASTRO2025
Post-ESMO 2025 Highlights: Advances in Prostate Cancer ResearchAndrew W. Hahn, MD2025
PCa Commentary | Volume 206 - October 2025Edward Weber, MD2025
Update on Göteborg-2 Trial: PSA Screening Followed by MRIJonas Hugosson, MD2025
Update on PRAISE-U Project - European Union Initiative in PC ScreeningMonique Roobol, PhD, MSc2025
Update on PROSCREEN: A Randomized Population-Based Screening Trail Combining PSA Kallikrein Panel and MRIAnssi Auvinen, MD, PhD2025
Organized Prostate Cancer Testing (OPT) in SwedenAnders Bjartell, MD, PhD, FEBU2025
Advancing Risk - Stratified Screening and Early DetectionSigrid V. Carlsson, MD, PhD, MPH2025
Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)Peter Albers, MD2025
Biomarkers for Prostate CancerRachel Hastings, PA-C2025
PET Tumor Board – Case 6: A Case of a 57-year-old with an Elevated PSA and Small Prostate VolumeE. David Crawford, MD2025
New Concepts in Molecularly Targeted Radiation in Prostate CancerA. Oliver Sartor, MD2025
Advanced Prostate Cancer Clinics (APCC) - LUGPA PerspectiveRonald P. Kaufman, Jr., MD2025
Challenging the Role of Pelvic Lymph Node Dissection at Robotic ProstatectomyJohn W. Davis, MD, FACS2025
Identification and Management of High-Risk Screening PopulationsBrian T. Helfand, MD, PhD2025
Biochemical Recurrence after Radical ProstatectomyChristian P. Pavlovich, MD2025
PCa Commentary | Volume 205 - September 2025Edward Weber, MD2025
Prostate Cancer Management Decisions from Germline and Somatic TestingLeonard G. Gomella, MD, FACS2025
PET Tumor Board Case 5: A Case of a 77-year-old Prostate Cancer Patient with Ulcerative Colitis and Uncertain PET FindingsE. David Crawford, MD2025
PET Tumor Board – Case 4: A Case of a 66-year old Male with Elevated PSA of 9.06 and MRI Showing PI-RADS Category 4 and 5E. David Crawford, MD2025
Update on Telesurgery and Novel Robotic SystemsDavid M. Albala, MD2025
PCa Commentary | Volume 204 - August 2025Edward Weber, MD2025
PET Tumor Board - Case 3: 62-year-old BRCA2-Positive Prostate Cancer Survivor with PSA RecurrenceE. David Crawford, MD2025
Prostate Cancer Detection Biomarkers, MRIAdam S. Kibel, MD2025
PCa Commentary | Volume 203 - July 2025Edward Weber, MD2025
Artificial Intelligence for Improving Prostate Cancer ManagementWayne G. Brisbane, MD2024
Patient Selection for Focal Therapy - Radiologic PerspectiveJurgen Fütterer, MD, PhD2024
Genomic Biomarker RoundtableLeonard G. Gomella, MD, FACS2025
PET Tumor Board - Case 2: A Case of a 72-year-old with Rising PSA and MRI Showing PI-RADSv2.1 Categories 4 and 5E. David Crawford, MD2025
Away from the Gleason Score and Towards Quantification of Pattern 4 for Treatment Decision Making in Localized Prostate CancerAndrew J. Vickers, PhD2024
Prostate Cancer: Current Treatment LandscapeAnne E. Lizardi, DNP, CRNP, RNFA2025
Prostate Cancer: Prevalence and Risk FactorsAnne E. Lizardi, DNP, CRNP, RNFA2025
Treatment of Prostate Cancer: Evaluation and DiagnosisAnne E. Lizardi, DNP, CRNP, RNFA2025
Focal Therapy Patient Selection: Urologist PerspectiveGeoffrey Sonn, MD2024
Need to Know: Rapid Fire PET Tumor Board DiscussionsE. David Crawford, MD2025
Prediction of Extraprostatic Disease: Updates on NeuroSAFE, Histologic Scanner, Conventional Nomograms/Imaging, & AI-Assisted Prostate Cancer MappingDavid M. Albala, MD2025
Interview of Dr. Neil H. Baum, MD on Prostate Cancer: Expert Advice for Helping Your Loved OneNeil H. Baum, MD2025
PET Tumor Board - Case 1: A Case of a 55-year-old Prostate Cancer Survivor with Rising PSA Five Years After Radical ProstatectomyE. David Crawford, MD2025
Secondary Biomarkers for Prostate Cancer Clinical Overview 2025Christian P. Pavlovich, MD2025
Darolutamide Plus Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume in the Phase 3 ARANOTE StudyE. David Crawford, MD2025
Radiopharmaceuticals in Advanced Prostate CancerSteven P. Rowe, MD, PhD2024
ADT and RadiationMira Keyes, MD, FRCPC, FABS2025
Staging Updates: Whole Body MRI and PET Imaging for Prostate CancerBrian T. Helfand, MD, PhD2025
Can Imaging Replace Prostate Biopsy - Primary Detection, Active Surveillance and Recurrent PCa?Veeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert2024
PARP in mCRPCDaniel P. Petrylak, MD2025
Focal Brachytherapy in 2025Peter J. Rossi, MD, FABS, FASTRO2025
mHSPC: Latest Approaches and Clinical TrialsTanya B. Dorff, MD2025
Optimizing Utilization of PSMA PET into a Urological PracticeDavid M. Albala, MD2025
The Undecided PCA Consult: Optimized Counseling, Treatment Choices, Avoiding Decision RegretJonathan D. Tward, MD, PhD, FASTRO2025
Grade Group 1 at Biopsy - Do We Need to Know More?John W. Davis, MD, FACS2025
Tips and Tricks of Endoscopic Anatomical Enucleation of the ProstatePierluigi Bove, MD2025
Biopsy Updates: Do We Have Clarity?Ronald P. Kaufman, Jr., MD2025
Treating Oligometastatic Prostate Cancer in the PSMA PET EraAndrew W. Hahn, MD2025
Updates on Global Screening Trials: Where Are We Headed Next?R. Jonathan Henderson, MD2025
MRI-Assisted Radiosurgery (MARS) Management of High Risk and Recurrent Prostate CancerSteven J. Frank, MD, FACR, FABS, FASTRO2025
Panel Discussion: Molecular Targeted Imaging (MTI)Christian P. Pavlovich, MD2025
MyProstateScore 2.0 (MPS2): A Novel, Noninvasive Urine Test Prior to Prostate BiopsyJeffrey J. Tosoian, MD, MPH2025
Transurethral Ultrasound Guided Prostate Ablation (TULSA): Clinical Trials and Real-world ResultsChristian P. Pavlovich, MD2025
Should Screening be Altered Based on Germline and Family History?Sigrid V. Carlsson, MD, PhD, MPH2024
PCa Commentary | Volume 202 - June 2025Edward Weber, MD2025
PCa Commentary | Volume 200 - April 2025Edward Weber, MD2025
Treating Neuroendocrine Prostate CancerWilliam K. Oh, MD2024
Transperineal Prostate Biopsy in the Office Setting Anesthetic ConsiderationsMichael A. Gorin, MD2024
UroVision Interview - Simon Criteria for Biomarkers in Urologic OncologyE. David Crawford, MD2025
Which Patients Do You Struggle With the Most, and What Makes You Sweat?John W. Davis, MD, FACS2025
Real-Time Intraoperative Neuromonitoring of Erectile and Urinary Functions During Radical ProstatectomyArthur L. Burnett II, MD, MBA, FACS2025
Current Advances of Liquid Biopsies in Prostate CancerEdwin M. Posadas, MD, FACP2025
Permanent Prostate Brachytherapy - Brian J. Moran Distinguished LectureBrian J. Davis, MD, PhD, FABS2025
Need to Know: UroVision Interview - Simon Criteria for Biomarkers in Urologic OncologyE. David Crawford, MD2025
UroVation Interview: Envision Sciences - Advancing Cancer Diagnosis and PrognosisE. David Crawford, MD2025
Managing Recurrence After Radical ProstatectomyAdam S. Kibel, MD2025
PCa Commentary | Volume 201 - May 2025Edward Weber, MD2025
Role of Whole Gland Ablation in Prostate CancerJames S. Wysock, MD, MSc2024
Digital Pathology for Detecting Prostate Cancer - TruCore PathologyAdam Cole, MD, FS2025
Hydrogel Rectal Spacer: Radiopaque vs. Non-radiopaqueRichard G. Stock, MD2024
Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of ColorQuoc-Dien Trinh, MD, MBA2024
Prostate Cancer in the Veteran Population RoundtablePeter F. Orio III, DO, MS, FABS, FASTRO2025
PROWESS: (PROstate Cancer Wearables, Exercise, and Structured Supports)Jamie Jacobs, PhD2024
Utilization and Disparity in Prostate Cancer Risk Assessment ToolsMichael S. Leapman, MD, MHS2024
Treatment of Oligometastatic DiseaseMary-Ellen Taplin, MD2024
Brachytherapy: The Historical Evolution, Techniques, and Efficacy in Prostate Cancer ManagementJohn E. Sylvester, MD, FABS2024
Prostate-Specific Antigen Response With Darolutamide Plus Androgen-Deprivation Therapy In Patients With Metastatic Hormone-Sensitive Prostate Cancer In ARANOTEE. David Crawford, MD2025
Panel Discussion: TechCon: Novel and New Technologies in Prostate CancerDavid M. Albala, MD2025
Prostate Cancer Risk Assessment in Black MenAdam B. Murphy, MD, MBA, MSCI2024
UTUC Staging, Diagnosis, Intraureteralpelvis Therapy, Endoscopic ManagementJennifer A. Linehan, MD2024
Intratumoral Immunotherapy for Cancer: Update 2024 of a Novel ApproachDavid G. Bostwick, MD, MBA, FCAP2024
Using Genetic Testing in Prostate Cancer: When and HowAlan H. Bryce, MD2024
Radiation Dose and Hormone Therapy: How Much is Enough?Nelson N. Stone, MD2024
Diet and Prostate Cancer: What We Need to Know to Tell our PatientsStacy Loeb, MD2024
Post-Treatment Assessment and Creating Imaging-Based Short- and Intermediate-Term Patient OutcomesFaina Shtern, MD2024
Management of High Risk Prostate CancerAdam S. Kibel, MD2025
Role of Digital Pathology and AI in Improving Diagnostic AccuracyDavid G. Bostwick, MD, MBA, FCAP2024
5-Alpha Reductase Inhibitors Increase the Risk of Aggressive Prostate Cancer: Fact or MythGerald L. Andriole, Jr., MD2025
Point Counterpoint: Risk Stratification for Biopsy - BiomarkersJuan Javier-DesLoges, MD, MS, FACS2024
Point Counterpoint: Risk Stratification for Biopsy - MRIPeter A. Pinto, MD2024
Adaptive RadiotherapyRichard G. Stock, MD2024
Starting a Transperineal Prostate Biopsy Program Cost Effective Strategy for ImplementationRichard C. Wu, MD2024
MicroUltrasound of the ProstateGerald L. Andriole, Jr., MD2025
Holmium Laser Enucleation of the Prostate (HoLEP): Current Era Techniques and OutcomesAmy E. Krambeck, MD2025
Point Counterpoint: Is Focal Therapy Ready for Prime Time (No)Michael Rothberg, MD2024
Point Counterpoint: Is Focal Therapy Ready for Prime Time (Yes)Ruben Olivares, MD2024
Immunotherapy in Prostate CancerSandy Srinivas, MD2024
PCa Commentary | Volume 198 - February 2025Edward Weber, MD2025
Expanding Treatment Options at Ambulatory Surgical Centers: LDR Brachytherapy for Prostate CancerE. David Crawford, MD2024
PCa Commentary | Volume 199 - March 2025Edward Weber, MD2025
PCa Commentary | Volume 197 - January 2025Edward Weber, MD2024
Gleason Scoring Has Served Us Well for More than 50 Years, But It Is Time to Start AfreshAndrew J. Vickers, PhD2024
PIRADS V2.1 - What a Urologist Needs to Know?Sadhna M. Verma, MD, MBA, FSAR2024
Multi-Disciplinary Approach to Advanced Prostate Cancer CareKelvin A. Moses, MD, PhD, FACS2024
Oral Abstracts - SV Recurrences After RadiationAaron E. Katz, MD, FACS2024
Through the Perineum or Through the Rectum: How to Best Biopsy the ProstateGuilherme Godoy, MD, MS2024
Energy Selection Ablative Technologies for Focal TherapyAndre Abreu, MD2024
PCa Commentary | Volume 196 - December 2024Edward Weber, MD2024
Utility of Micro-Ultrasound in Prostate Cancer Active SurveillanceAdam Kinnaird, MD, PhD, FRCSC2024
Bi Parametric Optimized 15 min Prostate MRI Protocol - Are we there yet?Mukesh Harisinghani, MD2024
Future Directions (FD) in Molecular Targeted Imaging (MTI) and Theranostics DiscussionRobert E. Reiter, MD, MBA2024
Update on the PROFILE and IMPACT StudiesJana McHugh, MB Bch BAO (Hons), MRCPI, FFR2023
Update: Studies Combining Secondary Biomarkers and MRILeonard G. Gomella, MD, FACS2025
Climacturia After Radical Prostatectomy: What is It? Why is It? How Do We Treat It?Brian S. Christine, MD2024
Horizons of Diagnosis and Treatment with PSMA PET MRIPaul D. Maroni, MD2024
Key Principles from the 2024 AUA Guidelines Updates on Salvage Prostate Cancer TherapyJustin J. Badal, MD2024
Results of the PRIME Trial Biparametric Versus Multiparametric MRI for Prostate Cancer Detection - ImpliVeeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert2024
Year in Review: Emerging Data and Advances in Prostate Cancer ScreeningSigrid V. Carlsson, MD, PhD, MPH2024
Update of Changes in the Early Detection of Prostate Cancer NCCN Guidelines 2024Preston C. Sprenkle, MD2024
Complications of Focal Therapy - Risk Factors, Timepoints, ManagementAmir Lebastchi, MD2024
KEYNOTE LECTURE - Introduction of Disruptive Technologies The Lessons From the Minimally Invasive SurgeryRalph V. Clayman, MD2024
Mechanisms and Management of RecurrencesAbhinav Sidana, MD, MPH, FACS2024
Oral Abstracts - Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia’s LIBERATE RegistryMohammadmehdi Adhami, MD2024
Oral Abstracts - Spacial Characterization and AI-Driven Prevention of Residual Cancer Following Focal TherapyPreston C. Sprenkle, MD2024
Oral Abstracts - Best Clinical Practices for Transperineal Postate BiopsyLorenzo Ramacciotti, MD2024
Outcomes of Recent Clinical Trials for Focal TherapyDerek J. Lomas, MD2024
Interpretation of Post Focal Therapy Imaging Target and PifabSadhna M. Verma, MD, MBA, FSAR2024
Optimal Surveillance Algorithm Following Focal Therapy of Prostate CancerHerbert Lepor, MD2024
The Changing Landscape of Focal Therapy for Prostate CancerHerbert Lepor, MD2024
Patient Selection: How to Pick a Focal Therapy CandidateDerek J. Lomas, MD2024
Urologist Led Advanced Prostate Cancer Practice Tips, Tricks and PitfallsAaron Berger, MD2024
TRAVERSE: Meaning of the Testosterone Safety TrialsMartin M. Miner, MD2024
The BARCODE 1 Study: Enrichment of Prostate Cancer Detection in Those with Higher Polygenic RiskRos Eeles, PhD, FRCP, FRCR2023
Metastatic Castrate Resistant Prostate Cancer - Immunotherapy and PARP InhibitorsAlan Tan, MD2024
Optimal Management of Biochemically Recurrent Nonmetastatic Prostate CancerAaron Berger, MD2024
Oligometastatic Prostate CancerDaniel Y. Song, MD2024
Metastatic Castrate Sensitive Prostate CancerRana R. McKay, MD, FASCO2024
Genetic Testing in Prostate Cancer ManagementAbhinav Sidana, MD, MPH, FACS2024
Course Introduction: Description of Terminology and Review of GuidelinesNatalie Reizine, MD2024
Optimizing Flow: Practical AI Applications in UrologyArun Rai, MD, MBA, MS2024
AI and Prostate Imaging and BiopsyBaris Turkbey, MD2024
Introduction to AI in HealthcareGiovanni Cacciamani, MD, MSc, FEBU2024
Rectal SpacerAbhinav Sidana, MD, MPH, FACS2024
Clinical Trials in Focal TherapyIzak Faiena, MD, MSCR2024
Prostate Cancer SurvivorshipHumberto Villarreal, MD, MSCI2024
Population of Men with Advanced Prostate Cancer: Sequencing of TreatmentArnulf Stenzl, MD2024
Radiation Therapy Planning Using Advanced Imaging – Pearls and PitfallsSean P. Collins, MD, PhD2024
Novel Targeted TherapiesDaniel P. Petrylak, MD2024
Transforming Prostate Cancer Care - The Emerging Role of Radio-Ligand TherapiesIlya Gipp, MD, PhD2024
Transperineal vs Transrectal Biopsy Clinical Trials: Mo' Data Mo' ProblemsArvin K. George, MD2024
PSMA PET for Preoperative Planning of Prostate Cancer: Nodes, Nerves and MarginsJames S. Wysock, MD, MSc2024
PET Scanning in Primary Detection of Prostate CancerSteven P. Rowe, MD, PhD2024
Utility of Micro-Ultrasound in Prostate Cancer Active SurveillanceStefano Fanti, MD2024
Current Status of External Validation of Inter-Reader Reproducibility for the Prostate Imaging Quality (PI-QUAL)Liang Wang, MD, PhD2024
Integrated Diagnostics for Risk Stratification and Active SurveillanceSanoj Punnen, MD, MAS, MBA2024
Emerging Role of Focal Therapy in the Management of Prostate CancerDaniel Y. Song, MD2024
Focal Brachytherapy for Prostate CancerBruno Nahar, MD2024
How to Best Select Doublet vs. Triplet Therapy in MCSPCScott B. Sellinger, MD, FACS2024
Criteria for the Development and Validation of Radiomic Tests in Diagnosis and Treatment of Prostate CancerErich Huang, PhD2024
Novel and Emerging Pathological Factors in Localized and Recurrent Prostate CancerGladell P. Paner, MD2024
Highlights from GU ASCO and ASCO 2024A. Edward Yen, MD2024
Keynote Lecture: Has Prostate Cancer Mortality Increased?Sigrid V. Carlsson, MD, PhD, MPH2024
Diet, Exercise, and Lifestyle: What Do We Know?Sigrid V. Carlsson, MD, PhD, MPH2024
Systemic Immunotherapy in Prostate CancerWilliam K. Oh, MD2024
Biology of the Radiotheranostic ApproachAlberto Vargas, MD2024
AI and Machine Learning: What the Future HoldsSigrid V. Carlsson, MD, PhD, MPH2024
How AI Improves Imaging InterpretationAlberto Vargas, MD2024
CAPTAIN: A Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation of the Prostate versus Radical ProstatectomyXiaosong Meng, MD, PhD2024
Novel Ways of Targeting the Androgen ReceptorDaniel P. Petrylak, MD2024
MRI in Localized and Recurrent Prostate CancerBaris Turkbey, MD2024
Genomics and Natural History of MRI Invisible vs Visible Cancers - Implications for Clinical PracticeLaurence Klotz, MD, FRCSC2024
PCa Commentary | Volume 195 - November 2024Edward Weber, MD2024
Update on PRAISE-U Project – European Union Initiative in PC ScreeningMonique Roobol, PhD, MSc2024
Overview of Liquid BiomarkersE. David Crawford, MD2024
Optimization of Prostate Biopsy – Micro-Ultrasound versus MRI (OPTIMUM)Laurence Klotz, MD, FRCSC2024
MRI PI-RADS Standardization and Clinical EvaluationClare Tempany, MB, BCh, BAO2024
Optimizing MRI Techniques for Prostate Cancer DiagnosisFergus Coakley, MD2024
Results from the Norwegian Prostate Cancer Consortium (NPCC)Jan Oldenburg, MD, PhD2024
Connected Care and Latest Developments in Prostate Cancer ManagementIlya Gipp, MD, PhD2024
Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)Peter Albers, MD2024
Overview of MCED - Performance and Impact on Prostate CancerEric A. Klein, MD2024
MRI-Based Prostate Cancer Screening in an Era of MCEDsMark Emberton, MD, FRCS2024
How Has the SP Robot Affected Our Approach to Radical Prostatectomy?Jeremy Slawin, MD, MBA2024
How has the SP Robot Affected Our Approach to Radical Prostatectomy?Jeremy Slawin, MD, MBA2024
The Bespoke Future of Cancer CareLeonard G. Gomella, MD, FACS2024
Differentiating PSMA Diagnostics & TherapeuticsPhillip J. Koo, MD2024
PCa Commentary | Volume 194 - October 2024Edward Weber, MD2024
Devastated Outlet in MenOuida L. Westney, MD2024
Alan Partin Lecture: The Genomics and Natural History of Visible vs. Invisible CancersLaurence Klotz, MD, FRCSC2024
Putting Germline Testing into Context: A Primer and Current KnowledgeAlan H. Bryce, MD2024
Micro Ultrasound and MRI of the ProstateGerald L. Andriole, Jr., MD2024
The Battle of Biopsies: Results of a Multi-institutional Randomized Trial of Transrectal vs Transperitoneal Prostate BiopsyMohamad E. Allaf, MD2024
Early Continence Recovery after Robotic Assisted Radical Prostatectomy: The Role of Prostatic ShapePierluigi Bove, MD2024
Renal Ablation Technologies – Impact on the Treatment of Small Renal MassesThomas W. Jarrett, MD2024
PCa Commentary | Volume 193 - September 2024Edward Weber, MD2024
Updates on the RADAR SeriesE. David Crawford, MD2024
mpMRI of the Prostate and Correlation with CT +/- PSMA PET findings: Prostate Imaging Lessons for the UrologistDesencia E. Thomas, MD2024
Counseling Men with Favorable Intermediate Risk Disease- How to Advise, What Evidence Do You Share?Dov Kadmon, MD2024
Advances in Treating the Primary and Sites of Metastases in Oligometastatic Prostate CancerJason A. Efstathiou, MD, DPhil2024
Getting Started with Focal Therapy for Prostate CancerIzak Faiena, MD, MSCR2024
Update on the State of the Art Radiation Treatments for Prostate CancerPeter F. Orio III, DO, MS, FABS, FASTRO2024
Rectal Spacing for All Forms of Radiation: Cryotherapy, HIFU, Tesla, and MorePeter F. Orio III, DO, MS, FABS, FASTRO2024
Role of Precision Medicine in the Diagnosis and Management of Prostate CancerLeonard G. Gomella, MD, FACS2024
Biomarkers for Radiation TherapyPeter F. Orio III, DO, MS, FABS, FASTRO2024
How Well Do You Know Doublets and Triplets? - A Pop QuizMarc B. Garnick, MD2024
Telesurgery for Prostate Cancer: Where Are We in 2024? - This Is a Novel Topic and Gaining Traction Around the WorldDavid M. Albala, MD2024
Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future DirectionsAndrew W. Hahn, MD2024
Advances and Controversies in Theranostic Approaches to Prostate CancerEric M. Rohren, MD, PhD, FACR2023
Quality Improvement American College of Radiology Program in Prostate MRIAndrei Purysko, MD2023
KEYNOTE LECTURE: Too Little or Just Enough? The Role of Focal Therapy in ProtecT EraFreddie Hamdy, MD2024
The Battle of Biopsies: Results of a Multi-institutional Randomized Trial of Transrectal vs Transperitoneal Prostate BiopsyMohamad E. Allaf, MD2024
Micro Ultrasound and MRI of the ProstateGerald L. Andriole, Jr., MD2024
Integrating Care in Advanced Prostate CancerJohn W. Davis, MD, FACS2024
PARPi in mCRPCDaniel P. Petrylak, MD2024
PCa Commentary | Volume 192 - August 2024Edward Weber, MD2024
Focal versus Radical - At What CostDeepika Reddy, MD2024
Panel Discussion: PROSTATE SAMPLING AND SPACINGSrinivas Vourganti, MD2024
Pelvic Lymph Node Dissection During Radical Prostatectomy: Should We Do It?Isaac Y. Kim, MD, PhD, MBA2023
Panel Discussion: Didactic Session 7: Emerging TherapiesWilliam K. Oh, MD2023
Panel Discussion: Didactic Session 6: Advanced DiseaseWilliam K. Oh, MD2023
Case Studies in Advanced Prostate CancerWilliam K. Oh, MD2023
Panel Discussion: Didactic Session 4: Advances in RadiotherapySteven J. Frank, MD, FACR, FABS, FASTRO2023
Panel Discussion: Didactic Session 3: Focal TherapyArvin K. George, MD2022
Panel Discussion: Didactic Session 2: RadioprotectionLeonard S. Marks, MD2022
Panel Discussion: Didactic Session 1: Prostate BiopsyJames A. Eastham, MD, FACS2022
Treatment of Oligometastatic Prostate Cancer in the Era of PSMA PET ImagingAndrew W. Hahn, MD2024
Clinical Trials in Focal Therapy - Endpoint, Design, UpdatesTaimur Shah, MD2024
Is It Cold in Here? Focal Cryoablation for Prostate CancerLouis Krane, MD2024
Pew Pew! Laser Applications for Prostate AblationSteven E. Canfield, MD2024
Versatile Irreversible ElectroporationPhillip Stricker, MBBS2024
Pearls and Pitfalls Of PSMA PETSandeep Arora, MBBS, FSAR2023
The Risks and Benefits of Rectal SpacersSrinivas Vourganti, MD2024
Imaging and Biomarkers in Patient Selection for Focal AblationEzekiel Becher, MD2024
The When and How of Post-Ablation SurveillanceSoroush Rais-Bahrami, MD2024
Novel Molecular Tracers for Prostate ImagingBaris Turkbey, MD2023
Artificial Intelligence for Improving Prostate Cancer Diagnosis and TreatmentMartin Eklund, PhD2023
The Prostate Cancer ProteomePaul C. Boutros, PhD, MBA2024
PSMA PET ImagingPhillip J. Koo, MD2023
Integration of Histology, Genomics and Proteomics with MRISteven S. Raman, MD2024
Why We Need Organized Screening ProgramsHendrik Van Poppel MD, PhD2024
Welcome and Opening RemarksFaina Shtern, MD2024
Embracing a New Normal of Innovation: Radiation Oncology Advances in Precision Diagnosis and Treatment for Prostate CancerSteven E. Finkelstein, MD, DABR, FACRO2024
Panel Discussion Part Two: PROSTATE IMAGINGBaris Turkbey, MD2024
Case Discussion 1 - Patient and Treatment SelectionAbhinav Sidana, MD, MPH, FACS2024
The Application of Stimulated Raman Histology to Urologic Malignancies - Human and Artificial Intelligent AssessmentJames S. Wysock, MD, MSc2024
The Baked Potato (Prostate): Focal Microwave AblationPeter K.F. Chiu, MD, PhD, FRCSEd2024
High Intensity Focused Ultrasound Ablation Outcomes - TR, In BoreBehfar Ehdaie, MD, MPH2024
Margin Call: Focal vs. Regional AblationPreston C. Sprenkle, MD2024Ablative/Focal TherapyLocalized/Locally Advanced, Prostate Cancer
PSMA Imaging as a Biomarker for Early Stage Prostate CancerRobert E. Reiter, MD, MBA2024
Update on Robotic Prostatectomy PSMA Scanning - Setting up a Program in Your PracticeDavid M. Albala, MD2024
Imaging for High-Risk Prostate Cancer: The Guidelines and BeyondJay D. Raman, MD2023
Infections Following Prostate Needle Biopsy – An Evidence-Based Approach to Tackling A Common ProblemJay D. Raman, MD2023
PCa Commentary | Volume 191 - July 2024Edward Weber, MD2024
An Expert Discussion of Testosterone Nadir and Clinical Outcomes in Patients with Advanced Prostate Cancer: A Post Hoc Analysis of Triptorelin Pamoate Phase III StudiesNeal D. Shore, MD, FACS
The Importance of Diagnosing and Treating Oligometastatic Prostate Cancer and ADT UsageMarc B. Garnick, MD2024
International, Multi-Disciplinary Consensus on Treatment of Advanced Prostate CancerSilke Gillessen, MD2024
Radiation Therapy Planning Using Advanced Imaging – Pearls and PitfallsSean P. Collins, MD, PhD2024
Focal Therapy for Prostate Cancer: Role of BrachytherapyDaniel Y. Song, MD2024
Understanding Metastatic Castration-Resistant Prostate CancerShell Liang, PhD2024
PCa Commentary | Volume 190 - June 2024Edward Weber, MD2024
Emergent Applications of Prostate Cancer Mapping with Artificial IntelligenceAlan Priester, PhD2024
Convergent Therapeutics: Next-Generation Targeted RadiotherapiesPhilip Kantoff, MD2024
Clinical Evaluation and Management of Men with Localized and Recurrent Prostate CancerJan Philipp Radtke, MD, MBA2024
Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging Based Short and Intermediate OutcomesDaniel Margolis, MD2024
Choosing Systemic Therapy for Men with Metastatic Hormone Sensitive Prostate CancerAndrew W. Hahn, MD2024
Clinical Trial of STHLM3 and MRITobias Nordstrom, MD, PhD2024
Prostate Cancer Screening Practices in EuropeMonique Roobol, PhD, MSc2024
NCCN Guidelines for Early Detection of Prostate Cancer 2023Preston C. Sprenkle, MD2024
Advanced Prostate Cancer: Sequencing of TreatmentArnulf Stenzl, MD2024
The Microbiome and Prostate CancerMichael A. Liss, MD, PhD, MAS, MBA, FACS2024
Multi-modality (MRI+PET) Imaging for Improved Detection of csPCDavid Margel, MD, PhD2024
Combination of Prostate Ablation with Systemic Therapy for Management of ProstateAbhinav Sidana, MD, MPH, FACS2024
Patient Selection for Prostate Cancer Focal Therapy: Urologic PerspectiveGeoffrey Sonn, MD2024
PSMA in Metastatic Prostate Cancer: Imaging as BiomarkerLouise Emmett, MD, FAANMS, FRACP, MBChB2024
Doublets and Triplets: Patient SelectionDavid S. Morris, MD, FACS2024
Diagnostic and Prognostic Biomarkers for Prostate CancerEricka Bagi, BSN, RN2024
Precision Diagnostics and Emerging Treatment StrategiesDavid M. Nanus, MD2024
Novel Targeted Treatment and Its Integration with Precision DiagnosticsDaniel P. Petrylak, MD2024
Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)Peter Albers, MD2024
PCa Commentary | Volume 189 - May 2024Edward Weber, MD2024
Micro-ultrasound and MRI for Visualization of Prostate CancerWayne G. Brisbane, MD2024
The Modern (Overlapping) Relationship Between Active Surveillance and Focal TherapyMark Emberton, MD, FRCS2024
LuPSMA: Imaging-Based Patient Eligibility Role of Tumor Heterogeneity & FDGHossein Jadvar, MD, PhD, MPH, MBA2024
PCa Commentary | Volume 188 - April 2024Edward Weber, MD2024
Industry Perspective: Illuccix® for Gallium-68-PSMA-11 PET Imaging of Prostate CancerBradley Fehrenbach, MD, MBA2024
Focal Therapy is Now Ready for Prime TimeHashim Ahmed, MD, PhD2024
Industry Perspective: BioProtect Balloon Implant™ SystemDaniel Y. Song, MD2024
PI-RADS Standardization and Risk Assessment - Recent Advances and Future PlansClare Tempany, MB, BCh, BAO2024
Focal CryoablationMichael A. Gorin, MD2023
Focal HIFUArvin K. George, MD2023
Integrated Diagnostics (Radiogenomics) and Patient Selection and Monitoring for Active Surveillance, Surgical, and Radiation TreatmentSanoj Punnen, MD, MAS, MBA2024
Construction and Multi-Center Validation of the Radiomics Model for Non-Invasive Identification of Active Surveillance CandidatesLiang Wang, MD, PhD2024
Selection and Outcomes of Image-Guided, Minimally-Invasive TreatmentAbhinav Sidana, MD, MPH, FACS2024
PCa Commentary | Volume 186 - February 2024Edward Weber, MD2024
ADT is the Building Block for Advanced Prostate Cancer TherapyE. David Crawford, MD
Molecular Imaging: PSMA PET/CTMichael Hofman MBBS, FRACP, FAANMS, FICIS, GAICD2024
Year in Review: Emerging Data and Advances in Prostate Cancer ScreeningSigrid V. Carlsson, MD, PhD, MPH2024
Prognostic and Predictive MarkersAshley E. Ross, MD, PhD2023
MRI-Based Prostate Cancer Screening in an Era of MCEDsMark Emberton, MD, FRCS2023
PCa Commentary | Volume 185 - January 2024Edward Weber, MD2024
Prostate: Anatomic ConsiderationsThomas M. Wheeler, MD2023
Optimizing MRI Targeted Biopsy - Including Endorectal Imaging for Tumor Localization and In-Bore Biopsy for Tissue DiagnosisFergus Coakley, MD2023
Update on IMPACT – Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers and Men with Lynch SyndromeRos Eeles, PhD, FRCP, FRCR2023
PCa Commentary | Volume 184 - December 2023Edward Weber, MD2023
Prostate Cancer Detection-Integrated Clinical SolutionDonald Baker, R.T.(R)(CT)(MR)2024
The Role of Radiotherapy in Oligometastatic Prostate Cancer and How to Treat the Primary in De Novo Oligometastatic DiseaseDaniel A. Hamstra, MD, PhD, FASTRO, FASCO2023
Testosterone to Improve the Diagnosis and Treatment of Prostate CancerMohit Khera, MD, MBA, MPH2023
Industry Perspective: Image-Guided Focal Laser Ablation for Prostate Cancer with CLS-TRANBERGSijo J. Parekattil, MD, FACS2023
Physics of Intraoperative Dose Planning for Focal BrachytherapyRen-Dih Sheu, PhD, DABR2023
PCa Commentary | Volume 183 - November 2023Edward Weber, MD2023
Novel Targeted Treatments for Metastatic DiseaseAlan H. Bryce, MD2023
Identifying Mutations and Optimizing Use of PARP InhibitorsWilliam K. Oh, MD2023
Cardiovascular Side Effects of Advanced Disease TherapiesWilliam K. Oh, MD2023
Immunotherapy in Metastatic Prostate CancerA. Oliver Sartor, MD2023
Metastatic Castrate-Resistant Prostate Cancer: Options and Possible SequencesA. Oliver Sartor, MD2023
Management of mHSPC-Singlets and Doublets and TripletsAlan H. Bryce, MD2023
Focal Brachytherapy for Prostate CancerJuanita M. Crook, MD, FRCPC2023
Transrectal Fusion BiopsyLeonard S. Marks, MD2023
PSMA Radiopharmaceuticals: Update 2023A. Oliver Sartor, MD2023
Treatment of Oligometastatic DiseaseJuanita M. Crook, MD, FRCPC2023
New Spacer Technology for Prostate Cancer Radiation TherapyPeter F. Orio III, DO, MS, FABS, FASTRO2023
Adjuvant-Salvage Radiotherapy Following ProstatectomyRichard G. Stock, MD2023
PCa Commentary | Volume 182 - October 2023Edward Weber, MD2023
The Evolution of the Role of Radical Prostatectomy in Prostate CancerLeonard S. Marks, MD2023
MRI Fusion Focal TherapyLeonard S. Marks, MD2023
Transperineal Fusion BiopsyMichael A. Gorin, MD2023
Combining Brachytherapy with SBRTRichard G. Stock, MD2023
MRI-Assisted Salvage Radiosurgery (MARS) Planning and TreatmentSteven J. Frank, MD, FACR, FABS, FASTRO2023
Sculpted Rectal Spacing for Focal BrachytherapyNelson N. Stone, MD2023
Active Surveillance: Intermediate Disease and High-Volume Grade Group 1 Prostate CancerJames A. Eastham, MD, FACS2023
Optimizing Biopsy Approach Before Precision ProstatectomyArvin K. George, MD2023
PCa Commentary | Volume 181 - September 2023Edward Weber, MD2023
PCa Commentary | Volume 180 - August 2023Edward Weber, MD2023
2023 Legislative and Regulatory Issues UpdateDavid M. Albala, MD2023
Future Directions in Smart Prostate Cancer Screening – Highlights from the 6th Annual Global Summit on Precision Diagnosis and Treatment of Prostate CancerFaina Shtern, MD2023
Appropriate Use of PSMA PET in Clinical PracticeGeoffrey B. Johnson, MD, PhD2023
Integration of Augmented Reality (AR) and Extended Reality (XR) into Urology Training and PracticeNelson N. Stone, MD2023
PCa Commentary | Volume 179 - July 2023Edward Weber, MD2023
Management of Disease Recurrence in Localized Prostate CancerLaurence Klotz, MD, FRCSC2023
Clinical Update on PSMA Diagnostics and TherapiesPhillip J. Koo, MD2023
Molecular ImagingAndrei H. Iagaru, MD, FACNM2023
Implications of the FDA Approval of Combination Talazoparib & Enzalutamide TherapyNeeraj Agarwal, MD, FASCO2022
Challenging Case Discussion Panel: Men's HealthMartin M. Miner, MD2023
Identification of Localized DiseasePeter F. Orio III, DO, MS, FABS, FASTRO2023
Multidisciplinary Approach to the Management of Advanced Prostate CancerDaniel P. Petrylak, MD2023
Implementation of Markers in Clinical PracticeDavid S. Morris, MD, FACS2023
Case Discussion: Early Detection of Prostate CancerThomas E. Keane, MD2023
Early Detection of Prostate Cancer: Navigating the Challenges in 2023E. David Crawford, MD2023
PCa Commentary | Volume 178 - June 2023Edward Weber, MD2023
Radioligand Therapy in Prostate CancerGeoffrey B. Johnson, MD, PhD2023
PSA Screening in 2023Gerald L. Andriole, Jr., MD2023
Therapeutic Radiopharmaceuticals in Prostate Cancer: What the Urologist Needs to KnowPhillip J. Koo, MD2023
Results From TRITON3Alan H. Bryce, MD2023
Review of the New Standard in Treatment and Global Issues: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis InhibitorsMarc B. Garnick, MD2023
Prostate MicroultrasoundGerald L. Andriole, Jr., MD2023
PCa Commentary | Volume 177 - May 2023Edward Weber, MD2023
MR Fusion Targeted Therapy: Emerging Management for Localized Prostate Cancer?Fernando J. Bianco, MD2023
Fusion-guided Ablation with Koelis ProMap-FTNiranjan Nayar, MHA2023
RADAR 6 & 7 | Detection of Advanced Prostate Cancer RecurrenceE. David Crawford, MD2023
Complications of Robotic Prostatectomy: Incidence, Predictors, Prevention, and ManagementJay D. Raman, MD2023
mCRPC – Inroads in Improved OutcomesDaniel P. Petrylak, MD2023
Forward Progress in Molecular Markers for Prostate CancerMatthew R. Cooperberg, MD, MPH2023
Selecting Candidates for Focal TherapyAbhinav Sidana, MD, MPH, FACS2022
Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Rana R. McKay, MD, FASCO2023
Prostate Cancer Screening in 2023Sigrid V. Carlsson, MD, PhD, MPH2023
PCa Commentary | Volume 176 - April 2023Edward Weber, MD2023
Patient's Journey: Experience with mCRPC and the Lutetium (Pluvicto) ShortageE. David Crawford, MD2022
OPTIMUM Trial – Current and Emerging Evidence Supporting 29MHz High- Precision, Real-Time Micro-UltrasoundPreston C. Sprenkle, MD2022
NCCN Guidelines for Treatment of Localized Prostate CancerKelvin A. Moses, MD, PhD, FACS2022
Modalities, Maps and Margins: Optimizing Oncologic EfficacyMark Emberton, MD, FRCS2022
Need to Know: Experience with Lutetium (Pluvicto) for Prostate Cancer TheranosticsEdwin M. Posadas, MD, FACP2022
Need to Know: The Impact of a Restricted Supply of Lutetium (Pluvicto)E. David Crawford, MD2022
Rationale for Focal TherapySamir S. Taneja, MD2022
PCa Commentary | Volume 175 - March 2023Edward Weber, MD2023
Liquid Biomarkers and MRI in Prostate Cancer – Complementary?Sanoj Punnen, MD, MAS, MBA2022
Cardiovascular Complications in Patients Undergoing ADTMarc B. Garnick, MD2022
Prostate Anatomy and Clinical Pathologic ConsiderationsThomas M. Wheeler, MD2022
ADT as Foundational Therapy, and the Need for Consensus on Consistent T Suppression, Goals, Monitoring, and Delaying Time to CRPCE. David Crawford, MD
How the Addition of Multiparametric MRI has Changed a Private Practice Setting in Prostate ScreeningRichard G. Barr, MD, PhD, FACR, FSRU, FAIUM2022
The Manogram: Role of MRI in Prostate Cancer ScreeningPeter A. Pinto, MD2022
PCa Commentary | Volume 174 - February 2023Edward Weber, MD2023
IP1-Prostagram Screening Study: Comparing PSA, MRI and UltrasoundHashim Ahmed, MD, PhD2022
PET Imaging for Selection of Focal Therapy CandidatesJérémie Calais, MD, PhD2022
Interviews with Icons – Urology Education and the Future of PCa Screening, Detection, and ManagementNeil H. Baum, MD2022
PCa Commentary | Volume 173 - January 2023Edward Weber, MD2023
Prostate MRI for the UrologistSadhna M. Verma, MD, MBA, FSAR2022
Prostate Biopsy Considerations – Transrectal vs. PerinealGuilherme Godoy, MD, MS2022
Deep Learning Accelerated MRI of the Prostate for Increased Throughput and MRI-targeted Biopsy for Improved Prostate Tissue Sampling - Sponsored by Siemens HealthineersMukesh Harisinghani, MD2022
Impact of PCa Risk on PCa Early DetectionA. Karim Kader, MD, PhD2023
Prostate Micro-ultrasoundGerald L. Andriole, Jr., MD2023
PSMA PET Imaging: A Primer for the Urologist or OncologistPhillip J. Koo, MD2022
PCa Commentary | Volume 172 - December 2022Edward Weber, MD2022
Virtual Genetics Board for Enhancing Knowledge and Practice of Prostate Cancer Genetic Testing - The ENGAGEMENT StudyVeda N. Giri, MD2022
PSMA PET for Improving the Diagnosis, Treatment, and Management of Prostate Cancer - AUA Abstract ReviewE. David Crawford, MD2022
New Standards of Care for Advanced Prostate CancerWilliam K. Oh, MD2022
Utilizing Molecular Characterization of Invasive Bladder Cancer: What It Means Now and In the FutureJennifer A. Linehan, MD2022
Appropriate Use of PSMA PET in Clinical PracticeThomas Hope, MD2022
Advanced Prostate Cancer Clinical Trials UpdatesDavid S. Morris, MD, FACS2022
PCa Commentary | Volume 171 - November 2022Edward Weber, MD2022
Current Status of PSMA PET in the United StatesPhillip J. Koo, MD2022
Transperineal Mapping Biopsy: Does Technique Matter?Nelson N. Stone, MD2022
Genetic Testing for Identifying Who is at Risk of Prostate Cancer and Lethal CancerJianfeng Xu, MD, MS, MPH, DrPH2022
Brachytherapy: The Royal Flush of Radiation Treatment for Men with High-Risk Prostate CancerMira Keyes, MD, FRCPC, FABS2022
Updates in Prostate Cancer BiomarkersMatthew R. Cooperberg, MD, MPH2022
How to Integrate PSMA PET Findings Into Treatment AlgorithmsJérémie Calais, MD, PhD2022
PCa Commentary | Volume 169 - September 2022Edward Weber, MD2022
Germline Genetics and Prostate Cancer Evolution and AggressivityPaul C. Boutros, PhD, MBA2021
Brachytherapy: What's New and Where are We Going?Peter J. Rossi, MD, FABS, FASTRO2022
Personalization of Prostate Cancer Care Through Integration of DataIlya Gipp, MD, PhD2021
Experience with 18F-rhPSMA7.3 for Prostate CancerWolfgang Weber, MD2021
Just the Beginning: What's Next for Radiotheranostics in Prostate Cancer?Geoffrey B. Johnson, MD, PhD2022
Doctor Knows Best? Why Prostate Cancer Care Must Be Transformed Into Digital HealthMichael H. Johnson, MD, FACS2021
PSMA PET-CT: Clinical ApplicationsNeal D. Shore, MD, FACS2022
Prostate High Dose-Rate (HDR) Brachytherapy as Boost and MonotherapyGerard Morton, MD, FABS2021
ADT Side Effects: Cardiovascular DiseaseE. David Crawford, MD
Transurethral Ultrasound Ablation (TULSA)Robert Princenthal, MD2022
Practical Applications and Clinical Utility of PYLARIFY Injection: Implications for Urology and Radiation OncologyPhillip J. Koo, MD2022
Utilization of Focal Therapy for Patients Discontinuing Active Surveillance of Prostate Cancer: Recommendations of an International Delphi ConsensusThomas J. Polascik, MD, FACS2022
Abstract Commentary: Association Between Patient-Reported Outcomes and Changes in Prostate-Specific Antigen in Patients with Advanced Prostate Cancer Treated with Apalutamide in the Spartan and Titan StudiesBenjamin H. Lowentritt, MD, FACS2022
Burning Questions and Controversies in the Management of Advanced Prostate Cancer PatientsScott B. Sellinger, MD, FACS2022
The Wild, Wild West of Radiation Oncology: An Update on Radiation Tools, Toys and TrialsPeter F. Orio III, DO, MS, FABS, FASTRO2022
Forward Progress in Molecular Markers in Prostate CancerMatthew R. Cooperberg, MD, MPH2022
ABS Initiatives to Enhance Training the Next Generation of BrachytherapistsDaniel G. Petereit, MD, FASTRO2021
ADT and Cognitive HealthMark A. Moyad, MD, MPH2022
Active Surveillance 2022: Who Qualifies, Who Does Not and How Should it be MonitoredLaurence Klotz, MD, FRCSC2022
Bone Health and ADTMark A. Moyad, MD, MPH2022
Racial Justice and Prostate CancerChristopher J. Kane, MD, MS, FACS2022
Industry Perspective: ConfirmMDx and Improving the Identification of Men at Risk for Clinically Significant Prostate CancerWim Van Criekinge, PhD2022
MRI-guided Transurethral Ultrasound Ablation (TULSA) for Prostate CancerLaurence Klotz, MD, FRCSC2022
Socioeconomic Aspects of Prostate BrachytherapyPeter F. Orio III, DO, MS, FABS, FASTRO2022
Highlights from the 5th Global Summit on Precision Diagnosis and Treatment of Prostate CancerFaina Shtern, MD2022
Genetic Testing & Next Generation DNA SequencingAlan H. Bryce, MD2022
PCa Commentary | Volume 166 - June 2022Edward Weber, MD2022
ADT and Brachytherapy: The Good, the Bad, and the UglyMira Keyes, MD, FRCPC, FABS2022
PCa Commentary | Volume 165 - May 2022Edward Weber, MD2022
Industry Perspective: AR-V7 Testing for Men with Advanced Stage Prostate CancerDaniel Shoskes, MD, MSc, FRCSC2022
Updates in Treatment Using ADT and Anti-AndrogensE. David Crawford, MD2022
High Intensity Focused Ultrasound for Prostate CancerHao G. Nguyen, MD, PhD2022
Role of Prostate Brachytherapy in Gleason 8-10 DiseasePeter F. Orio III, DO, MS, FABS, FASTRO2022
How to Utilize MRI for Focal Therapy PlanningSamir S. Taneja, MD2022
Focal Prostate CryotherapyThomas J. Polascik, MD, FACS2022
PSMA Targeted Therapies and the Role of the UrologistPhillip J. Koo, MD2022
Comparative Outcomes: Prostate Brachytherapy vs. EBRT vs. SBRT for Low/Intermediate Risk DiseaseMichael J. Zelefsky, MD2022
PCa Commentary | Volume 164 - April 2022Edward Weber, MD2022
Cancer Control in 1379 Men Undergoing HIFU: A Multi-institute 15-year ExperienceMark Emberton, MD, FRCS2022
Combining Therapy with SBRT and BrachytherapyRichard G. Stock, MD2022
ExactVu™ Micro-Ultrasound for Diagnosis of Prostate CancerPriya N. Werahera, PhD2022
Pathologist's Perspective on Biopsy Results: Transperineal Mapping vs. Fusion BiopsyM. Scott Lucia, MD2022
A Biochemical Definition of Cure Following Brachytherapy of Prostate CancerJuanita M. Crook, MD, FRCPC2022
Overview of the State of Genetic Testing and Future Applications in Prostate CancerBrian T. Helfand, MD, PhD2022
PCa Commentary | Volume 163 - March 2022Edward Weber, MD2021
Industry Perspective: The Oncotype DX Genomic Prostate Score Assay TestDaniel Shoskes, MD, MSc, FRCSC2022
Active Surveillance or Focal Therapy as Primary ManagementLaurence Klotz, MD, FRCSC2022
Prostate Imaging Elevated By Deep LearningMukesh Harisinghani, MD2022
Current and Emerging Role of Radiogenomics in Risk Assessment for Focal TherapyJohn Feller, MD2020
Management of Men With PI-RADS 4-5 Lesions and Negative BiopsySamir S. Taneja, MD2022
Active Surveillance: Who Qualifies, Who Does Not and How Should it be MonitoredLaurence Klotz, MD, FRCSC2022
Long-Term Outcomes with Monotherapy for LR and fIR Prostate CancerTimothy N. Showalter, MD, MPH, MBA2022
GU ASCO Symposium 2022 SummaryUlka Vaishampayan, MD2022
The Myths and Facts About Prostate BrachytherapySteven J. Frank, MD, FACR, FABS, FASTRO2022
Point-Counterpoint: Management of mCRPCRana R. McKay, MD, FASCO2022
The Sentinel Prostate Cancer Platform: Validation StudiesLaurence Klotz, MD, FRCSC2022
PSMA: Current State of the Art and Future VisionPhillip J. Koo, MD2022
Brachytherapy for Prostate CancerMira Keyes, MD, FRCPC, FABS2022
Urologic Perspective on the Current and Emerging Role of Multi-Modality Imaging and RadiogenomicsMohummad Minhaj Siddiqui, MD2022
PCa Commentary | Volume 162 - February 2022Edward Weber, MD2022
Active Surveillance - When Can You Continue Watching and When Do You Intervene?Michael A. Brooks, MD2022
Transperineal Biopsy & Classification of Risk Using Novel Gleason Pattern QuantificationBehfar Ehdaie, MD, MPH2022
Decisional Tools to Determine Need for Biopsy and Re-Biopsy in Men with Elevated PSAsGuilherme Godoy, MD, MS2020
Point-Counterpoint: Management of mCRPCAlan H. Bryce, MD2022
Point-Counterpoint: Management of mCRPC (Con)Alan H. Bryce, MD2022
Point-Counterpoint: Management of mCRPC (Pro)Rana R. McKay, MD, FASCO2020
MRI Guided Focal Laser AblationAytekin Oto, MD, MBA2022
Standard Treatments and Global PerspectiveMarc B. Garnick, MD2022
Reinforcing Consistent Testosterone Suppression in ADTE. David Crawford, MD
Local Therapy - Managing Locoregional (LR) Complications in Metastatic Prostate CancerA. Edward Yen, MD2021
Updates in mpMRIKirsten L. Greene, MD, MAS, FACS2021
PCa Commentary | Volume 161 - January 2022Edward Weber, MD2022
Changing Paradigm in Testosterone Therapy Treatment OptionsMohit Khera, MD, MBA, MPH2021
Use of MRI-Targeting Increases Overdiagnosis and OvertreatmentAndrew J. Vickers, PhD2021
Active Surveillance - When Can You Continue Watching and When Do You Intervene?Dov Kadmon, MD2022
Active Surveillance - When Can You Continue Watching and When Do You Intervene?Guilherme Godoy, MD, MS2022
Early Detection of Prostate Cancer: Navigating the Challenges in 2021E. David Crawford, MD2021
Panel Discussion – Focus on PSMAPhillip J. Koo, MD2021
Considerations to Improve Screening for Prostate CancerGerald L. Andriole, Jr., MD2021
Final Results from ACIS Trial of Apalutamide Plus Abiraterone/Prednisone in Patients with Chemo-Naive mCRPCRaoul S. Concepcion, MD, FACS2021
Updates of Changes in the Early Detection of Prostate Cancer NCCN Guidelines 2021Preston C. Sprenkle, MD2021
Urologic Perspective on the Clinical Utility of and Emerging Data on Micro-UltrasoundRafael Sanchez-Salas, MD2021
Radiologic Perspective on the Clinical Utility of and Emerging Data on Micro-UltrasoundSangeet Ghai, MD, FRCR2021
MRI: Can It Be Used to Plan Ablative Therapies?Robert E. Reiter, MD, MBA2021
PCa Commentary | Volume 160 - December 2021Edward Weber, MD2021
Emerging Role of PSMA ImagingSteven P. Rowe, MD, PhD2021
Role of ADT with RadiationSteven E. Finkelstein, MD, DABR, FACRO2021
PCa Commentary | Volume 159 - November 2021Edward Weber, MD2021
Use of Polygenic Risk Scores for Prostate Cancer ScreeningPeter R. Carroll, MD, MPH2021
Real World Utilization of Guideline Based Therapy in mCSPC: Update From the 2021 ASCO Annual MeetingNeeraj Agarwal, MD, FASCO2021
TITAN Phase 3 Trial with Apalutamide in Metastatic Castration Sensitive Prostate CancerNeeraj Agarwal, MD, FASCO2021
International Prostate Cancer Update 2021 Session Review: Next Generation Imaging - Focus on PSMAPhillip J. Koo, MD2021
The OPTIMUM Trial: 29 MHz Micro-Ultrasound vs. MRI in Diagnosis of Prostate CancerGerald L. Andriole, Jr., MD2021
Next Generation Imaging for Localization of Recurrent Prostate CancerBrian T. Helfand, MD, PhD2021
The PRONOUNCE Trial: The Cardiovascular Safety of Degarelix vs. LeuprolideThomas E. Keane, MD2021
International Prostate Cancer Update 2021 Session Review: Localized Prostate Cancer, Including ADT and Radiation OncologyLaurence Klotz, MD, FRCSC2021
Prostate Cancer Early Detection 2021Peter R. Carroll, MD, MPH2021
GUIDE - A New Initiative For a National Bio RepositoryE. David Crawford, MD2021
International Prostate Cancer Update 2021 Session Review: Biomarkers and Genetic TestingAlan H. Bryce, MD2021
Image-Guided Focal Treatment of Prostate CancerScott Eggener, MD2021
Recent Advancements in PI-RADS: mpMRI vs. bpMRIJelle Barentsz, MD, PhD2021
PCa Commentary | Volume 158 - October 2021Edward Weber, MD2021
MRI-Guided Focal Therapy: Initial Quality-of-Life and Oncologic OutcomesJames A. Eastham, MD, FACS2021
Integrating Theranostics Into a Group PracticeDavid M. Albala, MD2021
Treatment for Prostate Cancer with MRI-Guided Transurethral UltrasoundLaurence Klotz, MD, FRCSC2021
Active Surveillance in Favorable Intermediate-Risk Prostate CancerJames A. Eastham, MD, FACS2021
PSMA PET Imaging at Time of DiagnosisPeter R. Carroll, MD, MPH2021
Updates in ADT: Managing Adverse EffectsLaurence Klotz, MD, FRCSC2021
Efficacy of Enzalutamide Plus ADT in Men with De Novo (M1) mHSPC Versus Progression to mHSPC: Post Hoc Analysis of the Phase III ARCHES TrialDaniel P. Petrylak, MD2021
Focal Cryosurgery: Outcomes and ObservationsThomas J. Polascik, MD, FACS2021
Updates on PSMA Imaging and PSMA CAR T TherapyDaniel P. Petrylak, MD2021
PCa Commentary | Volume 157 - September 2021Edward Weber, MD2021
High Intensity Focused Ultrasound for Prostate Cancer: Guidelines, Complications, and OutcomesArvin K. George, MD2021
Role of PARP Inhibitors in Prostate CancerDaniel P. Petrylak, MD2021
Contemporary Brachytherapy: A View from the ABSIn Memory of Brian J. Moran, MD2021
Next Generation Imaging in Prostate Cancer - PYLARIFYE. David Crawford, MD2021
The Third Dimension in Prostate Cancer DiagnosisFrancisco G. La Rosa, MD2021
Testosterone Therapy in Men with Biochemical Recurrence and Metastatic Prostate CancerAbraham Morgentaler, MD, FACS2021
Radiation Oncology Perspective: Image-Guided Metastasis-Directed TherapySteven E. Finkelstein, MD, DABR, FACRO2021
Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate CancerDaniel J. George, MD, FASCO2021
The Prostate – Highlights of Prostate Cancer Advances As Covered in ASCO-SEPMarc B. Garnick, MD2021
Review of Sentinel Assay for Prostate Cancer DiagnosisLaurence Klotz, MD, FRCSC2021
Early Diagnosis of Prostate Cancer: A Path ForwardE. David Crawford, MD2021
PCa Commentary | Volume 156 - August 2021Edward Weber, MD2021
The Veteran's Prostate Cancer Treatment and Research ActGregory F. Murphy, MD2021
Patient Advocacy for Prostate Conditions: Advocate PerspectiveWendy L. Poage, MHA2021
Germline Genetics in Prostate CancerBrian T. Helfand, MD, PhD2021
Can We Trust TRUS Biopsies?Francisco G. La Rosa, MD2021
Prostate Cancer Risk Assessment: Focus on Early PSA and Hereditary RiskGerald L. Andriole, Jr., MD2021
Current Status of PSMA DiagnosticsJérémie Calais, MD, PhD2021
Genetic Testing and Prostate CancerRaoul S. Concepcion, MD, FACS2021
What’s New in Active Surveillance for Prostate Cancer in 2021Laurence Klotz, MD, FRCSC2021
Next Generation Imaging for Prostate CancerPhillip J. Koo, MD2021
Management of Biochemical RecurrencePeter R. Carroll, MD, MPH2021
Update on New Approaches Combining Brachytherapy with ImmunotherapySteven E. Finkelstein, MD, DABR, FACRO2021
Diet Only and Prostate CancerMark A. Moyad, MD, MPH2021
Surveillance After Image-Targeted Focal TherapyThomas J. Polascik, MD, FACS2021
Deciphering the Changing Landscape of Differential Delay in Cancer Diagnoses in Community Radiation and Medical OncologyMitchell O. Finkelstein2021
Future Trials of Lutetium-177Daniel P. Petrylak, MD2021
Role of ADT with RadiationKevin D. Healey, MS2021
Management of Oligometastatic DiseaseRobert E. Reiter, MD, MBA2021
Radium-223 Trial UpdatesDaniel P. Petrylak, MD2021
PCa Commentary | Volume 155 - July 2021Edward Weber, MD2021
Evaluation and Management of Localized and Recurrent Prostate Cancer: Genetic Cancer ProfilingAlan Pollack, MD, PhD2021
International Prostate Cancer Update 2021 Session Review: Men’s Prostate HealthE. David Crawford, MD2021
MRI-US Fusion Target Management of Prostate Cancer in the Office SettingFernando J. Bianco, MD2021
Current and Emerging Role of Radiogenomics in Risk AssessmentJohn Feller, MD2020
Pay for Performance Model to Improve Quality of Active Surveillance in Low-Risk Prostate CancerFranklin Gaylis, MD, FACS2021
Leveraging the EMR to Improve Quality in Clinical PracticeFranklin Gaylis, MD, FACS2021
Does the Radiation Dose Required to Eradicate Local Disease Differ by Gleason Grade Group?Nelson N. Stone, MD2021
Leveraging the EMR to Improve Quality in Risk Stratification for Prostate CancerFranklin Gaylis, MD, FACS2021
Screening and Prevention of Prostate Cancer 2021 (Part 3): Incorporating MRI for Early DetectionSigrid V. Carlsson, MD, PhD, MPH2021
Application of MRI Fusion Biopsy Results to Focal TherapyLeonard S. Marks, MD2021
The Role of Molecular Imaging to Improve Cancer Control Post-ProstatectomyPeter J. Rossi, MD, FABS, FASTRO2021
Screening and Prevention of Prostate Cancer 2021 (Part 2): Who Needs a Biopsy?Sigrid V. Carlsson, MD, PhD, MPH2021
Current and Emerging Imaging Tools for Improving Risk Assessment and Selection of Patients for BiopsyClare Tempany, MB, BCh, BAO2020
Screening and Prevention of Prostate Cancer 2021 (Part 1): Evidence for PSA ScreeningSigrid V. Carlsson, MD, PhD, MPH2021
PCa Commentary | Volume 153 - May 2021Edward Weber, MD2020
Does Anatomic Rectal Displacement Improve Dosimetry and Reduce Injury?Richard G. Stock, MD2021
Transrectal mpMRI Fusion BiopsyLeonard S. Marks, MD2021
Androgen Society 3rd Annual Meeting Review (Day 1)Abraham Morgentaler, MD, FACS2021
Freehand Transperineal Prostate Biopsy Under Local AnesthesiaMichael A. Gorin, MD2021
Management of Recurrent Prostate Cancer After Focal TherapyKelly L. Stratton, MD2021
The TRANSFORMER Study: Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With mCRPCSamuel R. Denmeade, MD2021
Can One Biopsy Event Determine Type and Amount of Focal Therapy Treatment?Nelson N. Stone, MD2021
Focal Therapy Compared to Radical ProstatectomySteven N. Gange, MD, FACS2021
Non-Invasive Molecular Imaging and its Impact on Management of the Localized Disease and Suspected RecurrenceAndrei H. Iagaru, MD, FACNM2021
TheraP Trial and Effectiveness of Lu-PSMA-617Daniel J. George, MD, FASCO2021
Pathologist's Perspective on Focal TherapyM. Scott Lucia, MD2021
Overview of Image-Guided, Minimally-Invasive Focal TreatmentJim C. Hu, MD, MPH2021
HIFU Bill Coding 2021Mark N. Painter, CPMA, MBS2021
Relugolix and Concomitant Treatment for Advanced Prostate CancerDaniel J. George, MD, FASCO2021
Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to SurgeryJ. Kellogg Parsons, MD, MHS, FACS2021
Brachytherapy and Focal Therapy OutcomesRichard G. Stock, MD2021
Case Study on HIFU for Prostate CancerVahan Kassabian, MD, FACS, FRCS (C)2021
Integrated Multi-Modality Diagnostic Evaluation of Prostate CancerSanoj Punnen, MD, MAS, MBA2021
Current State-of-the-Art Molecular and Multi-Modality Imaging and Theranostics of Prostate CancerWolfgang Weber, MD2021
Image-Guided Minimally-Invasive Whole Gland TreatmentSteven S. Raman, MD2021
The Case for Standard ImagingMichael L. Glodé2021
Rationale for Focal Therapy for Prostate CancerAbhinav Sidana, MD, MPH, FACS2021
Biomarkers and Clinical Decisions - Integrating with Clinical Parameters, Imaging & Prognostic InstrumentsMatthew R. Cooperberg, MD, MPH2021
Cardiovascular & Metabolic Risk Profiles of Hormonal Agents for Managing Advanced Prostate CancerCelestia S. Higano, MD2021
Active Surveillance 2021 - Patient Selection, Monitoring, and Innocuous InterventionsLaurence Klotz, MD, FRCSC2021
Castration Resistant Prostate Cancer - Developments and Challenges from 2020Emmanuel S. Antonarakis, MD2021
Active Surveillance 2021 - Imaging and BiomarkersLaurence Klotz, MD, FRCSC2021
Germline Genetics and Prostate Cancer Evolution and AggressivityPaul C. Boutros, PhD, MBA2021
Non-Metastatic CRPC: Finding Advanced Disease with Next Gen Imaging MattersGerald L. Andriole, Jr., MD2021
Future Directions in Molecular and Multi-Modality Imaging and Theranostics of Prostate CancerPhillip J. Koo, MD2021
The miR Scientific Sentinel AssayLaurence Klotz, MD, FRCSC2021
Liquid Diagnostics and Prostate CancerE. David Crawford, MD2021
HIFU Focal Therapy: Prostate Cancer - Emerging Data and Clinical Utility vs. Standard CareAndre Abreu, MD2020
New Prescribing Information on Survival Benefit for Nubeqa® (Darolutamide) ApprovedNeal D. Shore, MD, FACS2021
Active Surveillance Criteria and Follow-up ProtocolMichael A. Brooks, MD2021
High Intensity Focused Ultrasound (HIFU) Ablation in a Salvage SettingJohn H. Jurige, Jr., MD2021
Overall Survival with Sipuleucel-T in Patients Treated for Advanced Prostate CancerRana R. McKay, MD, FASCO2020
The HERO Study and the Approval of RelugolixNeal D. Shore, MD, FACS2020
Current Clinical Utility of MRI and Multi-Modality ImagingMasoom Haider, MD2020
Optimize Erectile Function Following Radical ProstatectomyMohit Khera, MD, MBA, MPH2020
In My Opinion: Biomarkers for the Diagnosis of Prostate CancerMichael A. Gorin, MD2020
Pros and Cons of Perineal vs. TRUS-Guided Prostate BiopsiesE. David Crawford, MD2020
Role of MR-Targeted Prostate Biopsy in Active SurveillanceBehfar Ehdaie, MD, MPH2020
PSMA PET Imaging in Advanced Prostate CancerJérémie Calais, MD, PhD2020
Clinical Case Discussion: Metastatic Prostate Cancer and Evidence for More Precision TherapyA. Edward Yen, MD2020
PSMA PET Gallium Scan Approved by FDARobert E. Reiter, MD, MBA2020
Focal Therapy (HIFU): Functional and Oncological OutcomesMark Emberton, MD, FRCS2020
Urologic Debate Part 2: MRI vs. Molecular Markers: Which One Should I Use? Markers PerspectiveE. David Crawford, MD2020
Urologic Debate Part 1: MRI vs. Molecular Markers - Which One Should I Use? MRI PerspectiveGuilherme Godoy, MD, MS2020
Patient Selection for Focal Therapy: What is an Optimal Biopsy Strategy?Kae Jack Tay, MBBS, MRCS(Ed), MMed (Surgery), MCI, FAMS (Urology)2020
Use of Germline and Somatic Molecular Testing in Prostate Cancer DiagnosisGuilherme Godoy, MD, MS2020
Advances in Imaging: a Radiologist’s PerspectivePhillip J. Koo, MD2020
Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening StatementJoseph C. Presti, Jr., MD, FACS2020
PET Imaging for Prostate CancerGerald L. Andriole, Jr., MD2020
Trials in Neoadjuvant Therapy for Patients with High-Risk Localized Prostate CancerRana R. McKay, MD, FASCO2020
Updates in PARP Inhibition and Germline Testing in Prostate CancerAlan H. Bryce, MD2020
Updates in BrachytherapyPeter J. Rossi, MD, FABS, FASTRO2020
Panel Discussion: Next Generation Genomics and Prostate Cancer BiomarkersLeonard G. Gomella, MD, FACS2020
Updates in Focal Therapy of Prostate CancerThomas J. Polascik, MD, FACS2020
Genetics and Biomarkers for Prostate Cancer and Bladder CancerAlan H. Bryce, MD2020
Germline Testing for Active SurveillanceBrian T. Helfand, MD, PhD2020
Kaiser Permanente Prostate Cancer Risk Calculator 1.0Joseph C. Presti, Jr., MD, FACS2020
Updates in Screening: Prostate Cancer GuidelinesGerald L. Andriole, Jr., MD2020
PCa Patients on ADT- Improving Bone Health Monitoring Through Specialty Clinic CollaborationMegan E. Milne, MD2020
Genetic Risk Score for Prostate Cancer ScreeningBrian T. Helfand, MD, PhD2020
Accuracy of ExactVu™ Micro-Ultrasound for Diagnosis of Prostate CancerPriya N. Werahera, PhD2020
Improving Specificity of PSA Screening with Serum and Urine Markers - Who Doesn’t Need a Prostate Biopsy?Daniel W. Lin, MD2020
HIFU: The European ExperienceRafael Sanchez-Salas, MD2020
Clinical Implications of Genetics in Prostate CancerA. Karim Kader, MD, PhD2020
Management of mCRPC in ChinaBo Dai, MD, PhD2020
Immunotherapy TrialsDaniel P. Petrylak, MD2020
HIFU for Prostate Cancer in AsiaSunao Shoji, MD, PhD2020
Genetic Testing and Next Generation DNA Sequencing in Prostate CancerAlan H. Bryce, MD2020
Panel Discussion on Challenges of Managing Androgen Deprivation Therapy Patients During COVID-19Richard G. Harris, MD, FACS2020
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019Veda N. Giri, MD2020
Theranostics & Radiopharmaceutical TrialsDaniel P. Petrylak, MD2020
Evaluation and Management of Recurrent Prostate Cancer Following Radiation TherapyAaron E. Katz, MD, FACS2020
GRU Challenging Case: Androgen Deprivation TherapyNeal D. Shore, MD, FACS2020
A Better Abiraterone: The Backdoor Pathway for Intracrine Androgen MetabolismJames L. Mohler, MD2020
Molecular Imaging For Staging and Advanced Disease – Axumin and PSMARobert E. Reiter, MD, MBA2020
Chemotherapy TrialsDaniel P. Petrylak, MD2020
Changing Landscape of mHSPC: New Approaches to an Old ProblemMichael S. Cookson, MD, MMHC2020
Usefulness of Adjustable Needle Sizes for BiopsiesJelle Barentsz, MD, PhD2020
Crossing the Divide from Transrectal to Transperineal BiopsyMichael A. Gorin, MD2020
Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19Richard G. Harris, MD, FACS2020
New Approaches to Combining Brachytherapy with ImmunotherapySteven E. Finkelstein, MD, DABR, FACRO2020
Genetics and Genomic Biomarkers: How Molecular Markers and mpMRI Play a RoleR. Jonathan Henderson, MD2020
Epidemiology & Genomics of Prostate Cancer in Asian MenYao Zhu, MD, PhD2020
Challenging Cases in Advanced Prostate Cancer: nmCRPCR. Jonathan Henderson, MD2020
MRI-Guided Transurethral Ultrasound Ablation (TULSA) in Patients with Localized Prostate CancerLaurence Klotz, MD, FRCSC2020
The Use of MRI to Determine the Target for Focal TherapyJelle Barentsz, MD, PhD2020
Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate CancerE. David Crawford, MD2019
29MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate BiopsiesNeal D. Shore, MD, FACS2020
Genetic Testing in Prostate CancerMohammad O. Ramadan, MD2019
Phase 1 Trial of ARV-110 in Patients with mCRPCDaniel P. Petrylak, MD2020
Anti-Androgen TrialsDaniel P. Petrylak, MD2020
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate CancerNeal D. Shore, MD, FACS2020
Panel on Androgen Deprivation Therapy: A Closer Review of the Cardiovascular RiskThomas E. Keane, MD2020
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate CancerCelestia S. Higano, MD2020
Multiparametric MRI for the Detection of Clinically Significant Prostate CancerJelle Barentsz, MD, PhD2020
The Capacity of MRI to Predict Extracapsular DiseaseJelle Barentsz, MD, PhD2020
Androgen Deprivation Therapy: A Closer Review of the Role of Anti-AndrogensThomas E. Keane, MD2020
What Role Do Markers Play in Establishing Active Surveillance or Definitive Care?Gerald L. Andriole, Jr., MD2020
Diet, Exercise + Prostate CancerDavid Utz2020
Are MRI Fusion Biopsies Necessary for Urologists?Jelle Barentsz, MD, PhD2020
Challenging Cases in Advanced Prostate Cancer- mHSPCE. David Crawford, MD2020
Next Generation Biomarkers - As Reflex, Combination, or First Line?E. David Crawford, MD2020
Radiation, Immunotherapy + the Abscopal EffectDavid Utz2020
What Does Suspicion for Prostate Cancer Mean, and What Metric Defines Prostate Cancer Risk?Jelle Barentsz, MD, PhD2020
Surgery for Recurrent Prostate CancerDavid Utz2020
Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate CancerAlan H. Bryce, MD2019
Prostate Imaging and Biopsy ControversiesNeal D. Shore, MD, FACS2020
New Concepts in Cavernous Nerve Localization and Functional Recovery after Radical ProstatectomyArthur L. Burnett II, MD, MBA, FACS2020
Cesium-131 Prostate Brachytherapy: A Single Institutional Long-Term ExperienceRonald M. Benoit, Jr., MD2020
Clinical Trial: Exercise For Metabolic DysregulationDavid Utz2020
Integrating MRI and Molecular Markers to Detect Aggressive Prostate CancerSanoj Punnen, MD, MAS, MBA2019
Technical and Diagnostic Limitations to Partial Prostate Ablation for Prostate CancerMichael O. Koch, MD2019
Advanced Prostate Cancer: What’s ChangingRichard G. Harris, MD, FACS2020
Recognizing and Managing the Side Effects of Androgen Deprivation TherapyAlicia K. Morgans, MD, MPH2019
Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS StudyE. David Crawford, MD2020
Dr. Oliver Sartor on COVID-19: This Week in New Orleans and The Race for A TreatmentDavid Utz2020
Dr. Susan Slovin: NYC + Covid-19 April 1, 2020David Utz2020
The Role of Genetic Testing in Prostate CancerA. Karim Kader, MD, PhD2020
Clinical Trial: PROVENGE® + Active SurveillanceDavid Utz2020
Sarcopenia in the Prostate Cancer PatientMark A. Moyad, MD, MPH2020
Review of the Role of MRI-Targeted Biopsy vs Systematic Biopsy in Prostate CancerMukesh Harisinghani, MD2019
Exercise and Prostate Cancer: Prevention and Bettering Outcomes in Localized and Advanced DiseaseArturo Mendoza-Valdés, MD2020
The Prostate – Most Diseased Organ in the Male BodyRyan P. Terlecki, MD, FACS2020
Urinary Health Issues Following Treatment for Prostate CancerRyan P. Terlecki, MD, FACS2020
Ethnic Disparities in Sexual Dysfunction Outcomes After Prostate Cancer Treatment: Myth or Reality?Arthur L. Burnett II, MD, MBA, FACS2020
State of the Art: Nutrition and Prostate CancerMark A. Moyad, MD, MPH2020
Transperineal Prostate Biopsy Under Local Anesthesia: Systematic and MRI-Ultrasound Fusion BiopsyPeter K.F. Chiu, MD, PhD, FRCSEd2020
Combining Radiation + ImmunotherapyDavid Utz2020
Retzius-Sparing Robotic-Assisted Laparoscopic Radical Prostatectomy (RARP): Rationale, Selection & TechniqueDaniel C. Parker, MD2019
New Approaches to Metastatic Hormone Sensitive Prostate CancerMichael S. Cookson, MD, MMHC2019
Helping Patients Navigate the World of Clinical TrialsDavid Utz2020
Prostate Cryoablation: Tips and TricksThomas J. Polascik, MD, FACS2020
Expanding the Role of Surgical Management of High-Risk Prostate CancerMichael O. Koch, MD2019
Current and Emerging Imaging Tools for Improving Risk Assessment, Selection of Patients for Biopsy, and Tissue SamplingSangeet Ghai, MD, FRCR2019
Testosterone Therapy in Men with Organ-Confined Gleason 6-7 Prostate Cancer After Radical ProstatectomyCarolyn A. Salter, MD2020
The Live Primary Cell Phenotypic Test (LPCP) for Prostate CancerDavid M. Albala, MD2019
Contrast-Enhanced Ultrasound of the ProstateEthan J. Halpern, MD2019
The Cardiovascular Effects of Orchiectomy Versus LHRH AgonistsJeremy Y.C. Teoh, MBBS, FRCSEd, FCSHK, FHKAM2020
More Arrows in Our Quiver - Targeting the Adaptive Molecular Landscape of Advanced Prostate CancerMartin Gleave, MD, FRCSC, FACS2019
Recent Clinical Radionuclide Therapy Advances in mCRPCUlka Vaishampayan, MD2020
Overview of Treatment for Advanced Prostate Cancer, including Metastatic Disease – Novel TreatmentChristopher J. Sweeney, MBBS2019
Prostate Cancer Initial Staging and Evaluation of Recurrent Disease with PSMA-Targeted PETSteven P. Rowe, MD, PhD2019
Biochemical Recurrence After Local Therapy: Assessment and ManagementPeter R. Carroll, MD, MPH2019
Treating a Patient Denied Coverage Based on Not Conforming to NCCN GuidelinesJames L. Mohler, MD2020
Molecular Imaging of Prostate CancerWolfgang Weber, MD2019
Considerations for the Clinical Impact of Next Generation Imaging in Prostate CancerAshley E. Ross, MD, PhD2019
Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Con ArgumentDavid Utz2019
Prostate Cancer Screening and Early Detection: Should We Follow the NCCN Guidelines? Pro ArgumentA. Karim Kader, MD, PhD2019
Image-Guided Biopsy and TreatmentDaniel Margolis, MD2019
Standard Treatment for Advanced Prostate CancerDavid M. Nanus, MD2020
Radiation Oncology Perspective on Treatment Planning of Localized DiseaseAshesh B. Jani, MD, MSEE, FASTRO2019
Precision Radiation Therapy: Low- to Intermediate-Risk Prostate CancerMichael J. Zelefsky, MD2019
Germline Predisposition for Prostate Cancer Among African Americans and Other Minorities: What Do We Know?Curtis A. Pettaway, MD2020
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and AggressivenessColin C. Pritchard, MD, PhD2020
Prostate Cancer Screening & Genetic Testing: The NCCN PerspectiveDavid Utz2020
Current NCCN Recommendations for Prostate Cancer Genetic TestingJames L. Mohler, MD2020
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling PerspectiveScott M. Weissman, MS, LCGC2020
Next Generation Updates: Advances in Radiation Oncology: Prostate CancerDavid C. Beyer, MD2019
The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials PerspectiveWilliam L. Dahut, MD2020
Is MRI Fusion Biopsy the New Gold Standard of Diagnosis? Con ArgumentE. David Crawford, MD2019
Current Prostate Cancer Genetic Testing Capabilities and ConsiderationsRobert Pilarski, MS, LGC, MSW, LSW2020
Is MRI Fusion Biopsy the New Gold Standard of Diagnosis? Pro ArgumentA. Karim Kader, MD, PhD2019
The HERO Study and the Approval of RelugolixDaniel J. George, MD, FASCO2020
The Effect of Local Antibiogram-Based Augmented Antibiotic Prophylaxis on Infection-Related Complications Following Prostate BiopsyRaoul S. Concepcion, MD, FACS2019
ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life-Prolonging Therapy in mHSPC PatientsAndrew J. Armstrong, MD, MSc, FACP2019
Update on the ARCHES Trial: New Indication for Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Christopher J. Sweeney, MBBS2019
Genetic Testing in Prostate Cancer: Ethical & Legal ConsiderationsVictor R. Cotton, MD, JD2019
Radiation Oncology Perspective on Treatment of Oligometastatic DiseaseJason A. Efstathiou, MD, DPhil2019
State of the Art in “Smart” Prostate Cancer Screening: Defining the Need for Precision DiagnosticsSigrid V. Carlsson, MD, PhD, MPH2019
PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM MutationsMaha H. Hussain, MD, FACP, FASCO2019
Multi-Parametric MRIMasoom Haider, MD2019
nmCRPC: Is Navigating the M0 Space the Next Moon Shot?E. David Crawford, MD2019
RADAR III: Next Generation ImagingE. David Crawford, MD2019
Radiogenomics in Active Surveillance: How Can We Integrate mpMRI and Genomics to Monitor Prostate CancerSanoj Punnen, MD, MAS, MBA2019
Phase III HERO Trial: Once-Daily, Oral Relugolix Results in 96.7% Testosterone Suppression in Men with Advanced Prostate CancerNeal D. Shore, MD, FACS2019
Non-Invasive Molecular Imaging - FluciclovineGerald L. Andriole, Jr., MD2019
Integration of Germline Testing in Prostate Cancer ScreeningThomas J. Polascik, MD, FACS2019
Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier ScoreFred Saad, MD, FRCS, CQ, FCAHS2019
Novel Combination of Circulating miRNAs for Specific Detection in Prostate CancerFumihiko Urabe, MD, PhD2019
Prostate Cancer Genetic Testing: How to Hedge Bets in Selecting Patients for Surveillance, and When to Pull the Trigger on TreatmentMichael A. Brooks, MD2019
A Urologist's Perspective on Germline TestingMichael S. Cookson, MD, MMHC2019
Regionally Advanced Prostate CancerA. Edward Yen, MD2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate CancerNeil F. Mariados, MD2019
TITAN Study Leads to FDA Approval of Apalutamide for Patients with Metastatic Castration-Sensitive Prostate CancerKim N. Chi, MD2019
Multicenter Clinical Trial of Real-Time Prostate Cancer Diagnosis Using Optical Spectroscopy Guided Prostate BiopsyJames S. Wysock, MD, MSc2019
Image Guided Prostate BiopsyGerald L. Andriole, Jr., MD2019
Locally Advanced Prostate CancerDov Kadmon, MD2019
Current State of Exosome-Based BiomarkersJohan Skog, PhD2019
Hormone Therapy in High Risk Prostate CancerPatrick W. McLaughlin, MD2019
Discussion of FDA Industry Guidelines for Developing Gonadotropin-Releasing Hormone Analogues for Advanced Prostate CancerBen Eppard2019
Focus on Prostate Microultrasound: Fluciclovine and PSMA Gallium PETRyan S. Hsi, MD, FACS2019
Management of Localized High-Risk Prostate CancerAdam S. Kibel, MD2019
Surgery versus Radiation Therapy - A Surgeon's PerspectiveAdam S. Kibel, MD2019
Neoadjuvant Therapy for High-Risk Prostate CancerAdam S. Kibel, MD2019
Advanced PET Imaging for Prostate Cancer StagingNelson N. Stone, MD2019
The Staggering Benefit of PSA Screening in Potentially Lethal Prostate CancerPatrick W. McLaughlin, MD2019
Focal Therapy of Prostate CancerLeonard S. Marks, MD2019
Screening for Prostate Cancer: PSA: Why 1.5 is the New 4.0E. David Crawford, MD2019
Temporal Shifts in Grade and Stage of Prostate Cancer: A Whole Mount AnalysisM. Scott Lucia, MD2019
Germline and Somatic Mutations: Can They Change Therapy?William K. Oh, MD2019
FDA Guidance for Developing Gonadotropin-Releasing Hormone Analogues for Treating Advanced PCaBen Eppard2019
Transperineal Mapping Biopsy Defines Tumor Type and LocationNelson N. Stone, MD2019
Salvage Lymph Node Dissection for Prostate CancerPaul D. Maroni, MD2019
MRI-US Image Fusion Prostate BiopsyJohn F. Ward, MD, FACS2019
Does the PROMIS Trial Impact Prostate Cancer Screening?John F. Ward, MD, FACS2019
Androgen Targeted Therapy Across the Continuum of Prostate CancerE. David Crawford, MD2019
Prostate Cancer GenomicsDavid Utz2019
Progress in Prostate Cancer GradingM. Scott Lucia, MD2019
Can MRI Be Used to Select Patients for Focal Therapy or To Guide Therapy?Robert E. Reiter, MD, MBA2019
AR Resistance Mechanisms: Focusing on Variants and TestingRaoul S. Concepcion, MD, FACS2019
MRI/US Fusion BiopsyLeonard S. Marks, MD2019
Pathologist’s Perspective on Focal TherapyM. Scott Lucia, MD2019
The Importance of a Post-Treatment Biopsy in the Management of Patients Treated with Radiotherapy for Localized Prostate CancerMichael J. Zelefsky, MD2019
3DBiopsy™: Transperineal Mapping Biopsy in 2019Nelson N. Stone, MD2019
Long-term Morbidity of ADT and Radiation TherapyNelson N. Stone, MD2019
The Use of Genomic Markers and Prostate Biopsy DecisionsE. David Crawford, MD2019
New Considerations for Oligometastatic Prostate CancerRaoul S. Concepcion, MD, FACS2019
Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate CancerGerald L. Andriole, Jr., MD2019
Bone Metastases and Mortality: Can We Be Doing More?Leonard G. Gomella, MD, FACS2019
TRUS Biopsy, MRI, and PROMIS TrialPriya N. Werahera, PhD2019
Prostate Cancer Screening: The Latin American PerspectiveArturo Mendoza-Valdés, MD2019
Emerging Indications for a Novel Absorbable Hydrogel SpacerLawrence I. Karsh, MD2019
Timing of ADT with Chemotherapy in 2019Thomas E. Keane, MD2019
Summarizing the RADAR GuidelinesPhillip J. Koo, MD2018
Point Counterpoint: The Optimal Nadir T Level on ADT Is <20mg/mLJohn W. Davis, MD, FACS2019
Navigating the M0 SpaceE. David Crawford, MD2018
Second Opinion Diagnosis in Prostate PathologyFrancisco G. La Rosa, MD2019
Androgen Receptor Targeted Treatments of Prostate Cancer Slide DeckE. David Crawford, MD2019
Pivotal Trial of MRI-Guided Transurethral Ultrasound Ablation in Men with Localized Prostate CancerScott Eggener, MD2019
Prostate Cancer - No Biopsy in Case of a Normal MRISigrid V. Carlsson, MD, PhD, MPH2019
How to Optimize the Use of Prostate-specific Antigen in the Current EraSigrid V. Carlsson, MD, PhD, MPH2019
Prompt Prostate Genetic Score: A New Tool for Targeted Prostate Cancer ScreeningA. Karim Kader, MD, PhD2016, 2019
Androgen Annihilation as a New Therapeutic Paradigm in Advanced Prostate CancerR. Jonathan Henderson, MD2019
PARP in Combination with Standard-of-Care TreatmentDaniel P. Petrylak, MD2019
Focal Therapy for Localized Prostate Cancer: Is There a “Middle Ground” Between Active Surveillance and Definitive Treatment?John W. Davis, MD, FACS2019
Prostate Cancer Active Surveillance in 2019Sigrid V. Carlsson, MD, PhD, MPH2019
MicroRNA Expression Profiles Identify Clinically Significant Prostate CancerLaurence Klotz, MD, FRCSC2016, 2019
AR-V7 Predicts Response in CRPCRaoul S. Concepcion, MD, FACS2018
MR Guided BiopsyJohn C. Chang, MD, PhD2018
RADAR III | Next Generation Imaging PresentationE. David Crawford, MD2019
New Applications and Clinical Possibilities in Prostate Cancer with Micro-UltrasoundE. David Crawford, MD2019
Using High Resolution Micro-Ultrasound for Prostate Biopsies for Active SurveillanceLaurence Klotz, MD, FRCSC2019
29 MHz High Resolution Micro-Ultrasound: Improving Real-Time Targeting of Prostate BiopsiesNeal D. Shore, MD, FACS2019
Navigating the M0 Space- Results of RADAR IIINeal D. Shore, MD, FACS2019
RADAR III | Next Generation ImagingE. David Crawford, MD2019
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to KnowMichael S. Cookson, MD, MMHC2018
It is Not Time to Abandon Transrectal Prostate Biopsy for Perineal BiopsyErik P. Castle, MD, FACS2018
It is Time to Abandon Transrectal Prostate Biopsy for Perineal BiopsyDavid Utz2018
Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate CancerPhillip J. Koo, MD2018
Agonists vs. Antagonists for the Treatment of Advanced Prostate CancerThomas E. Keane, MD2019
There is a Role for Currently Available Biomarkers: Genomics in the Risk Stratification of Prostate CancerDavid Utz2018
Biomarkers in Localized Prostate Cancer: Sure You Can, But Why Would You?Alan H. Bryce, MD2018
Prostate Cancer and Early Detection: Should We Follow the NCCN Guidelines?Sigrid V. Carlsson, MD, PhD, MPH2018
Prostate Cancer Screening: The NCCN PerspectiveDavid Utz2018
The USPSTF Prostate Cancer Screening Recommendation: A Swinging PendulumSigrid V. Carlsson, MD, PhD, MPH2018
The Pros of Focal Therapy for Prostate CancerJeffrey A. Jones, MD2018
Prostate Cancer Focal Therapy: Is it the Right Time for your Practice?John W. Davis, MD, FACS2018
Prostate Cancer Early Diagnosis ScreeningGuilherme Godoy, MD, MS2018
Role of MRI in the Current Management of Prostate CancerDov Kadmon, MD2018
The Pros and Cons of Imaging for Biopsy GuidanceGuilherme Godoy, MD, MS2018
The Pros and Cons of Genomic Markers for Biopsy GuidanceJohn W. Davis, MD, FACS2018
DNA Specimen Provenance Assay: Preventing Overdiagnosis of Prostate CancerTed Schenberg2018
Immunotherapy for Castration Resistant Prostate CancerDaniel P. Petrylak, MD2018
Next Generation Prostate Brachytherapy for AblationThomas J. Pugh, MD2018
A Novel Micro-Ultrasound System for Improving Transrectal Prostate BiopsyNeal D. Shore, MD, FACS2018
The Role of Targeting DNA Repair Mutations in Advanced Prostate Cancer with PARP InhibitorsDaniel P. Petrylak, MD2018
PSMA Imaging: Beyond MRI in Prostate CancerRobert E. Reiter, MD, MBA2018
Emerging Technology in Radiation Oncology: Indications for a Novel Absorbable Hydrogel SpacerSteven E. Finkelstein, MD, DABR, FACRO2018
Use of Radiopharmaceuticals: Updates on Ongoing Clinical TrialsPhillip J. Koo, MD2018
Genomic Markers and DNA Sequencing TestingDaniel W. Lin, MD2018
PCa Commentary | Volume 127 - October 2018Edward Weber, MD2018
Testosterone Replacement and Focal TherapyMohit Khera, MD, MBA, MPH2018
Mapping Pathology as a Guide to Focal Therapy: The Role of Mapping Biopsies and Tissue MarkersM. Scott Lucia, MD2018
The Future of Genomic Markers and DNA Sequencing in Prostate CancerDaniel W. Lin, MD2018
Hypofractionation for Prostate CancerDavid Utz2018
Genetic Testing for Inherited Prostate CancerLeonard G. Gomella, MD, FACS2018
FDUS 2018 - Next Generation Therapeutic Layering and SequencingLeonard G. Gomella, MD, FACS2018
FDUS 2018 - Next Generation Advanced and Castration-Resistant Prostate CancerEvan Y. Yu, MD2018
FDUS 2018 - Next Generation Imaging in Localized Prostate CancerPhillip J. Koo, MD2018
Sequencing of Adjuvant TherapiesDaniel P. Petrylak, MD2018
Prostatectomy: What is the Future?John F. Ward, MD, FACS2018
Should Testosterone Levels Influence Decision to Biopsy?Mohit Khera, MD, MBA, MPH2018
PCa Commentary | Volume 126 - September 2018Edward Weber, MD2018
Long-Term Outcomes of HDRJuanita M. Crook, MD, FRCPC2018
Long-Term Outcomes of Permanent BrachytherapyRichard G. Stock, MD2018
How Does Radiobiology Guide Dose, Fraction, and Source Selection?David Utz2018
Minimizing Morbidity and Maximizing Outcomes with ADTLaurence Klotz, MD, FRCSC2018
Neuroendocrine Tumors | Not so Rare?Josh Mailman, MBA2018
Does Radiation Therapy Favor Radical Prostatectomy in Long-Term QOL?Juanita M. Crook, MD, FRCPC2018
NET Background and TherapyArturo Loaiza-Bonilla, MD, MSEd, FACP2018
Prevention and Management of Rectal ToxicityRichard G. Stock, MD2018
Focal BrachytherapyJuanita M. Crook, MD, FRCPC2018
Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice | Interesting CasesRobert Flavell, MD, PhD2018
Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer PracticePhillip J. Koo, MD2018
Focal CryotherapyJohn F. Ward, MD, FACS2018
Adjuvant or Salvage RT Post-Radical ProstatectomyDavid Utz2018
Determining Patterns of Failure: Advanced ImagingRichard G. Stock, MD2018
Update on Prostatectomy Versus Observation TrialsGerald L. Andriole, Jr., MD2018
Changing Distribution, Size and Grade of Prostate Cancer: Whole-Mount Prostatectomy AnalysisM. Scott Lucia, MD2018
Should MRI Be Used to Monitor for AS? Pro ArgumentPeter A. Pinto, MD2018
Should MRI Be Used to Monitor for AS? Con ArgumentNelson N. Stone, MD2018
3DBiopsy™ Transperineal Mapping BiopsyNelson N. Stone, MD2018
AUA/ASTRO/SUO Guidelines on Clinically Localized Prostate CancerRiccardo Autorino, MD, PhD, FEBU2018
Biomarkers for Prostate Cancer: Whom to TreatGerald L. Andriole, Jr., MD2018
Prostate Cancer Screening: Who? Why? How?Gerald L. Andriole, Jr., MD2018
Management of Post Prostatectomy Vesicourethral StenosisChris M. Gonzalez, MD, MBA, FACS2018
Is Focal Ablation of Prostate Cancer Ready for Prime Time?David Utz2018
Radical Prostatectomy for Oligometastatic Prostate Cancer: Is There Any Benefit?Riccardo Autorino, MD, PhD, FEBU2018
Screening for Prostate Cancer: PSA: Why 1.5 is the New 4E. David Crawford, MD2018
Transperineal Prostate Biopsy: State of the ArtRoberto Miano, MD2018
Multimodal Approach to Advanced Prostate CancerMartin Gleave, MD, FRCSC, FACS2018
SpaceOAR Hydrogel - Prostate-Rectum Spacing in Radiation TherapyLawrence I. Karsh, MD2018
The LUGPA Alternative Payment Model (APM) on Newly Diagnosed PCa and the Role of Active SurveillanceR. Jonathan Henderson, MD2018
M0 Space and The SPARTAN TrialEric J. Small, MD, FASCO2018
Advanced Disease — A Real Need for Understanding and Shared CareDaniel P. Petrylak, MD2018
Integrating the AUA Guidelines into Your PracticeMichael S. Cookson, MD, MMHC2018
Bone Metastases and Mortality — Can We Be Doing More?Leonard G. Gomella, MD, FACS2018
Update on Radiopharmaceuticals— Choosing a Companion Drug to Radium-223Phillip J. Koo, MD2018
The Role of Molecular Imaging in Managing High Risk and Recurrent Prostate CancerRobert E. Reiter, MD, MBA2018
Immunotherapy 101 for the UrologistRaoul S. Concepcion, MD, FACS2018
The Role of Targeting DNA Repair with PARPDavid Utz2018
Timing of ADT and ChemotherapyThomas E. Keane, MD2018
New Considerations for Oligometastatic Prostate CancerThomas J. Pugh, MD2018
Point Counterpoint in ADT—Agonists versus AntagonistsLawrence I. Karsh, MD2018
Current Mortality Rates on Prostate Cancer PatientsJohn W. Davis, MD, FACS2018
Current Findings on High Intensity Focused Ultrasound (HIFU)Neil E. Fleshner, MD, MPH, FRCSC2018
MR/US Fusion Target Office Cryoablation: Short-term OutcomesFernando J. Bianco, MD2018
The Ups and Downs of MRI Interrogation of the GlandRobert E. Reiter, MD, MBA2018
3D Biopsy – The Complete Interrogation of the GlandNelson N. Stone, MD2018
Prostate Inflammation and Prostate Cancer: What do I need to know?J. Curtis Nickel, MD, FRCSC2018
AR-V7 in Castration Resistant Prostate CancerEmmanuel S. Antonarakis, MD2018
Prostate BrachytherapyIn Memory of Brian J. Moran, MD2018
Active Surveillance: From Biology to Bedside Who fails, why, and how can we prevent this?Laurence Klotz, MD, FRCSC2018
The Role of FSH in Prostate CancerMarc B. Garnick, MD2018
Updates on the ERSPC and the PLCO TrialsGerald L. Andriole, Jr., MD2018
The Evolution of Understanding the USPSTF: Recommendations and ControversyNeal D. Shore, MD, FACS2018
An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPCMaha H. Hussain, MD, FACP, FASCO2018
The Burden of Prostate Cancer Today and in the FuturePatrick C. Walsh, MD2018
The Role of Genetic Testing for Inherited Prostate Cancer RiskVeda N. Giri, MD2017
Molecular Diagnostic of Prostate Cancer Based on Non Invasive Liquid BiopsiesJack A. Schalken, PhD2018
Imaging of Prostate Cancer Patients Following Definitive TherapyPhillip J. Koo, MD2017
Radiogland Therapy Optimization of PSMA-Targeted RadiationScott T. Tagawa, MD2018
An Overview of MRI Guided Biopsies for Prostate CancerRobert Abouassaly, MD, MS2017
Novel Hormonal Therapies for Prostate CancerAlan H. Bryce, MD2017
MRI in the Management of Prostate Cancer: What Urologists Need to KnowMichael S. Cookson, MD, MMHC2017
Updates in Radiation Oncology: Of Brachytherapy and BeamsDavid C. Beyer, MD2017Imaging & Diagnostics, RadiationLocalized/Locally Advanced, Prostate Cancer, Locally Advanced
HIFU: Ready for Prime TimeDavid C. Beyer, MD2017
HIFU is not Ready for Prime TimeErik P. Castle, MD, FACS2017Clinical TrialsLocalized/Locally Advanced, Prostate Cancer
Timing and Optimization of Radium 223 in CRPCPhillip J. Koo, MD2017
Therapeutic Use of Genetic Testing in Advanced Prostate CancerAlan H. Bryce, MD2017
Prostate Cancer Survivorship: Value to Patients & ProvidersRyan P. Terlecki, MD, FACS2017Localized/Locally Advanced, Prostate Cancer
Germline and Somatic DNA Repair Defects in Prostate CancerAlan H. Bryce, MD2017
Sexual and Urinary Health After Treatment for Prostate CancerRyan P. Terlecki, MD, FACS2017Localized/Locally Advanced, Prostate Cancer
Testosterone and the ProstateE. David Crawford, MD2017
The Negative Impact of Testosterone TreatmentRyan P. Terlecki, MD, FACS2017
Erectile Dysfunction and the Detection of Subclinical Cardiovascular DiseaseRyan P. Terlecki, MD, FACS2017
The Role Of Shared Decision Making in Prostate CancerMatt T. Rosenberg, MD2017
Identifying the Toothless Lions in Prostate CancerE. David Crawford, MD2017
Biomarkers: A Way Forward with Prostate Cancer Early DetectionE. David Crawford, MD2017
Prostate Cancer: Why the Controversy?Michael S. Cookson, MD, MMHC2017
Testosterone Therapy, the FDA, and CVD Risk ControversiesMatt T. Rosenberg, MD2017
ERA 223 Study | Concerns About Using Radium-223 and AbirateroneE. David Crawford, MD2017
Prostate Physiology: The Most Diseased Organ in the Male BodyRyan P. Terlecki, MD, FACS2017
Urinary Molecular Marker Tests in Bladder Cancer: An Overview of CxbladderSiamak Daneshmand, MD2017
Q&A Ask the Expert | Re-Evaluating Patients with Gleason 8Francisco G. La Rosa, MD2017
Hereditary Prostate CancerDavid Utz2017
To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part IDavid Utz2017
To the Point: Focal or Definitive Therapy for Prostate Cancer: MRI vs. Mapping Part IINelson N. Stone, MD2017
Therapeutic Layering for Treating Castration Resistant Prostate CancerE. David Crawford, MD2017
Ask the Expert: What Are Some of the Challenges for Urologists Treating Metastatic Castrate Resistant Prostate Cancer Patients?Lawrence I. Karsh, MD2017
Ask the Expert: What Combinations of Immunotherapy for Prostate Cancer Are Most Promising?Raoul S. Concepcion, MD, FACS2017
Ask the Expert: What Combination Drugs with Radium-223 Are Best for Treating Prostate Cancer?Leonard G. Gomella, MD, FACS2017
Shared Decision MakingMatt T. Rosenberg, MD2017
Ask the Expert: Do Low Volume Metastatic Disease Patients Benefit from Early Docetaxal?Michael S. Cookson, MD, MMHC2017
Ask the Expert: Will More Individuals Over Time Be Diagnosed with Prostate Cancer?Gerald L. Andriole, Jr., MD2017
Ask the Expert: What Are Some Considerations When First Treating Prostate Cancer Patients?Daniel P. Petrylak, MD2017
What Tools Can Be Used to Predict Who Will Respond to Certain Prostate Cancer Drugs?Raoul S. Concepcion, MD, FACS2017
Ask the Expert: Should Radium-223 Be Used Earlier in Prostate Cancer Treatment?Leonard G. Gomella, MD, FACS2017
Ask the Expert: Which New Biomarkers Can Help Guide Treatment for Prostate Cancer?Daniel P. Petrylak, MD2017
Ask the Expert: Is Photodynamic Therapy Being Combined with Other Therapies?James A. Eastham, MD, FACS2017
Ask the Expert: What Changes Are Happening in Anti-Androgen Therapy for Prostate Cancer?Neal D. Shore, MD, FACS2017
Ask the Expert: Should Photodynamic Therapy Be Used as a Single or Multi-Pronged Treatment Strategy?James A. Eastham, MD, FACS2017
Ask the Expert: Which Non-Genomic Biomarkers Are Most Useful for Monitoring Patients After Initial Treatment?In memory of Alan W. Partin, MD, PhD2017
Ask the Expert: What Are the Barriers to Focal Therapy Becoming More Widely Accepted?Thomas J. Polascik, MD, FACS2017
Ask the Expert: For Which Patients Is Photodynamic Therapy Appropriate?James A. Eastham, MD, FACS2017
Ask the Expert: What Role Do Risk Stratification Tools Play in Focal Therapy?Thomas J. Polascik, MD, FACS2017
Ask the Expert: Which Non-Genomic Biomarkers Are the Most Useful for Stratifying Patients?In memory of Alan W. Partin, MD, PhD2017
Ask the Expert: What Are the Options in Treating Persistently Elevated PSA and Negative Biopsy?M. Scott Lucia, MD2017
Ask the Expert: How Can Genomic Markers Be Used Best to Stratify Which Patients to Treat?Gerald L. Andriole, Jr., MD2017
What Are Best Risk Stratification Tools When Placing Patient on Active Surveillance?Laurence Klotz, MD, FRCSC2017
Ask the Expert: Are There Genomic Tests to Determine Need for a Repeat Biopsy?M. Scott Lucia, MD2017
Should Androgen Receptor Targeting Be Given Earlier for Prostate Cancer?Charles J. Ryan, MD2017
Mortality Statistics After Prostatectomy and RadiationJohn W. Davis, MD, FACS2017
Ask the Expert: How Do Urologists and Medical Oncologists Differ in Their Approach to Prostate Cancer?Lawrence I. Karsh, MD2017
Other Side Effects: Perception vs. EvidenceNeal D. Shore, MD, FACS
Ask the Expert: What Changes Are Happening in Anti-Androgen Therapy?Neal D. Shore, MD, FACS2017
The Role of Genetic Testing and Next Generation Imaging for Prostate CancerLeonard G. Gomella, MD, FACS
Biomarkers for Localized Prostate CancerAshley E. Ross, MD, PhD2017
An Overview of the Management of Prostate Cancer with Androgen ReceptorsRaoul S. Concepcion, MD, FACS2017
What Are Ways to Improve PSA?Gerald L. Andriole, Jr., MD2017
Short Course: Prostate Cancer Prevention, Screening, and BiomarkersBen Eppard
When to Use Hormone Therapy with Radiation TherapyPatrick W. McLaughlin, MD2017
Intermittent HT, Quality of Life, and Testosterone RecoveryLaurence Klotz, MD, FRCSC2017
Testosterone and Prostate Cancer: Is There a Link?Abraham Morgentaler, MD, FACS2017
Nutrition and Prostate Cancer: What We Think We Know and What We Actually KnowStephen J. Freedland, MD2017
Patterns of Failure Following the Brachytherapy Management of Prostate CancerRichard G. Stock, MD2017
Post Prostatectomy RadiationPatrick W. McLaughlin, MD2017
Which Should We Use: Brachytherapy, Monotherapy, or Combined EBRT and BrachytherapyJuanita M. Crook, MD, FRCPC2017
Targeted Focal Therapy for Localized Prostate CancerArdeshir R. Rastinehad, DO, FACOS2017
Focal HIFUPerinchery Narayan, MD
Active Surveillance and Our Role in Local TherapyJuanita M. Crook, MD, FRCPC2017
Active Surveillance Results and Implications of Prospective StudiesLaurence Klotz, MD, FRCSC2017
Focal BrachytherapyJuanita M. Crook, MD, FRCPC2017
Urinary Morbidity: Prevention and ManagementNelson N. Stone, MD2017
The Anatomy of SuccessPatrick W. McLaughlin, MD2017
Targeted Prostate Biopsy Is the FutureArdeshir R. Rastinehad, DO, FACOS2017
3-Dimensional Image Guided BiopsyNelson N. Stone, MD2017
Association of Hypogonadism to LifestyleNelson N. Stone, MD2017
How Should We Monitor Patients During Surveillance?Michael S. Leapman, MD, MHS2017
Personalized Therapy for Prostate Cancer Due to Genetic TestingsStephen J. Freedland, MD2017
Metabolic Side Effects of ADTStephen J. Freedland, MD2017
Erectile Function After BrachytherapyNelson N. Stone, MD2017
Morbidity and Quality of Life: Brachytherapy or ProstatectomyJuanita M. Crook, MD, FRCPC2017
TRUS Biopsy: Does it Still Have a Role?Michael S. Leapman, MD, MHS2017
ADT Impact on Cardiovascular HealthJehonathan H. Pinthus, MD, PhD, FRCSC2017
Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Slide Deck from 2017 AUA SymposiumE. David Crawford, MD2017
Prostate Cancer: A Review of Current Prostate Cancer Markers and a Novel Model of OrganizationE. David Crawford, MD2017
Genetic Predictors of RadiosensitivityRichard G. Stock, MD2017
Can Genomics Improve Upon Best Clinical Risk Stratification?Michael S. Leapman, MD, MHS2017
Biomarkers: PSA, 4K, or PHI?Nelson N. Stone, MD2017
Radium-223 in Advanced DiseaseRichard G. Stock, MD
Role of Local Radiation Therapy in the Metastatic SettingRichard G. Stock, MD2017
Update on Radiopharmaceuticals: Choosing a Companion Drug to Radium-223Daniel P. Petrylak, MD2017
Novel Biomarker-Guided Treatment: PSMA, PAR, HDACs, etc.Daniel P. Petrylak, MD2017
Targeting AR in Castration-Resistant Prostate CancerRaoul S. Concepcion, MD, FACS2017
Neuroendocrine Prostate Cancer (NEPC)Jehonathan H. Pinthus, MD, PhD, FRCSC2017
New Concepts in Androgen Deprivation TherapyThomas E. Keane, MD2017
Point-Counterpoint: Early Chemotherapy is BetterDaniel P. Petrylak, MD2017
S.A.2M.2 : The Best “Natural” and Researched Heart Healthy Pills for Patients Concerned About Prostate CancerMark A. Moyad, MD, MPH2017
The Benefits and Challenges (Present and Future) for the Urologist Treating mCRPCLawrence I. Karsh, MD2017
Advanced Disease: A Real Need for Understanding and Shared CareDaniel P. Petrylak, MD2017
An Update of the European/Swedish Screening TrialDavid Utz2017
Non-genomic Biomarkers for Early Diagnosis and Prognosis Prevention of Prostate CancerIn memory of Alan W. Partin, MD, PhD2017
The "Who's" of Genomic Markers: Who to TreatGerald L. Andriole, Jr., MD2017
The "Who's" of Genomic Markers: Who to Re-BiopsyM. Scott Lucia, MD2017
The "Who's" of Genomic Markers: Who to BiopsyE. David Crawford, MD2017
Impact of the USPSTF Recommendations on ScreeningGerald L. Andriole, Jr., MD2017
What's New in Immunotherapy?Raoul S. Concepcion, MD, FACS2017
Vascular Targeted Photodynamic Therapy for Prostate TumorsJames A. Eastham, MD, FACS2017
Cryotherapy: Update on the International COLD RegistryJ. Stephen Jones, MD, FACS, MBA2017
MRI Guided Biopsy and AblationScott Eggener, MD2017
Updates in BrachytherapyMack Roach III, MD, FACR2017
Active Surveillance: Who is the Right Patient and What is the Right Protocol?Laurence Klotz, MD, FRCSC2017
Current Findings on High Intensity Focused Ultrasound (HIFU)Thomas J. Polascik, MD, FACS2017
New Horizons in Focal TherapyThomas J. Polascik, MD, FACS2017
Highlights from the 9th International Symposium on Focal Therapy and ImagingThomas J. Polascik, MD, FACS2017
Updating the Concepts of Biosynthesis Inhibitors and Anti-AndrogensNeal D. Shore, MD, FACS2017
Debate: How Should We Manage Oligometastatic Disease?Mack Roach III, MD, FACR2016
The Impact of Local Treatment of the Prostate in Patients with Newly Diagnosed Metastatic Prostate CancerPiet Ost, MD, PhD2017
Bone Targeted Agents in Metastatic Prostate Cancer: Denosumab, Bisphosphonates and Radium-223Noel Clarke, MBBS, FRCS, ChM2017
Managing Prostate Cancer in Elderly/Unfit PatientsNicolas Mottet, MD, PhD2017
EAU Guidelines for Monitoring Prostate Cancer Patients Under TreatmentNicolas Mottet, MD, PhD2017
Next Generation Sequencing of Prostate Tumors: Use of Individualized Biomarkers for Prognosis and TreatmentMartin Spahn, MD2017
Update on Mechanisms of Resistance in Castration-Resistant Prostate CancerKarim Fizazi, MD, PhD2017
Debate: Comparative Effectiveness of Surgery versus RadiationLaurence Klotz, MD, FRCSC2017
Sequencing, Combination or Individualised Treatment?Karim Fizazi, MD, PhD2017
Vitamin D and Prostate CancerThomas E. Keane, MD2017
Focal Therapy for Men with Intermediate Risk Prostate Cancer and a Solitary Lesion Should Be the Standard of CareMark Emberton, MD, FRCS2017
Predicting Survival of Men with Prostate Cancer after Radical ProstatectomyAxel Merseburger, MD, PhD2017
Prevalence of CVD and Assessment of CV Risk in Patients with Prostate CancerAlexander Lyon, MD, PhD2017
Active Surveillance or: Shrinking the Gray ZoneLaurence Klotz, MD, FRCSC2017
ADT: Mechanisms of CV DiseaseE. David Crawford, MD2017
Imaging of Metastatic Prostate Cancer: Whole Body MRI and Novel PET TechniquesAnwar R. Padhani, MBBS, FRCP, FRCR2017
The Role of PCP in Prostate Cancer Screening 2017Matt T. Rosenberg, MD2017
Current and Future Approaches to Androgen Deprivation Therapies: Focus of AntiandrogensE. David Crawford, MD2017
Role of mpMRI: Implication and ImplementationNelson N. Stone, MD2016
When to Biopsy: The Role for PSA and Novel BiomarkersStacy Loeb, MD2016
Why 1.5 is the New 4.0 for the PCP?Matt T. Rosenberg, MD2016
Prostate Cancer Screening: What We’ve Learned and Where We Should GoGerald L. Andriole, Jr., MD2016
Biomarkers in Genitourinary CancersE. David Crawford, MD2015
Historical View of Hormone Therapy: The European PerspectiveFrans M.J. Debruyne, MD, PhD2015
Highlights from the 24th International Prostate Cancer UpdateE. David Crawford, MD2014